81
This Provisional PDF corresponds to the article as it appeared upon acceptance. Copyedited and fully formatted PDF and full text (HTML) versions will be made available soon. Evaluation of the current knowledge limitations in breast cancer research: a gap analysis Breast Cancer Research 2008, 10:R26 doi:10.1186/bcr1983 Alastair Thompson ([email protected]) Keith Brennan ([email protected]) Angela Cox ([email protected]) Julia Gee ([email protected]) Diana Harcourt ([email protected]) Adrian Harris ([email protected]) Michelle Harvie ([email protected]) Ingunn Holen ([email protected]) Anthony Howell ([email protected]) Robert Nicholson ([email protected]) Michael Steel ([email protected]) Charles Streuli ([email protected]) ISSN 1465-5411 Article type Research article Submission date 30 August 2007 Acceptance date 27 March 2008 Publication date 27 March 2008 Article URL http://breast-cancer-research.com/content/10/2/R26 This peer-reviewed article was published immediately upon acceptance. It can be downloaded, printed and distributed freely for any purposes (see copyright notice below). Articles in Breast Cancer Research are listed in PubMed and archived at PubMed Central. For information about publishing your research in Breast Cancer Research go to http://breast-cancer-research.com/info/instructions/ Breast Cancer Research © 2008 Thompson et al., licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

  • Upload
    others

  • View
    0

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

This Provisional PDF corresponds to the article as it appeared upon acceptance. Copyedited andfully formatted PDF and full text (HTML) versions will be made available soon.

Evaluation of the current knowledge limitations in breast cancer research: a gapanalysis

Breast Cancer Research 2008, 10:R26 doi:10.1186/bcr1983

Alastair Thompson ([email protected])Keith Brennan ([email protected])

Angela Cox ([email protected])Julia Gee ([email protected])

Diana Harcourt ([email protected])Adrian Harris ([email protected])

Michelle Harvie ([email protected])Ingunn Holen ([email protected])

Anthony Howell ([email protected])Robert Nicholson ([email protected])

Michael Steel ([email protected])Charles Streuli ([email protected])

ISSN 1465-5411

Article type Research article

Submission date 30 August 2007

Acceptance date 27 March 2008

Publication date 27 March 2008

Article URL http://breast-cancer-research.com/content/10/2/R26

This peer-reviewed article was published immediately upon acceptance. It can be downloaded,printed and distributed freely for any purposes (see copyright notice below).

Articles in Breast Cancer Research are listed in PubMed and archived at PubMed Central.

For information about publishing your research in Breast Cancer Research go to

http://breast-cancer-research.com/info/instructions/

Breast Cancer Research

© 2008 Thompson et al., licensee BioMed Central Ltd.This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),

which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Page 2: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

1�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

Research��ar ticle�

Evaluation� of� the� current� knowledge� limitations� in� breast� cancer�

research:� a� gap� analysis �

Alastair�T hompson1�K eith�B rennan2,�A ngela�C ox3,�J ulia�G ee4,�D iana�H arcourt5,�A drian�

Harris6,�M ichelle�H arvie7,� Ingunn� Holen8,�A nthony� Howell9,�R obert�N icholson10,�

Michael�S teel11,�C harles�S treuli12�

On�be half�of � Breast�C ancer�C ampaign�G ap� Analysis�M eeting,�2�N ovember� 2006,�

London,�U K.�

1Department�of �S urgery� and�M olecular� Oncology,�U niversity�o f�D undee,� Ninewells�

Avenue,�D undee,�D D1�9 SY,�U K.�a [email protected]

2Wellcome�T rust�C entre�f or�C ell�M atrix�R esearch,�F aculty�of � Life�S ciences,�U niversity�o f�

Manchester,� Oxford�R oad,�M anchester,�M 13�9P T,�U K.�ke [email protected]

3Institute�f or�C ancer�S tudies,�U niversity�o f�S heffield�M edical�S chool,�B eech�H ill�R oad,�

Sheffield,�S 10�2R X,� UK.�a [email protected]

4Tenovus�C entre�f or�C ancer�R esearch,�W elsh�S chool�of �P harmacy,�C ardiff�U niversity,�

Redwood�B uilding,� King�E dward�V II�A venue,�C ardiff,�C F10�3N B,�U K.�

[email protected]� �

5The�C entre�f or�A ppearance�R esearch,�S chool�of � Psychology�U niversity�of �t he�W est�of �

England,� Frenchay�C ampus,�C oldharbour� Lane,� Bristol,�B S16�1Q Y,�U K.�

[email protected]

6Cancer�R esearch�U K�M olecular�O ncology� Laboratories,�W eatherall� Institute�of �

Molecular�M edicine,�J ohn�R adcliffe�H ospital,�U niversity�of �O xford,�H eadley�W ay,�

Headington,�O xford,�O X3�9D S,�U K.�a [email protected]

7Family�H istory� Clinic,�N ightingale� &�G enesis�P revention�C entre,�W ythenshawe�

Hospital,� Southmoor�R oad,�M anchester,�M 23�9 LT,UK.�

[email protected]

8Academic�U nit�of �C linical�O ncology,�S chool�of � Medicine�a nd� Biomedical�S ciences,�

University�o f�S heffield,� Beech�H ill�R oad,�S heffield,�S 10�2R X,� UK.�

[email protected]

Page 3: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

2�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

9Breast�C ancer�P revention�C entre,�S outh�M anchester�U niversity�H ospitals�N HS�T rust,�

Wilmslow�R oad,�M anchester,�M 20�4B X,�U K.�A [email protected]

10Tenovus�C entre�f or�C ancer�R esearch,�W elsh�S chool�of �P harmacy,�C ardiff�U niversity,�

Redwood�B uilding,� King�E dward�V II�A venue,�C ardiff,�C F10�3N B,� UK.�

[email protected]

11University�of �S t�A ndrews,�B ute�M edical�S chool,�U niversity�o f�S t�A ndrews,�F ife,�K T16�

9TS,�U K.�c [email protected]

12Wellcome�T rust�C entre�f or�C ell�M atrix�R esearch,�F aculty�of � Life�S ciences,�U niversity�

of�M anchester,�O xford�R oad,�M anchester,�M 13�9 PT,�U K.�

[email protected]

Corresponding� author:�A lastair�T hompson:�l [email protected]��

Page 4: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

3�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

Abstract�

Background �A �g ap�a nalysis�w as� conducted�t o�de termine�w hich�a reas�of �br east�c ancer�

research,�i f�t argeted�b y� researchers�a nd� funders,� could�pr oduce�t he� greatest�i mpact�on�

patients.��

Methods� Fifty�s ix�B reast�C ancer�C ampaign� grant� holders�a nd�pr ominent�U K�br east�

cancer�r esearchers�pa rticipated�i n�a � gap� analysis�of �c urrent�br east�c ancer�r esearch.� Before,�

during�a nd�f ollowing�t he� meeting,� groups�i n�s even�ke y� research� areas�pa rticipated�i n�

cycles�of �pr esentation,�l iterature�r eview�a nd�di scussion.�S ummary�pa pers�w ere�pr epared�

by�e ach� group�a nd�c ollated�i nto�t his�pos ition�pa per�hi ghlighting�t he� research�g aps,� with�

recommendations�f or�a ction.�

Results �G aps�w ere�i dentified�i n�a ll�s even�t hemes.� General�ba rriers�t o�pr ogress�w ere�l ack�

of�f inancial� and�pr actical� resources,�a nd�poor � collaboration�be tween�di sciplines.�C ritical�

gaps�i n�e ach�t heme�i ncluded�( 1)� genetics:�know ledge�o f� genetic� changes,�t heir�e ffects�a nd�

interactions;�( 2)�i nitiation�of �br east�c ancer:�how �de velopmental�s ignalling�p athways�c ause�

ductal�e longation�a nd�br anching� at�t he�c ellular�l evel�a nd�i nfluence�s tem�c ell�d ynamics,�

and�how �t heir�di sruption�i nitiates�t umour�f ormation;�( 3)�pr ogression�of �b reast�c ancer:�

deciphering�t he�i ntracellular�a nd�e xtracellular�r egulators�of �e arly�p rogression,�t umour�

growth,�a ngiogenesis�a nd�m etastasis;�( 4)�t herapies�a nd�t argets:�unde rstanding�w ho�

develops�a dvanced�di sease;�( 5)�di sease�m arkers:�i ncorporating�i ntelligent�t rial�de sign�i nto�

all�s tudies�t o�e nsure�ne w� treatments�a re�t ested�i n�p atient�g roups�s tratified�us ing�

biomarkers;�( 6)�p revention:�s trategies�t o�pr event�o estrogen-receptor�ne gative�t umours�a nd�

the�l ong-term�e ffects�of � chemoprevention�f or�o estrogen-receptor�pos itive�t umours;�( 7)�

psychosocial�a spects�of �c ancer:��t he�us e�of �a ppropriate�ps ychosocial�i nterventions,�a nd�

the�pe rsonal�i mpact�of � all�s tages�o f�t he�di sease�a mong�pa tients�f rom�a �r ange�of �e thnic�a nd�

demographic�ba ckgrounds.��

Conclusion �T hrough�r ecommendations�t o�a ddress�t hese�ga ps�w ith�f uture� research�,�t he�

long-term�be nefits�t o�pa tients�w ill�i nclude:�be tter�e stimation�of �r isk�i n�f amilies�w ith�br east�

cancer�a nd�s trategies�t o�r educe�r isk;�be tter�pr ediction�of �dr ug�r esponse�a nd� patient�

prognosis;�i mproved�t ailoring�of �t reatments�t o�pa tient�s ubgroups� and�de velopment�of �ne w�

therapeutic� approaches;�e arlier�i nitiation�of �t reatment;�m ore�e ffective�us e�of ��r esources�f or�

screening�popul ations;�a n�e nhanced�e xperience�f or�pe ople�w ith�or �a t�r isk�of � breast�c ancer�

Page 5: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

4�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

and�t heir�f amilies.�T he� challenge�t o�f unding�bodi es�a nd�r esearchers�i n� all�di sciplines�i s�t o�

focus�on�t hese� gaps�a nd�t o�dr ive�a dvances�i n�know ledge�i nto�i mprovements�i n�pa tient�

care.�

Page 6: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

5�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

Introduction�

Significant�a dvances�i n�t he�pr evention,�di agnosis� and�m anagement�of �br east�c ancer�ha ve�

been�m ade�i n�r ecent� years�ba sed�on�t he�c linical� application�of �s cientific�di scoveries.�

However,�br east�c ancer�r emains�a �c omplex�di sease�pr ocess� affecting�m illions�w orld�w ide,�

where� further� advances�i n�s cientific�know ledge� and�c linical�c are�c ould�i mprove�m any�

lives.� It�i s�t imely�t o�r eview�t he�c urrent�pos ition�of �br east�c ancer�r esearch�a s� funding�

bodies,�r esearchers�a nd� clinicians�w ork�i n�a n�e xciting�a ge�of �di scovery�but �ha ve�l imited�

resources.�� �

In� November�2006,�t he�r esearch�c harity� Breast�C ancer�C ampaign,� convened�a �pa nel�of �

leading�b reast� cancer�r esearchers,�a s� an�i nitial�e vent,�t o�de bate�a nd�i dentify� the�l imitations�

of�c urrent�r esearch�i nto�t he�pa thophysiology,�de tection,�t reatment,�pr evention�a nd�

psychosocial�a spects�of �b reast�c ancer.�T he� aims�of �t his�a nalysis�w ere:�

(i)� To�de termine�t he� gaps�i n�our �know ledge�of �b reast�c ancer�t hat,�i f�r esolved,�

could�r esult�i n�be nefits�t o�pa tients�

(ii)� To�e ncourage�br east�c ancer�r esearchers� and�f unding�bodi es�w orldwide�t o�

focus�t heir�r esources�on�t he�hi ghlighted�a reas�o f�r esearch�t o� achieve�a �

substantive�i mpact�f or�pa tients.�

(iii)� To�m ake�r ecommendations�f or�pr iority�a ction.�

This�g ap� analysis�r epresents�a �uni que�i nsight�i nto�br east�c ancer�r esearch�i n� the�U K�a nd�

the�c hallenges�i nvolved�i n�di recting� efforts�t o�a reas�i n�ne ed�of �f urther�i nvestigation�l ikely�

to�r esult�i n�a dvances�i n�t he�m anagement�of �br east�c ancer.�

Page 7: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

6�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

Materials� and� methods�

Current�a nd�f ormer�m embers�of �t he� Breast�C ancer�C ampaign�S cientific� Advisory� Board�

leading�s cientists�a nd�c linicians�r esident�i n�t he�U K�w ere�i nvited�t o�pa rticipate�i n�t he� gap�

analysis�m eeting.�T he�c hoice�of �pa rticipants�w as�b ased�on�publ ication�r ecord,�r esearch�

activity�a nd� clinical�s tature,�a nd�s elected�us ing�a �d ata�ba se�o f�r esearchers�d eveloped�s ince�

the�i nception�of �B reast�C ancer�C ampaign�i n�1988.��

Seven�ke y�r esearch�a reas�w ere�s elected� for�r eview�i n�t he�g ap� analysis�b y�t he�B reast�

Cancer�C ampaign� and�t he�S cientific�A dvisory� Board�t aking�i nto�a ccount�U K,�E uropean�

and�U SA�t hemes�i n�s cientific�m eetings�f ocussed�o n�br east�c ancer�a nd�U K� Government�

analyses�of �r esearch�f unding�s treams:��

(i)� Genetics�of �br east�c ancer�

(ii)� Initiation�of �br east�c ancer�

(iii)� Progression�of �br east�c ancer�

(iv)� Therapies� and�t argets�i n�br east�c ancer�

(v)� Disease�m arkers�i n�br east�c ancer�

(vi)� Prevention�of �br east�c ancer�

(vii)� Psychosocial� aspects�of �b reast�c ancer.��

Prior�t o�t he�e vent,�pa rticipants�w ere� asked�t o�r eview�r elevant�l iterature� and� construct�s hort�

presentations�s ummarising�t heir� areas�of �e xpertise� and�i dentifying�pot ential� research�

gaps.� Key�pa rticipants�ha d�a lready� conducted,�pub lished�a nd/or�r eviewed�s ystematic�

evidence,�l iterature� reviews�a nd�e vidence�ba sed� guidelines.�A s�a �r esult�t hey� were�

considered�t o�be �opi nion� leaders�i n�t heir� field.�F urther,�a dditional,�s ystematic�l iterature�

reviews�f or�e ach�of �t he�s even�a reas�und er�c onsideration�w as�not �pe rformed.�

For�e ach�t heme,�s ix�t o�t en�U K�br east�c ancer�r esearchers�o f�na tional�or �i nternational�

standing�i n�t heir�f ields�of �r esearch�w ere�i nvited� and�a ccepted�pa rticipation�i n�t he�e vent.�

Twenty�t hree�i nvitees�de clined�t o�c ontribute�t o�t he�ga p�a nalysis.��

On�2�N ovember�2006�t he�one �da y�m eeting�w as�c onvened�i n� London,�U K.� In�i nitial�

subgroup�s essions,�e ach� participant� gave� a�pr esentation�t o�t heir�g roup�on�p re-agreed�

Page 8: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

7�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

topics�r elevant�t o�t he� gap�a nalysis� for�t heir�a ssigned�br east�c ancer�r esearch� area�on� which�

he�or �s he�i s�e xpert.��C onstructive�de bate�o f�t he�c ontent�a nd�t he�i ssues�r aised� by�t he�

presentations�w as� explored�f urther.� Breast�C ancer�C ampaign�s taff�m embers�a cted�a s�

facilitators�t hroughout�t he�a nalysis�pr ocess.�

Issues�e xplored�dur ing�t he�ga p�a nalysis�w ere�s tructured�a round�t he� following�que stions:��

(i)� What�do�w e�a lready�kno w?�

(ii)� What�a re�t he� gaps�i n�our � knowledge?�

(iii)� What�a re�t he�pr oblems�t hat�ne ed�t o�be �ov ercome�t o�f ill�t hese�ga ps?�

(iv)� What�a re�t he�t ranslational�i mplications?�

After�c ollating�t he�i nformation�r esulting�f rom�t hese�di scussions�f or�e ach�of �t he�s even�

themes,�t his�f our�poi nt�s tructure�w as�us ed�t o�pr esent�t he�c ontent�of �e ach�t heme�t o�t he�

other�pa rticipants�a nd�t o� discuss�t heir�f indings�i n�a n�ope n�f orum.��

This�i terative�pr ocess�c ontinued�a s�e vidence�ba sed�e xpert�opi nion�f rom�t he�one �da y�

meeting�w as�c ross� referenced,�s haped� and�de veloped�dur ing�s ubsequent�w eeks.�E ach�

group� formulated�a �s ummary�p aper�f or�t heir� research�a rea,�i ncorporating� key� references,�

which�w as�t hen� circulated�t o�t he�pa rticipants�of �t he�r espective� groups�f or�f urther�

refinement.�T hese�s even� themes�w ere�c ollated�i nto�a �uni fied�pos ition�pa per,�pr esented�

here.�

Page 9: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

8�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

Results� and� discussion�

1.�G enetics�of �B reast�C ancer�( Table�1) �

What�do�w e� know?�

Several� genes�be aring�hi gh-penetrance�m utations� have�be en�i mplicated�i n�i nherited�

predisposition�t o�br east�c ancer,�t he�m ost�i mportant�of �t hese�be ing�i n�t he� BRCA1�a nd�

BRCA2�g enes.�H owever,� BRCA1�a nd�B RCA2�a ccount�f or�l ess�t han�5% �of � all�br east�

cancer,�a nd�i n�r ecent� years,�br east�c ancer�s usceptibility� genes�ot her�t han� BRCA1�a nd�

BRCA2�ha ve�be en�i dentified.�T hese� genes�f all�i nto�t wo�br oad�c ategories:��

(i)� Those�c ontaining�r are�m oderate-penetrance�a lleles�s uch�a s� CHEK2,� ATM�a nd�

BRIP1 �[ 1,2,3]� �

(ii)� Those�c arrying�m ore�c ommon�l ow-penetrance�a lleles�[ 4].�L arge� genome-wide�

association�a nd�c andidate�g ene�s tudies�t o�i dentify�t he�l atter�a re�j ust�be ginning�t o�be ar�f ruit�

[5-8].��

Intermediate�ph enotypes� such�a s�r adiosensitivity� and�m ammographic�de nsity� have�qui te�

strong� genetic�c omponents�a nd�f urther�s tudy�of �t hese�m ay�pr ovide�s ome�i nsight�i nto�

novel�br east�c ancer�s usceptibility� genes.�

Since�t he�br east� cancer� genes� BRCA1�a nd� BRCA2� were� cloned�i n�1994�a nd� 1995,�

research�e fforts�ha ve�c oncentrated�on�d eveloping� an�unde rstanding�of �t he� cellular�

functions�of �t he�l arge�m ultidomain�pr oteins�e ncoded�b y� BRCA1�a nd� BRCA2�a nd�t he�

mechanisms�b y� which�l oss�of �t heir�f unctions�c auses�br east�c ancer.�A n�und erstanding�of �

these�m echanisms�i s�r elevant�not �onl y�t o�f amilies� with� BRCA1�a nd� BRCA2�m utation�

carriers�but �a lso�i n�s poradic�br east�c ancer,�i n�w hich�t he�s ame�or �r elated� genetic�pa thways�

may� also�be �a berrant.�

Cells�de ficient�i n�B RCA1�a nd�B RCA2�a re�e xquisitely�s ensitive�t o�D NA-damaging� agents�

and�a re�d efective�i n�r epairing�D NA�doubl e-strand� breaks�b y�hom ologous�r ecombination,�

being�i mpaired�i n�t he�r ecruitment�a nd�f ilament�f ormation�of �t he�r ecombination�pr otein�

RAD51�[ 9,10].�M ore�r ecently,�ne w�f unctions�ha ve�be en�i dentified� for�bot h�pr oteins:�

Page 10: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

9�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

BRCA1�a nd�i ts�pa rtner� BARD1�f orm�a n�E 3-ubiquitin�l igase�t hat�i s�r ecruited�t o�s ites�of �

DNA�da mage�a nd�a ctivated�b y�t he�D NA�d amage� checkpoint,�pr omoting�ubi quitylation�

[11].�T he�f irst�i n�vi vo�s ubstrate�f or�s uch�ubi quitylation�e vents�ha s�be en�i dentified�a s�C tIP�

[12].��

An�i mportant�de velopment�i n�r ecent� years�ha s�b een�t he�i dentification�of �t he�l inks� between�

the�B RCA1�a nd� BRCA2�pa thways�a nd�pr oteins�i nvolved�i n�F anconi� anaemia.�S everal�

genes�c ause�F anconi�a naemia,�a nd�m ost�of �t hese�e ncode�pr oteins�t hat�a re�i nvolved�i n�a �

complex�t hat�ubi quitylates�F ANCD2�a t�K 561.�T he� FANCD1,� FANCJ�a nd� FANCN �g ene�

products�a ct�dow nstream�of �t his�s tep.� FANCD1�w as�f ound�t o�be �t he� BRCA2�g ene�[ 13].�

FANCJ�e ncodes� BRIP1,� which�i nteracts�w ith�t he� BRCT�dom ain�of �B RCA1�a nd,�of �not e,�

mutations�i n�t his�g ene�c an�a lso�c ause�b reast�c ancer�[ 3].�L astly,� FANCN �e ncodes�P ALB2,�

which�i nteracts�w ith� BRCA2,�a nd�i s�a lso�a �br east�c ancer�s usceptibility� gene�[ 14].�

What�ar e�t he�gaps ?�

There�r emain� gaps�i n�our �know ledge�of � cancer�pr edisposition�g enes,�bot h�i n�i dentifying�

genes�r esponsible� for�l ow�pe netrance�di sease�a nd�t he�i nteractions�w ith�e nvironmental�

factors.� Increasing�know ledge�of � BRCA1�a nd� BRCA2�a cts�a s�a n� exemplar�r esulting�i n�

improved�pa tient�c are.�H owever,�d eficiencies�r emain�i n�our �unde rstanding� of�how �

BRCA1�or �B RCA2�d ysfunction�c auses�br east�c ancer,�f or�e xample�i t�i s�unc lear�w hy�

BRCA1�de ficiency�i s�a ssociated�w ith�t riple-negative�( basal-like)�br east�c ancer.��W e�a lso�

need�t o�f ind�ot her�pr oteins�t hat�i nteract�w ith�B RCA1�a nd�B RCA2�a nd� elucidate�t he�pos t-

translational�m odifications�t hat�oc cur�a s� a�r esult�o f�t hese�i nteractions.�F or� example,�t he�

functional�c onsequences� of�C tIP�ubi quitylation�a nd�i ts�i mplications�f or�R AD51�

recruitment�a re�not � yet�k nown;�f urthermore,�i t�i s�l ikely�t hat�t here�a re�ot her� substrates�f or�

BRCA1/BARD1.�

Only�a � relatively�s mall�pr oportion�of �br east�c ancers�a re�c aused�b y�l oss�of � BRCA1�or �

BRCA2�f unction;�m ost�a rise�a s�a �r esult�of �s omatic�m utation�or �c hanges�i n�e xpression�of �a �

number�of �ot her� genes.�T he�l ist�of �g enes�s howing� somatic�poi nt�m utations�i n�br east�

cancers�i s�be ginning�t o�b e�i dentified�us ing� genome-wide�s equencing�a pproaches�[ 15].�

Page 11: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

10�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

Epigenetic�c hanges�s uch� as�D NA�m ethylation�a nd� histone�m odification�c an� cause�l oss�or �

gain�of � gene� expression,�a nd�ge nome-wide�s creens�f or�t hese�a re�be ing� actively�pur sued.�

More�w ork�i s�ne eded�i n� both�of �t hese�a reas.�

To�da te,�l ittle�ha s�be en�d one�t owards�c ataloguing� larger-scale� genetic�r earrangements,�

such�a s�t ranslocations,�de letions�a nd�a mplifications,�w hich�oc cur� frequently�a nd�a re�

hallmarks�of �t umour�c ells�a nd�ha ve�be en�pa rticularly�us eful�i n�t he�ha ematological�

malignancies.�T hese� changes� also�ne ed�t o�be � related�t o�t umour�s ubtype.�R eciprocal�

translocations�s eem�t o�be �c ommon;�f or�e xample,�one �t ranslocation�c auses�a bnormal�

expression�of �t he�N RG1�g ene�w hich� encodes�l igands�of �t he�e pidermal� growth�f actor�

receptor�( EGFR)�f amily�[ 16].�W ork�ha s�be gun�t o�c haracterise�a nd� catalogue�t hese�e vents�

using�hi gh-resolution�D NA�m icroarrays.� In�f uture� it�w ill�be �i mportant�t o�de vise�

approaches�t o�e xamine�s equence�l evel,�e pigenetic�a nd�l arge-scale� changes� together�a nd�

relate�t hese�t o�c linical�f eatures�t o�f orm�a �c omplete� and�i ntegrated�pi cture.�

As�c ommon,�l ow�pe netrance�a lleles� continue�t o�be �i dentified,�F uture� challenges�l ie�i n�

identifying�t he�c ausative� variants�w ithin�t he�ha plotype�bl ocks�c ontaining�t he�a ssociated�

marker�s ingle�nuc leotide� polymorphism�( SNP).�F irst,�t his�r equires�hi gh-throughput�

sequencing�c apacity�t o�d etect�a ll�c ommon�va riants�i n�ha plotype�bl ocks�s panning�t ypically�

30–150kb,�i n�a t�l east�48�pe ople.�S econd,�c ase�a nd�c ontrol�D NA�c ollections�f rom�non -

European�popul ations�a re�ne eded�t o�s eparate�a lleles�t hat�a re�c ompletely� correlated�i n�

European�popul ations.�T hird,�s ensitive�bi ological� assays�ne ed�t o�b e�de veloped�t o�

determine�t he�di fferences�i n�f unction�of �t he�pot entially�c ausative�a lleles.� It� will�be �

important�t o�e ncourage�a � high�de gree�o f�c ollaboration�be tween�r esearch� groups,�i n�

particular�b etween� epidemiology� and�ba sic�bi ology.� Furthermore,�t hese�s tudies�w ould�

benefit�f rom�s hared�r esources�i ncluding�f irst�c lass�s ample�c ollections,�s uch�a s�a �U K�

national�c ontrol�s et.�

A�pot entially�us eful�but �c urrently�unde r-developed�a pproach�i s�t o�e xamine� other�

phenotypes�l inked�w ith�br east�c ancer�t hat�a re�t hemselves�ge netically�d etermined.�T hese�

Page 12: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

11�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

include�m ammographic�d ensity,�r adiation�s ensitivity,�c ell�m igration�a nd� circulating�l evels�

of�hor mones�a nd� growth�f actors.��

What�ar e�t he�pr oblems?�

The�num bers�of �p atients�r equired�f or� gene�s earches�r equire�l arge�na tional� and�

international�c onsortia.�T he�qua lity,�qu antity�a nd� form�of �t he�c linical�m aterial�( blood�

derivatives,�f rozen�t issue,�f ormalin�f ixed�t issues),�a nd�t he�ha ndling�or �p roducts�f rom�t hese�

present�a �s ignificant�c hallenge.�T he�i ncreasing�s ophistication�of �e quipment�a nd�t he�l evel�

of�t echnical� expertise�a re�r eflected�i n�t he�ne ed�t o�i ntegrate�t he�d ata�i n�a �m eaningful� way�

presenting�a �s ubstantial�b ioinformatics�c hallenge.� Techniques�f or�hi gh-throughput�r e-

sequencing�a re�be ing�d eveloped�but �f unding�i s�n eeded�t o�m ake�t hese� accessible.�

Thus,�t his�t ype�of �r esearch�i s�pa rticularly�r esource� intensive�a nd�r equires�a �h igh�l evel�of �

collaboration.�

�Translational� implications�

Therapies�b ased�on�de veloping�unde rstanding�o f�t he�r ole�of � BRCA1�a nd� BRCA2�i n�D NA�

repair� are� already�i n�c linical�t rials�( including�c isplatin�a nd�P ARP�i nhibitors),�a nd�

improving�our �unde rstanding�of �t he�m any� functions�of �B RCA1�a nd� BRCA2�w ill�no�doubt �

generate�f urther�t argets�f or�t herapy.� Increasing�e fforts�t o�unde rstand� genetic�e vents�s hould�

allow�us �t o:�

(i)� Classify�br east�t umours�a ccording�t o�t he�s ignalling�pa thways�t hat�a re�

disrupted�a nd�t o�pr edict�p rognosis�a nd� response�t o� therapy�

(ii)� Determine�t he� relevance� of�s omatic�e vents�t o�pr ognosis�a nd�r esponse�t o�

therapy�

(iii)� Generate�ne w,�t argeted�t herapies�b ased�on�t arget� discovery.�

Identifying� combinations�of �i nherited�va riants�t hat�pr edispose�t o�br east�c ancer�w ill�a llow�

us�t o�e stimate�r isk�be tter� in�f amilies�w ith�br east�c ancer�a nd�h elp�t o�c haracterise�de fective�

signalling�p athways.�D NA�c ollections�f rom�c ancer�pr evention�t rials�a nd� clinical�t rials�of �

radiotherapy� and�c hemotherapy�a re�und erway�t o� relate�D NA�v ariants�t o�t reatment�

response.�W hile�t he�t rial� populations�of �t he�U K,�E urope�a nd�t he� US�m ay�p rovide�

Page 13: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

12�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

complimentary�d ata,�i nternational�e xchanges�of �s uch�i nformation�s hould�e nhance�f uture�

patient�m anagement.��

Page 14: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

13�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

2.�I nitiation�o f�B reast�C ancer�( Table�2) �

To�de cipher�t he�m olecular�ba sis�of �t he�i nitiation�a nd�pr ogression�of �br east�c ancer,�i t�i s�

critical�t hat�w e�f ully�und erstand�t he�ke y� features�a nd�g enes�i nvolved�i n�nor mal�m ammary�

development.�C hanges�t o�de velopmental�pr ocesses�m ay�l ead�t o�t umour�i nitiation�a nd�t he�

influences�of � endocrine�a gents,� growth�f actors�a nd�e nvironmental�c arcinogens�on�nor mal�

and�de veloping�br east�c omponents�i s�l argely�unkn own,���

What�do�w e� know?�

Significant�pr ogress�ha s� been�m ade�i n�d etermining�t he�l ocal�f actors�t hat�c ontrol�a ll�s tages�

of�m ammary�de velopment,�l argely�t hrough�t he� generation�of �a n� extensive�a rray�o f�

transgenic�a nd�kno ckout� mouse�s trains�[ 17].� Such�a nimal�m odels�a re� complemented�b y�

classic�e mbryological� approaches�t hat�e nable�t he�t ransplantation�of �a � complete�m ammary�

gland,�du ctal�r udiments�o r,�m ore�r ecently,�s tem�c ells�i nto�c leared�f at�pa ds�[ 18-20].�T hese�

approaches�ha ve�i mparted�c onsiderable�kno wledge�a bout�a �w ide� array�of �d evelopmental�

signalling�p athways�t hat� are�now �kno wn�t o�be �d ysregulated�i n�t umours.�F or�e xample,�

amphiregulin/EGFR�s ignalling�i s�r equired�f or�t he� branching�a nd�out growth�of �t he�duc tal�

epithelial�t ree�dur ing�pub ertal�de velopment�[ 21,22],�w hile�ove r-expression�of �bot h�t he�

ligand�a nd� receptor,�a nd�t he�r elated� receptor�E rbB2,�i s�a ssociated�w ith�poor �pr ognosis�i n�

breast�c ancer�[ 23].�O ther�e xamples�i nclude�t he� IGF,�i ntegrin,�N otch,�N F-!B,�S TAT,�

TGF-� and�W nt�pa thways�[ 24-29].�

What�ar e�t he�gaps ?�

Tissue�a rchitecture�

Many�o f�t he�s ignalling�p athways�c ontrolling�nor mal�m ammary�d evelopment�ha ve�be en�

identified�a nd�t he� genetic�c ircuit�di agrams�t hat�l ink�t he�di fferent�pa thways� are�e merging�

[17].�H owever,�i t�i s�not �c lear�how �t hese�s ignals�c ause�duc tal�e longation�or � branching�a t�

the�c ellular�l evel,�or �e ven�how �t hey�m aintain�nor mal�duc tal�or �a cinar�a rchitecture.�

Although�a nalysis�ha s� focussed�on�e pithelial�c ells,�t he�s tromal,�e ndothelial�a nd�i mmune�

components�a re� also�c rucial�f or�de velopment�[ 30].�F or�e xample,�f ibroblasts�a nd�

macrophages�a re�r equired�f or�duc tal� growth�[ 31].� However,�m any�of �t he�s troma-derived�

signals�a re�poor ly�unde rstood,�a s�i s�t he�r eciprocal� communication�be tween� epithelium�

Page 15: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

14�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

and�s troma�a nd�t he�s ignalling�pa thways� controlled� by�i nteraction�of �l uminal�a nd�

myoepithelial�c ells.�

In� addition,�t he�i mportance�of �c ell�a dhesion�a nd�t he�e xtracellular�m atrix�ha s�be en�

underestimated,�a lthough�i t�i s�be coming�i ncreasingly�c lear�t hat�bot h�a dhesion�a nd�m atrix-

derived�s ignals�m odify�m any�s ignalling�pa thways� and�pr ovide�a �s patial�c heckpoint�f or�

developmental�de cisions�[ 32].� Critically,� changes�i n�c ell�a dhesion,�t hrough� matrix�

remodelling�o r�a ltered�a dhesion�r eceptors,�unde rpin�bot h�t issue�di sorganisation�i n�e arly�

breast�c ancer�a nd�pr ogression�t o�m alignancy�[ 33,34],�but �t heir�i nvolvement� in�t umour�

initiation�i s�not �w ell�unde rstood.�

Stem�c ells�

The�r ecent�de velopment�of �t echnologies�a llowing� enrichment�of �m ammary� gland�s tem�

cells�ha s�be en� a�s ignificant�s tep�f orward�[ 19,20,35].�H owever,�i t�i s�s till�not � possible�t o�

purify�t hese�c ells�t o�hom ogeneity,� and�w e�do�not �f ully�unde rstand�t heir�l ocation�w ithin�

the�duc ts�or �t he�m echanisms�i nvolved�i n�t heir�di fferentiation�i nto�l uminal�a nd�

myoepithelial�c ells�[ 36,37].�M oreover,�i t�i s�not �c ertain�w hether� cancer�s tem�c ells�a re�

derived�f rom�no rmal�s tem�c ells�or �a n�i ntermediate�pr ogenitor�c ell,�or �how � they� are�

influenced�b y�s tromal�f actors�[ 38].�I n�f act,�i t�i s�f ar� from�c lear�t hat�t umours�a re�de rived�

from�s tem/progenitor�c ells�a t�a ll,�a s�oppos ed�t o�r eprogrammed�di fferentiated�c ells,�l et�

alone�w hether�di fferences�be tween�c ancer�s tem�c ells�m ight�be �r esponsible�f or�t he�

development�of �di fferent� tumour�s ubtypes.��

Although�c onsiderable�pr ogress�ha s�be en�m ade�t owards�unde rstanding�t he� mechanisms�

controlling�e pithelial�a poptosis�i n�t he�m ammary� gland,�w e�know �l ittle�a bout�t he�

sensitivity�of �s tem/progenitor�c ells�t o�a poptosis�s ignals�[ 39,40].�C ells�of �t he�m ain�duc ts�

survive�i nvolution,�w hile�a lveoli�a nd�t erminal�duc ts�a re�l ost,�a lthough�t he�r eason�f or�t his�

difference�i s�not �c lear.�

Page 16: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

15�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

We�a lso�ha ve�l ittle�unde rstanding�of �how � early�p regnancy�a nd�f unctional�di fferentiation�

of�t he�br east�pr otects�a gainst�c ancer,� and�w hether� this�i s�r elated�t o�s tem�c ell�d ynamics�

[41].�

Consequently,�w e�ur gently�ne ed�m ore�a ppropriate�i n�vi vo�a nd�c ulture�m odels�t o�r esolve�

the�m echanisms�of �bot h� normal�br east�de velopment�a nd�t umour�i nitiation.� Furthermore,�

use�of �t hese�s ophisticated�m odels�ne eds�t o�be come�m ore�w idespread.�

What�ar e�t he�pr oblems?�

Culture�m odels�

Breast�c ancer�h as�t raditionally�be en�s tudied�b y�c ell�a nd�m olecular�bi ologists�us ing�l ong-

lived�c ell�l ines�t hat�a re�d erived�f rom�l ate�s tage�t umours�a nd�w hich�di splay�f ew�of �t he�

cellular�pr operties�of �nor mal�br east�e pithelial�c ells.� In� addition,�w e�now �a ppreciate�t hat�

breast�c ancer�i nvolves� growth�i n�t hree�di mensions�a nd�t he�c ontribution�of �v arious�br east�

cell�t ypes.�F urthermore,�t echniques�f or�s tudying�t he�i nitiation�a nd�pr ogression�of �c ancer�

are�l argely�r estricted�t o�a nalysing�t he�l uminal�e pithelium.�R ecently�t here�h as�be en�a �s hift�

from�t wo-dimensional�t o�t hree-dimensional�c ulture�m odels,�w hich�be tter� reflect�t he�t issue�

environment�f ound�i n�vi vo�[ 42,43].�H owever,�m ost�of �t hese�m odels�s till�c ontain�onl y�

luminal�e pithelial�c ells.� In�t he�f uture,�c ulture�m odels�c ontaining� all�m ammary�c ell�t ypes,�

as�w ell�a s�t hose�a menable�t o�e xamining�duc tal�br anching,�m odelling�t he�s tem�c ell�ni che,�

and�e ven� assessing� whether�a n�i solated� cell�i s�a �s tem�c ell,�w ill�pr ovide�f ertile�a venues� for�

analysis�[ 44].��

Excellent�i maging�t echnologies�a re�e merging�t o�e xplore�t he�d ynamic�na ture� of�m ammary�

gland�d evelopment�a nd�n eoplasia�bot h�i n�c ulture�a nd�i n�vi vo;�a pplying�t hem�t o�hum an�

cancer�c ells�a nd�e nsuring�t heir�w idespread�us e�w ill�be �of �e normous�va lue�[ 45,46].�

Genetic�a nalyses�

Expression�of �t ransgenes�or �ge ne�a blation�s pecific�t o�t he�m ammary� gland�i s�us ually�

achieved�b y�pl acing�t he�t ransgene�o r�C re�r ecombinase�unde r�t he�c ontrol�of � a�m ilk�g ene�

promoter�or �t he�M MTV� promoter�[ 47].�H owever,�t hese�pr omoters�a re�a ctive�onl y�i n�

Page 17: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

16�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

luminal�e pithelium�a nd,�i n�t he�c ase�o f�t he�m ilk�pr otein�g enes,�l imited�t o�a �pa rticular�

developmental�s tage.�M ore�r ecently,�t he�ke ratin�5� promoter�ha s�be en�us ed�t o�t arget�

myoepithelial�a nd�b asal�c ells�[ 48].�D espite�t his,�a �w ider�va riety�o f�pr omoters�w ould�

improve�t he�s patial�a nd/or�t emporal�c ontrol� gene�o f�e xpression.�T his�w ill�be �he lped�

considerably�b y� generating�a n� atlas�of �m ammary� gland�d evelopment.�F urther�r efining�

markers�t o�i dentify�s tem� and�pr ogenitor�c ells,�a nd� fibroblasts,�w ill�pi npoint� other�va luable�

promoters.�G reater�us e�of �i nducible�t ransgene�s ystems,�s uch�a s�t he�T et-On� system,�w ill�

allow�t ransgene� expression�t o�be �r estricted�t o�s pecific�t ime�i ntervals�[ 49].� �

Another�s ignificant�pr oblem�w ith�e xisting�pr omoters�i s�t hat�t heir�e xpression�i n�t he�

luminal�e pithelium�de pends�on�i ts�di fferentiation;�a ctivity�i s�t herefore�l ost�i f�a �t ransgene�

causes�t ransdifferentiation�or �de differentiation�w ithin�a �t umour.�T he�pr oblem�c an�be �

overcome�t hrough�t he�de velopment�of �‘ hit�a nd�r un’�t ransgenics.�T hese�i nclude�l ines�

where�t he� expression�of �a �t ransgene�i s�unde r�t he�c ontrol�of �a �hous ekeeping� gene�but �i s�

prevented�b y� a�l ox-stop-lox�c assette.�E xcision�of �t he�s top�c odon�b y�c rossing�w ith�m ice�

carrying� a� gland-specific� Cre�r ecombinase�t hen�l eads�t o�c ontinuous�a nd�c onsistent�

transgene� expression.�T hese�a nd�s imilar�s ophisticated�s trategies�w ill�a llow� the�m ore�

realistic�a ctivation�of �br east�c ancer�onc ogenes,�a nd�w ill�pr ovide�be tter�opp ortunities�t o�

understand�how �t hey� cause�di sease�w ithin�t he�c orrect�t issue�e nvironment.� It�w ould�a lso�be �

valuable�t o�pr oduce�a �s eries�of �t ransgenic� reporter� gene�m ice� equivalent�t o�t he�T OPGAL�

strain,�t o�m onitor�c hanges�i n�de velopmental�s ignalling�pa thways�[ 50].�

There�w ill�a lso�be � great�b enefit�i n�ge nerating�be tter�m ouse�m odels�of �s pecific�t ypes�o f�

human�br east�c ancer,�r anging�f rom�t riple�n egative� breast�c ancer�( oestrogen� receptor�

negative,�pr ogesterone� receptor�ne gative�a nd�H ER2�ne gative)�t o�oe strogen�r eceptor�

positive�t umours.�S imilarly,�s traightforward�p rotocols�f or�i mplanting�a nd� growing�

primary�hum an�c ancer� cells�i n�t he�c leared�m ammary� fat�pa d�of �i mmunocompromised�

mice�a re� required.�S ignificant�pr ogress�ha s�be en�m ade�i n� generating�s uch�hu manised�

models,�but �i t�i s�s till�not � possible�t o�i mplant�i ndividual�c ells�[ 51]. � �

Page 18: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

17�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

Translational� implications�

Continuing�t o�s tudy�nor mal�br east�de velopment�w ill�pr ovide�m any�us eful�i nsights�i nto�t he�

earliest�s tages�of �b reast�c ancer�i nitiation.�T umour� development�de pends�on� signals�

between�t he�s troma,�m yoepithelial�c ells�a nd�l uminal�c ells,�a nd�t herefore� gaining�a �b etter�

understanding�of �how �t hese�c ells�c ommunicate�i n� normal�m ammary� gland� and�e arly�

breast�di sease�w ill�pr ovide�ne w�oppor tunities�f or�i ntervention.��

In� addition,�w e�know �l ittle�a bout�t he� genetic�c hanges�t hat�oc cur�i n� atypias,�l obular�or �

ductal�c arcinoma�i n�s itu�( DCIS)� [52],�a lthough�t hey� are�m ost�l ikely�t o�b e�w ithin�

components�of �t he�s ignalling�pa thways�t hat� control�nor mal�de velopment.�P roducing�

timelines�of �t hese�m utations�f or�di fferent�br east�c ancer�s ubtypes,�s imilar�t o�t hose�

generated�f or� colon�c ancer�[ 53],�w ould�be �a �m ajor�s tep�f orward.�M olecular� profiling�of �

breast�c ancers�ha s�be gun� to�c lassify�t umours�[ 54],�a nd�r elating�t hem�t o�t he� TNM�

classification�w ill�be �c linically�v aluable�f or�bi omarker�a nalysis� and�t herapy.�D ifferences�

between�pr ofiles�m ay�r epresent�a lterations�i n�s pecific�s ignalling�pa thways,�s o�m apping�

this�i nformation�ont o�a �t imeline�of �w hen�m utations�oc cur�i n�br east�c ancer� will�e nable�

clinicians�t o�t ailor�s pecific�t reatments�t o�i ndividuals.�

Page 19: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

18�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

3.�P rogression�of �B reast�C ancer�( Table�3) �

Intracellular�i nputs�

What�do�w e� know?� �

The�oe strogen� receptor,�r eceptor�t yrosine�ki nase�( RTK)�a nd�D NA� repair�pa thways� are�

key� research� areas�t o�und erstand�t he�i ntracellular�i nputs�f or�gr owth�a nd�pr ogression�of �

invasive�br east�c ancer.�.� �

It�i s�now �e stablished�t hat�s teroid�hor mone/�oe strogen�r eceptor�a lpha�( ERa)� input,�a �

fundamental�dr iver�f or�t he�gr owth�of �m any�b reast� cancers,�s hould�not �be �c onsidered�

independent�of �a dditional�s ignalling�n etworks.�T his�nuc lear�E Ra�m ay�i nterplay�w ith�E Rb �

and�t here�i s�e merging�e vidence�t hat�m embrane-localised�E Ra�m ay� also�ha ve�a �r ole.�A �

web�of �R TK�s ignalling� also�c ontributes�t o�br east�c ancer� growth�a nd�p rogression,�a nd�

these�pa thways� can�i nteract�w ith�E R�w hen�pr esent�[ 55-57].� Previous�e xperimental�

deciphering�of �E R� and�R TK�pa thways�ha s�p rovided�pr oof�of �p rincipal�t hat�us eful�

biomarkers�a nd�t herapies�( for�e xample�e ndocrine�t herapies,� erbB�a nd�ki nase�i nhibitors)�

can�s tem�f rom�c oncerted� research�i n�br east�c ancer� growth�s ignalling�bi ology�[ 58].��

DNA�da mage�r esponse�( DDR)�pa thways� and�m echanisms�f or�m itotic�c hromosome�

segregation�a re�a lso�of �i nterest�w hen� considering� breast�c ancer� growth,�pr ogression�a nd�

selectivity.�T hey�c an�b e�s ubject�t o�ge netic�a lteration,�a ssociating� with�t umorigenesis�f or�

inherited�( for� example�B RCA�pr oteins)�a nd�f or�s poradic�( for�e xample�A urora�A :�30–60% �

overexpression)�br east�c ancer�be cause�t hey�c ause� genetic�i nstability�t hat�m ay�p ermit�

secondary� alteration,�a ccelerating�t he�de velopment�of �c ancer.�E qually,�t here�a re�m ajor�

implications�f or�t herapeutic�e fficacy,�f or�e xample�f or�pol y� (ADP-ribose)�po lymerase�

inhibitors�a nd�B RCA�m utations,�a nd�a lso�r esistance�t o�t axanes�w hen�A urora�A �i s�

amplified�[ 59].��

What�ar e�t he�gaps ?�

Research�i nto�E R�a nd�R TK�s ignalling�i s�i ntense.�F urther�de ciphering�t he�c omplexities�of �

breast�c ancer�s ignal�t ransduction�pa thways,�t heir�r egulation�a nd�i nterplay,�i ncluding�

Page 20: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

19�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

elucidating�do wnstream� gene�e ffects�i s�i mportant,�not �l east�be cause�t herapeutic�r esistance�

is�a �pe rsistent�pr oblem�f or�a ll�t herapies�t argeting�k nown�pa thways.��

There� are� also�l imitations�i n�our �a bility�t o�s ubsequently�e valuate�R TK� and� ER�s ignalling�

aspects�e merging� from�e xperimental�s tudies�i n�c linical�di sease� and�t o�r apidly�t ranslate�

findings�i nto�c linically�us eful�bi omarkers� and�t argets�f or�ne w�d rug�de velopment.� �

Furthermore,�t he�br eadth� of�D DR�a nd�m itotic�r egulator�a lterations�unde rlying�t he�

pathogenesis�of �br east�c ancer�a nd�i ts�s ubtypes,�or �t he�poi nt�a t�w hich�D DR�a lterations�

might�c ontribute�t o�di sease�pr ogression�i s�unknow n.�

��

Extracellular�i nputs�

What�do�w e� know?�

Local�pa racrine�pa thways,�( for�e xample�t hose�i nvolving�T GF!s),�c ell�i nvasion�i nto�t he�

extracellular�m atrix�a nd�a ngiogenesis�a ll�c ontribute�t o�c ancer� growth� and� metastasis.�

Selective�i nhibitors�of �a nti-Src�a nd�a nti-HGF/Met,�f or�s ome�of �t he�i dentified�pa thways�

involved�i n�m etastasis�a nd�i nhibition�of �a ngiogenesis��( for�e xample�b y�t argeting�va scular�

endothelial�gr owth�f actor�s ignalling)�a re�a lready�i n�c linical�pr actice�[ 60].��

What�ar e�t he�gaps ?�

Substantial�que stions�r emain�a bout�t he�bi ology�o f�a ngiogenesis�a nd�m etastasis.�W hile�

studies�of �a ggressive�b reast�c ancer�c ells�i n�vi tro�ha ve�a llowed�s ignificant�p rogress�i n�

understanding�a dhesion�a nd�m igration�t hrough�m atrix,�m atrix�de gradation�( including�

mechanisms�of �m atrix�m etalloproteinases)� and�i n� vitro�i nvasiveness,�s ubsequent�

translational�a pplications�ha ve�pr oved�l imited.� �

We�ha ve� yet�t o�f ully� explore�t he�br eadth�of �pot ential�pos itive�a nd�ne gative�r egulators�of �

invasion�a nd�m etastasis,�t heir�m echanisms�a nd�i nterplay,� and�t he�r ole�of �t he� interaction�of �

tumour�c ells�w ith�t he�s tromal�m icroenvironment�a nd�i mmune�s ystem�dur ing�m etastasis.�

The�pr opensity�f or� cancer�t o�m etastasise,�a pparently�s electively,�t o� certain� end�or gans�i s�

poorly�und erstood.��W hether�hum an�br east�c ancers�c ontain�i nherently�m igratory�s tem�

Page 21: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

20�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

cells�or �w hether�m etastatic�c apacity�i s�a cquired,� and�a lso�t ime-dependent�p rogression�

events,�not ably�do rmancy� and� reactivation�of �m icrometastasis�a t�pa rticular�s econdary�

sites,�r emain�poor ly�de fined.��

Equally,�l ittle�i s�know n�a bout�t he�e merging�r elationship�be tween�r esistance� to�

conventional�t herapies�( for�e xample�e ndocrine�t herapies)�a nd�m etastasis�[ 61],�or �t he�

degree�o f�r edundancy�o f� invasive�e lements�or �a ngiogenic�pa thways�t hat�m ay� contribute�t o�

therapeutic� resistance�t o� anti-invasive�a nd�a nti-angiogenic� approaches.�

Ductal�c arcinoma� in�s itu�an d�v ery�e arly�pr ogression�i n�br east�c ancer�

What�do�w e� know?��

Around�50% �of �D CIS�w ill�pr ogress�t o�i nvasive�di sease�i f�unt reated,�w ith�12 –20%�

recurring�l ocally�a t�10� years�de spite�br east�c onserving�s urgery�a nd�r adiotherapy.� Links�

have�be en�s uggested�be tween�e arly�pr ogression�a nd�m echanistic�a lterations�bot h�w ithin�

the�e pithelial�c ells�a nd�i n�t he�i nterplay�w ith�a ssociated�ba sement�m embrane,�

myoepithelial�a nd�s tromal�c ells,�a nd�m echanical�c onstraints�[ 62,63].�H ER2�pos itivity�a nd�

HER4�ne gativity,�a nd�hi gh�l evels�of �c yclo-oxygenase-2�( COX-2)�m ay�h ave�s ome�

relevance�t o�i nvasive�r ecurrence�[ 64].�

What�ar e�t he�gaps ?��

There�i s�s till�a �s ubstantial�g ap�i n�ou r�know ledge�o f�t he�c ausative� factors�und erlying�

progression�of �D CIS�t o�i nvasive�di sease� and,�i n�ge neral,�t here� are�no� compelling�

biomarkers�t hat�c an�r obustly�p redict�i nvasive� recurrence.�W e�a lso�l ack�bi omarkers�t hat�

can�s elect�f or�pa tients�w ho�m ight�be nefit�f rom�e xisting�t herapies,�s ince�E R�a nd�H ER2�

(and�E GFR)�s tatus�a re�no t�r outinely�m easured�i n�D CIS�out �w ith�c linical�t rials�a nd�s o�

treatment�i s�c urrently�b ased�on�m orphological�a ssessment.�E qually,�t here�a re�f ew�t argets�

in�D CIS�t o�s ubvert�pr ogression�ot her�t han�E R�f or� ER�pos itive�D CIS,�w ith�E R-negative�

DCIS�t hus�be ing�pa rticularly�p roblematic.�

Issues�r egarding�t he�ve ry�e arly�pr ogression�of �br east�c ancer�r eflect�t hose�f or�i nvasive�

breast�c ancer.�T here�a re�s ubstantial�g aps�i n�our � ability�t o�p erform�bi ological�i nvestigation�

Page 22: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

21�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

of�t he�i ntracellular�a nd�e xtracellular�f actors� (notably�i nterplay�b etween�s troma,�

myoepithelial�a nd� epithelial�c omponents)�unde rlying� growth�a nd�pr ogression�of �D CIS,�t o�

dynamically�m onitor�e arly� progression,�a nd�t o�s ubsequently�m anipulate�i mplicated�

pathways�t o�a ddress�t heir�t herapeutic�pot ential.�

What�ar e�t he�pr oblems?� �

Improved�pr eclinical�m odels�

We�ne ed�t o�de velop�be tter�pr eclinical�m odels�i n�or der�t o�r eveal�m ore� accurately�t he�

mechanisms�i nvolved�i n�g rowth�a nd�pr ogression�of �br east�c ancer�a nd�t o� evaluate�

potential�t argets.�T his�i s�pa rticularly�i mportant�w hen�t rying�t o�i nterpret�t he� mechanisms�

of�m etastasis�be cause�di ssemination�c ommonly�oc curs�a t�i naccessible�s ites,�m aking�

clinical�r esearch�m aterial�e xtremely�di fficult�t o�ob tain.�H owever,�i t�i s�e qually�r elevant�i f�

we�a re�t o�bui ld�on�f indings�m ade� using�i n�vi tro�m onolayer�c ulture�s tudies�f or�gr owth�

signalling�m echanisms.��

Models�a re�ne eded�t o�a llow�r esearchers�t o�i nvestigate�m ore�a ccurately�t he� influence�of �

microenvironment,�t he�i mpact�of �t he�i mmune�s ystem�a nd�s ite-specific�m etastasis,�a nd�

time-dependent�pr ogression�i ncluding�t he�phe nomenon�of �dor mancy.� In�vi vo�m odels�w ill�

be�e ssential�t o�s tudy�t hese�a reas,�a nd�r esearchers� may� also�be nefit�f rom�i n�vi tro�t hree-

dimensional�a ssays� encompassing�s tromal�c omponents,�m atrix�a nd�t umour�e pithelial�c ells�

[65],�a s�w ell�a s�s tudies�o ver�e xtended�c ulture�t ime�i n�vi tro�a nd�a ssociated�a nimal�m odels.��

Increased�us e�o f� genetically�m odified�a nimal�m odels�w ill�be �va luable,�a s�w ill�g enetic�

manipulation�of �i ndividual�t argets�( for�e xample�us ing�R NAi)�a lone�or �i n�c ombination�

with�e xisting�a gents�i n�m odel�s ystems�t o�a ddress�h ow�m echanisms�of � growth�a nd�s pread�

might�be �e xploited�t o�pr ovide�ne w�t argeted�t herapies.�S tudies�of �ve ry�e arly� progression�

will�a lso�r equire�i mproved�m odels,�not ably�us e�of � in�vi tro�c ultures�of �pr imary�o r�

mammosphere�D CIS�( again�e xtending�t o�l onger-term�c ulture),� and�of �hum an�D CIS�

xenograft� and�t ransgenic� (for�e xample�M MTV/HER2)�m odels.��

Page 23: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

22�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

Alongside�t argeting�i ndividual�c andidate�e lements,�m ore�s peculative� approaches�a re�

warranted�t o�br oadly�s creen�f or�s ynthetic�l ethality,�f or�e xample�us ing�R NAi�l ibraries.�W e�

will�a lso�ne ed�t o�e mbrace�f ully�i n�vi vo�i maging�t echnologies�t o�de cipher�t he�d ynamics�o f�

metastasis�( and�e qually�o f�ve ry�e arly�pr ogression)� at�a �c ellular�l evel�a nd�r elate�t his�t o�

signalling�m echanisms�( for�e xample�us ing�i n�vi vo�f luorescent� reporter�a ssays).��

Powerful�r eal-time�i maging�s tudies�i n�a nimal�m odels�a re� emerging�w hich�i ndicate�t hat�

the�m otile�phe notype�m ay� be�t ransient�a nd� confined�t o�a �s ubpopulation�of � cells�a t�t he�

tumour�pe riphery�i n�di sease�m etastasising�i n�vi vo�S uch�he terogeneity�i s�not �e asily�

modelled�w ith�i n�vi tro�s tudies.�T hese�obs ervations�i llustrate�t he�pow er�of �i maging�

systems�f or�d eciphering� breast�c ancer�bi ology,�w here�t he�d ata�ha ve�i mplications�f or�

interpreting�w hole�t umour�m icroarray/proteomic�p rofiles�a nd�c learly�c onfirm�t hat�t ime-

dependent�s tudy�of �m etastasis�a t�a �c ellular�l evel�i s�e ssential.��

Appropriate� clinical�s amples�

Appropriate� clinical�s amples�a re�n eeded�t o�t ranslate�e xperimental�f indings� into�us eful�

predictive�bi omarkers,�a nd�t o�c onfirm�t hat�t herapeutic�s trategies�s temming� from�ba sic�

research�a re�r elevant�i n�p atients.�M eaningful�s tudy�w ill�r equire,�w here�pos sible,�i mproved�

access�t o�c linical�m aterial�w ith�pa rallel�t herapeutic�r esponse� and�s urvival�d ata,�

encompassing�t issue�m icroarray�( TMA)�a nd�f ull-section�r esources.�S tudies�w ill�be nefit�

from�i mproved�a ccess�t o� clinical�s amples�of �pr imary,�l ocal�r ecurrent,�l ymph�node �a nd�

distant�m etastatic�( where�a ccessible)�br east�c ancer,�i deally� comparing�m atched�s amples�

from�pa tients�t o�t rack�pot ential�bi omarkers�of �p rogression.�S tudies�of �ve ry�e arly�

progression�w ill�a lso�ne ed�i ncreased�a ccess�t o�c linical�D CIS�m aterial�t o�ve rify�t he�

relevance�of � experimental�a ssociations�w ith�i nvasive�r ecurrence,� considering� gene�

expression�s ignatures�bot h�f or�D CIS� and�i nvasive� disease,�pr eferably�f rom�t he�s ame�

patient.��

It�i s�a lso�i mportant�t hat�r esearchers�obt ain�m aterial�f rom�s equential�s amples�( with�pa rallel�

outcome�da ta),�t aken�be fore�a nd�dur ing�t reatment� with�c onventional�t herapies,�a nd�f rom�

biologically�di rected�i nnovative�t rials�of �t argeted� therapies.�C linical�t rial�d esign�s hould�

Page 24: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

23�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

increasingly�i ncorporate�i mproved�t issue�c ollection�a nd�pa thology�s upport�( which�ha s�

often�be en� considered� as� an�a fterthought).� Experience�i ndicates�t hat�n eoadjuvant�s tudies�

and,�w here�pos sible,�a ccess�t o�pa tient�s amples�t reated�l onger�t erm�w ill�be �p articularly�

valuable.��

Studying�s amples�obt ained�dur ing�t reatment�w ith� anti-invasive�a gents�( or,�i ndeed,�a ny�

new�a gents)� will�a llow�r esearchers�t o�e valuate�t he� ability�of �bi omarkers�a nd�c ellular�

endpoints�s temming�f rom�e xperimental�s tudies�t o�pr ovide�s urrogates�f or� drug� response,�

an�i mportant�a im�i n�t he�a bsence�of �l ong-term�out come�da ta.�T his�c ould�be � achieved�b y�

examining�c irculating�t umour�c ells�a nd�s ampling� lymph�node s�dur ing�t reatment.� In�

addition,�e valuation�of �a nti-invasive�a gents�c ould� benefit�s ignificantly�f rom�

improvements�i n�t umour�t issue�i maging�of �f unctional�r eporters.�

These�ne eds�f or�c linical�t issue�c learly�r epresent�a �s ignificant� challenge,�p articularly� given�

that�r esearch�m ust�c omply� with�t he�e thical�a nd�l egal�c onsiderations.�T o�be � achievable,�

patient�r ecruitment�t o�t rials�m ust�be �i mproved�a nd,�c ollection�a nd�s haring�of �t issue�

resources�c oordinated.�F or�D CIS�s tudies,�s equential�c linical�s amples�t aken� pre-

operatively�dur ing�t reatment�w ith�c urrently�a vailable�a gents�( endocrine�t herapies,�e rbB�o r�

COX-2�i nhibitors)�or �w ith�e merging�ne w�t herapies,�a re�ne eded�t o�c onfirm� mechanisms�

and�pr edictive� capacity,� and�s o�e nhanced�t rial�de sign�a nd�b etter�r ecruitment�of �D CIS�

patients�i s�a lso�e ssential.�

Consideration�of �ge ne�pr ofiles�

Greater�a ttention�ne eds�t o�be �g iven�t o�ge ne�pr ofiles�a nd�t he�i mpact�of � genetic�l esions�i n�

malignant�e pithelial�c ells�a nd�i n�t he�s tromal�ba ckground�i n�c linical�t rial�de sign�a nd�du ring�

selection�of �pa tients�f or�t herapy.�E xpression�pr ofiling�a t�t he�m RNA�a nd�p rotein�l evel�ha s�

revealed�s everal�s ubtypes�of �br east�c ancer,�a nd�i t�i s�i mportant�t hat�i ntracellular�a nd�

extracellular�pr ocesses�of �g rowth�a nd�pr ogression�a re�f urther� explored�i n�r elation�t o�t hese,�

both�t hrough�m odels�t hat�a im�t o�r ecapitulate� each� class�a nd�t hrough�r epresentative�

clinical�m aterial.��

Page 25: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

24�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

The�non- tumour�c ontent� of�bi opsies�s hould�a lso�be �c onsidered�s ince�e vidence�i s�e merging�

to�s uggest�t hat�t his�ha s�a � significant� effect�on� gene�e xpression�pr ofiles�[ 66].�E qually,�

several�s tudies�i ndicate�t he�i mportance�o f�c onsidering�s pecific�l esions�i n�r elation�t o�

therapeutic� response�f or� example�A urora�ki nase�o verexpression�a nd�t axane�r esistance,�

BRCA2�l oss�a nd�r esponse�t o�pl atinum-based�t herapy�[ 67],�t opoisomerase� II�a lpha�

amplification�a nd�e pirubicin�r esponse�[ 68].�C onsidering�t hese�pa rameters�m ay�not �onl y�

improve�pa tient�s tratification�f or�m ore�e ffective�t rial�de sign,�but �m ay� also�a llow�s maller�

patient�c ohorts�t o�be �s tudied,�i f�t hese�a re�s elected�r ationally�f or�t herapy� according�t o�t he�

status�of �t he�dr ug�t arget�o r�m olecular�l esion.�

Improved�r esearch�r eagents�

Better� research� reagents� are�ne eded�t o�c ontinue�t o�a ccurately�de fine�ne w�p athways�i n�

experimental�m aterial�a nd�t o�s tudy�c linical�s amples�t o�ve rify�t hese�pa thways�a s�

biomarkers�i n�r elation�t o�pa thology�a nd�out come.�

Signalling�m echanisms�i n�c linical�s amples�c an�b e�de tected�us ing�i mmunohistochemistry,�

including�t he�us e�o f�phos pho-specific� antibodies�[ 69,70].�H owever,�i f�a ssociations�a re�t o�

be�a ccurate� and�m eaningful,�t his�ur gently�r equires�a ssays�t hat�ha ve� a�r eproducible,�

sensitive�a nd�s pecific�p erformance�i n�s uch�m aterial,�i ncorporating�i mproved�qua lity�

control�a s�ha s�be en�a chieved�f or�E Ra�a nd� HER2�a ssays�[ 71-73].�T echnologies�s uch�a s�

fluorescence� resonance�e nergy�t ransfer�( FRET)�h ave�t he�pot ential�t o�m easure�i nterplay�

between� elements�( for�e xample�r eceptor�di merisation)�i n�s uch�m aterial.�H owever,�i n�a ll�

instances�t hese�m ethodologies�w ill�r equire�c onsensus�r egarding�e valuation� which��s hould�

also�a im�f or�qua ntitative� analysis,� for�e xample�t hrough�i mage� analysis.�M ore�a ccurate�

quantification�m ay�pot entially�i ncorporate�l uminescent�qua ntum�dot s�a s�a n�a lternative�

approach�t o�vi sualise�t umour�m arkers.��

Research�t o� reveal�ne w�b iomarkers�a nd�d rug�t argets�i n�e xperimental�a nd�c linical�m aterial�

will�a lso�i ncreasingly�n eed�t o�i ncorporate�hi gh-throughput� gene�pr ofiling�w ith�

microarrays�a nd�T MA�v alidation,�a s�w ell�a s�pr oteomics.� In�t hese�l atter� areas,�qua lity�

control�ur gently�ne eds�t o� be�a ddressed�a nd�bi oinformatic�c apabilities�m ust� be�

Page 26: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

25�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

significantly�e nhanced�o n�a �na tional�l evel�i f�w e�a re�t o�m anage� and�m eaningfully�i nterpret�

the�i ncreasing�vol ume�of � signalling�d ata�t hat�w ill�e merge�i n�r elation�t o�c ellular�e ndpoints�

and�c linical�out come.��

Research�i nfrastructure�

Overcoming�t hese�v arious�ba rriers�h as�obvi ous�i mplications�f or�r esearch�i nfrastructure.�

Studies�w ill�ne ed�t o�be �i ncreasingly�m ultidisciplinary�i f�w e� are�t o�i dentify� relevant�

determinants�of �br east�c ancer� growth�a nd�pr ogression;�f or�e xample�r equiring�i ntegration�

of�m ultiple�e xpression/signalling�s tudies,�bi oinformatics,�i maging�t echnologies,�i mproved�

in�vi tro�a nd�i n�vi vo�m odels,�g enetic�m anipulation�a nd�c linical�e xamination.�T his�w ill�

depend�on�a �b ackbone�o f�r ealistic�s upportive�f unding,�not �onl y�t o�m aintain� core�s trategies�

and�a ssociated�qu ality� control,�but �t o�e nsure�a ccess�t o�ne w�t echnologies�t o� pursue�

innovative�r esearch� avenues�( for� example�i n�vi vo � imaging,� genetically� engineered�m odels�

and�hi gh-throughput�ge nomic�s creening).��

A�c ritical�m ass�of � expert�s taffing�i s� essential,�i ncluding�e xpanding�t he�br east�c ancer�

research�t alent�pool �t hrough�i mproved� research�t raining�a nd�m ore� clearly�s tructured�

career�d evelopment.�T he� need�f or� carefully�c ollected�a nd�doc umented�c linical�t issue�w ith�

serial�bi opsies�t aken�dur ing�t herapy�w ith�de fined�t reatments,�T MAs,�s amples�f rom�di stant�

sites�a nd�l ocal�r ecurrences�m ade�a vailable�t o�i nvestigators�i s�ke y.�R ecent�l egislative�

changes�ha ve�m ade�t his� more�di fficult�a nd�bot h�s urgical�a nd�pa thology�s upport�a re�

needed� at�s enior�l evel.� Both�s pecialities�ha ve�s uffered�s evere� cutbacks;� collaborative�

contributions�b y�a cademics�i n�t hese�a reas�a re�i mportant�a nd�de serve�f unding,�i n�a ddition�

to�s upporting�t he�hi ghest� quality�pe er�r eviewed�i ndependent�r esearch.��

Pathology�t raining�w ill�be �i ncreasingly�i mportant� as�w e�e xpand�our �t echnical�c apabilities�

for�i nvestigating� clinical� material.�S tandardisation�of �a ntibodies�a nd�ot her� reagents�i s�

needed�t o�c ompare� results�be tween�i nvestigators.� Research� would�a lso�be nefit�f rom�

increased�s haring�of � experimental�a nd�c linical�r esources.� Finally,�i ncreased� investigator-

driven � studies�a nd�c ollaboration�w ith�i ndustry�w ill�be �e ssential�i f�w e� are�t o�i mprove�

Page 27: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

26�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

patient�r ecruitment�f or�c linical�s tudies�a imed�a t�unde rstanding�bi ological�f actors�dr iving�

selective�r esponse.��

Translational� implications� �

If�r esearch�c an�b e�t ailored�t o�t he�di verse�que stions�a bout�t he�i ntracellular� and�

extracellular�pr ocesses�u nderlying�b reast�c ancer� growth�a nd�pr ogression,�t his�s hould�l ink�

tumour�m echanisms�t o�di sease�c lassification�a nd�p rognosis.��

To�s ome�e xtent�t his�pr ocess�i s�unde rway�t hrough� microarray�s tudies,�w hich�ha ve�l ed�t o�

the�c lassification�of �i nvasive�br east�c ancer�i nto�f our�c ategories� –�l uminal,�ba sal,�

HER2/neu�ove r-expressing�a nd�no rmal�[ 74]�–�a nd�t he�de velopment�of �va rious�g ene�

expression�s ignatures�t hat�c an�pr edict�out come.�H owever,� we�ne ed�t o�bui ld�on�t hese�

studies;�f irst,�s o�w e�c an�i dentify� earlier�pa tients�a t� increased�r isk�of �di ssemination�a nd�

therefore�a llow�s election� for�a nti-invasive�t herapy� and,�s econd,�t o�pr ovide� robust�

biomarkers�t o�e ffectively�pr edict�t herapeutic�r esponse�w ith�g rowth�i nhibitors.�F illing�t he�

gaps�out lined�f or�ve ry� early�pr ogression�m ay�i mprove�s election�of �p atients�w ith�D CIS�f or�

adjuvant�r adiotherapy�or � endocrine�t herapies,�w hile�a voiding�unn ecessary�t reatment�i n�

others.��

Equally,�i t�i s�l ikely�t hat� we�w ill�r eveal�c ellular�t argets�f or�de veloping�ne w� agents�t o�t arget�

breast�c ancer�pr ogression�e ffectively�a nd�s electively�( as� well�a s�be ing�a ble�t o�m easure�t he�

target�pa thways�d ynamically�dur ing�t herapy�t o�m onitor�c linical�e fficacy�of � novel�

inhibitors�a nd�i mprove�t rial�de sign).�T ogether,�s uccessful�r esearch�s hould�a llow�t herapy�

to�be �i ncreasingly�i ndividualised�a nd�i nclude�c ombination�s trategies�a iming� to�m aximally�

subvert�t umour�r esistance�a nd�di sease�pr ogression,�i mproving�t he�out look�f or�pa tients.� �

Page 28: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

27�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

4.�T herapies�an d�T argets�i n�B reast�C ancer� (Table�4) �

Treatment�of �b reast�c ancer�ha s�i mproved�ov er�t he� past�de cades,�a nd�ha s�l ed�t o�a n�

increased�s urvival�r ate�f or�pa tients�w ith�t umours�c onfined�t o�t he�br east.�T his�i s�pa rtly�due �

to�br east�s creening�r esulting�i n�e arly�di agnosis�but �a lso�t he�a ppropriate�s election�f or�

patients�of �t he�s urgical� approach,�r adiotherapy,� chemotherapy�r egimen�a nd� more�r ecent�

therapies.��

What�do�w e� know?�

The�i ntroduction�of �ne w�t herapeutic�s trategies� –�i ncluding�ne wer� adjuvant�e ndocrine�

treatments,�r adiotherapy� scheduling,� chemotherapy� combinations�a nd�nov el�a gents�s uch�

as�t rastuzumab�–�ha s�c ontributed�t o�t he�i ncrease�i n�di sease-free� and,�i n�s ome�c ases,�

overall�s urvival.�H owever,�br east�c ancer�r ecurs,�s ometimes�m any� years�a fter�di agnosis,�

and�t he�t reatment�o f�m etastatic�di sease�r emains�pa lliative.�T hus,�not �a ll�t herapies�us ed�a re�

effective�a nd� a�pr oportion�of �pa tients�( perhaps�a � majority�f or�s ome�t herapies)� get�one �or �

more�t reatments�w hich� either�a re�not �r equired�or �f ail�t o�s tem�t he�di sease.�

Selection�of �m ultimodality� therapy�f or� an�i ndividual�pa tient�b y� a�m ultidisciplinary�t eam�i s�

based�on�t he�e xtensive�e vidence�ba se�f or�i ndividual�a nd�c ombination�t herapies�

summarised�e lsewhere.�

What�ar e�t he�gaps ?�

Incomplete�unde rstanding�of �t he�bi ology�of �b reast�c ancer� �

Our�unde rstanding�of �t he�m any� cellular�a nd�m olecular�pr ocesses�i nvolved�i n�t he�

development�of �br east�c ancer�i s�s till�i ncomplete.�T his�ha mpers�t he�i dentification�of �ne w�

therapeutic�t argets�a s�w ell�a s�t he�opt imal�us e�of �t he�t argets�w e�know �a bout.� We�ha ve�

limited�know ledge�of � which�s ignals�dr ive�b reast�c ancer� cell� growth,� and�ho w�t hey�

promote�t he�i nvasive�na ture�of �t he�di sease.� In� addition,�t he�r ole�of �t he�s urrounding�

healthy�t issues�i n�t umour�de velopment,�bot h�a t�t he�pr imary�a nd�m etastatic�s ites,�ne eds�t o�

be�c larified.��

Page 29: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

28�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

Current�t hinking�i s�t hat�t o�e radicate�c ancer�c ells� we�m ay�ne ed�a �c ombination�of �t herapies�

targeting�t he�t umour�c ells,�t heir�m icroenvironment�a nd,�pot entially,�t heir�bl ood�s upply.� �

We�c annot�de termine�w ho�g oes�on�t o�d evelop�a dvanced�di sease�

Despite�our �be st�e fforts�a �pr oportion�of �pa tients�w ill�de velop�a dvanced�di sease,�a nd�w e�do�

not�c urrently�ha ve�r eliable�t ools�t o�pr edict�w ho�t hese�pa tients�a re.� By�us ing� tumour�g rade,�

pathological�node �s tatus,� tumour�s ize�a nd�ot her�pa thology�f eatures,� a�num ber�of �m odels�

have�be en�de signed�t o�a ssess�t he�r isk�of �pa tients�d eveloping�m etastatic�di sease�i ncluding�

the�N ottingham�P rognostic� Index�a nd�A djuvant�O nline.�H owever,�t here� are�no�

established�m olecular�m arkers�us ed�i n�c linical�pr actice�t o�de termine� with�c ertainty�

whether�a �b reast�t umour�i s�l ikely�t o�m etastasise�t o� other�s ites,�a nd�t herefore� no�e asy�w ay�

of�s electing�pa tients�a t�e arly�s tages�of �t he�di sease� who�w ill�r equire�m ore�i ntensive�

treatment�t o�pr event�t umour�pr ogression.��

In� addition,�t here�a re�no�s imple,�non- invasive�m ethods�a vailable�f or�d etecting�t he� early�

stages�o f�t umour�pr ogression,�a nd�pa tients�of ten�p resent�w ith�r elatively� advanced�

(symptomatic)�di sease.��

Insufficient�know ledge�t o�pr ovide�pr ecise,�i ndividualised�t herapies�

One�of �t he�m ain�pr oblems�w hen�t reating�br east�c ancer�i s�t o�de termine� which�pa tients�w ill�

benefit�f rom�pa rticular�t herapeutic�s trategies,�e nsuring�opt imal�r esults�f or� each�i ndividual�

patient.�N ot�onl y�i s�t his�ke y�t o� achieving�t he�b est�pos sible�out come�f or�pa tients�w ho�a re�

likely�t o�r espond�t o�a ny� given�t reatment,�but �a lso�t o�a void�t reating�t hose�w ho�w ill�not �

benefit.��

A�f ew�t argeted�t reatments�a re�a vailable�( for�e xample�e ndocrine�t reatments� and�

trastuzumab)�t hat�r ely�on �i dentifying�a � receptor�pr esent�on�t he�t umour�c ells.�

Understanding�t he�bi ology� of�b reast�c ancer�be tter�i s�l ikely�t o�he lp�us �de velop�ne w�a nti-

cancer�a gents�t hat�e ffectively�t arget�s pecific�r eceptors�pr esent�i n�onl y� a�s ubset�of �pa tients.��

Page 30: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

29�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

In� addition�t o�t he�bi ological�c haracteristics�of �t he�t umours,�e ach�p atient�ha s� an�i ndividual�

capacity�t o�m etabolise�dr ugs.�T his�l eads�t o�va riations�i n�dr ug�ha lf-life�t hat� may�p artly�

explain�w hy�t he�r esponse�r ate�va ries�be tween�pa tients�r eceiving�i dentical�t reatments.�F or�

example,�m any�c ommonly� used� anti-cancer� agents�( including�c isplatin,�dox orubicin,�

tamoxifen�a nd�e toposide)�a re�m etabolised�i n�t he�l iver�b y�e nzymes�of �t he�p4 50�g roup,� and�

there�a re�doc umented�va riations�i n�t he�a ctivity�of �t hese�e nzymes�be tween�i ndividuals.��

Finally,�t he�opt imisation�a nd�c ombination�of �t he�c urrent�t herapies�t o�f it�i ndividual�

patients�i s�of ten�ba sed�on �a �t rial�a nd�e rror� approach,�r ather�t han� a�c lear�und erstanding�of �

the�bi ology�of �t he�t umour.��

How�t o�de cide�w hen�t o�s top�t reatment?�

We�l ack�s uitable�m ethods�f or�e arly�d etermination� of�r ecurrence� and�t reatment�f ailure�

For�m ost�c urrent�t herapies,�t here�i s�l ittle�l ong�t erm�da ta�t o�s upport�w hen�i t�i s�s afe�t o�s top�

treatment.� If�p atients�e xperience�no�s ide-effects�a nd�a re�f ree� from�c ancer�t hey� are�l ikely�

to�w ant�t o�c ontinue�t heir� therapies�e ven�i n�t he�a bsence�of � any�pr oven�be nefit.�T here�a re�

no�e asy,�non- invasive,� reproducible�m ethods�a vailable�f or�r outinely�m onitoring�

subclinical�di sease�pr ogression�a nd�r esponse�t o� adjuvant�t reatment,�a nd�w e� rely�on�

patients�t o�pr esent�w ith�s ymptoms�i n�or der�t o�e stablish�w hether�t he�t umour�ha s�r ecurred.�

Who�w ill�de velop�dr ug-resistant�t umours?� �

The�ba sis�of �dr ug�r esistance�i s�not �w ell�unde rstood,�a nd�a s�a �c onsequence� we�ha ve�no�

reliable�m ethods�of �pr edicting�w ho�w ill� go�on�t o�d evelop�r esistance�t o�t he�c ommonly�

used�t herapies.�W e�do�no t�know �how �t o�a void�a �r esistant�phe notype�d eveloping,�a nd�i s�i t�

not�c lear�w hether� changes�i n�t he�f requency�of �dr ug�a dministration�a nd/or�l ength�of �

treatment�c ontribute�t o�t his�pr ocess.�

Incomplete�unde rstanding�of �t he� role�of �t he�i mmune�s ystem�

We�do�not �f ully�und erstand�how �be st�t o�us e�t he�i mmune�s ystem�t o�our �a dvantage�i n�br east�

cancer�t reatment,�e ither� as�a �va ccine�or �i n�t he�f orm�of �i mmunotherapy.� Lack�of �s uitable�

model�s ystems�f or�s tudying�t he�i mmune�r esponse,�a s�w ell�a s�t he�m any�f undamental�

Page 31: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

30�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

differences�b etween�t he�s pecies�m ost�c ommonly�u sed�( rodents)� and�hum ans�ha ve�

hampered�p rogress�i n�t his�a rea.� In�a ddition�w e�a lso�l ack�unde rstanding�of �h ow�t umour�

cells�s uppress�t he�i mmune�r esponse�t o� ensure�t heir�s urvival�a nd� growth.�

How�do�a nti-cancer�t reatments�a dversely�a ffect�c ancer�c ells?�

Experimentally,�i t�i s�be coming�a pparent�t hat�t reatment�of �br east�c ancer�c ells�w ith�

endocrine�t herapies� can�r apidly�a ctivate�a lternative�s ignal�t ransduction�pa thways,�w hich�

may�l imit�t he�i nitial�a nti-tumour�r esponse,�a llow�r esistance�t o�de velop�a nd,�ul timately,�

encourage�i nvasive�b ehaviour�[ 75].�F or�e xample,� EGFR/HER2�s ignalling�i s�t riggered�b y�

anti-oestrogens�i n�va rious�hor mone-responsive�b reast�c ancer�m odels�t hat�m aintain�

residual�dow nstream�ki nase�a ctivity,�pr oliferation�a nd�c ell�s urvival�[ 76].� Interestingly,�

‘compensatory’�i nduction�of �a lternative�s ignal�t ransduction�i s�a �phe nomenon�s hared�b y�

other�t ypes�of �a nti-cancer�t herapy,�i ncluding�a nti-growth�f actors,� chemotherapy� and�

radiotherapy�[ 77-79].��

The�f ull�br eadth� and�c ellular�i mpact�of �s uch� compensatory�s ignalling�i s�l argely�unknow n�

in�br east�c ancer.� To�f ill�t his�g ap�w e�ne ed�t o�us e�hi gh-throughput�di scovery� tools�t o�pr ofile�

multiple�s ignalling�pa thways� and�t o�e xplore�t he�c oncept�i n�a �br oader�p anel� of�m odels�

reflective�of �t he�va rious�br east�c ancer�s ubtypes.� In�a ddition,�a lthough�c hanges�i n�s ome�

signalling� elements�( for�e xample�H ER2,�a ctivity�o f�va rious�ki nases�i ncluding�M APK,�

JNK�a nd�p38) �ha ve�be en� reported�t o�be �i n�pl ace�b y�t he�t ime�of �r elapse,�t he�d rug-induced�

concept�i s�l argely�un explored�i n�pa tients.�W e�ne ed�i ncreased�a ccess�t o�‘ on�t herapy’�

clinical�s amples�t o�r ectify� this.��

What�ar e�t he�pr oblems?�

There� are�m any� reasons�f or�t hese� gaps�i n�our �kno wledge,�i ncluding:��

(i)� A�l ack�of �s uitable�m odel� systems�r eflecting�t he�c omplexity�a nd�di versity� of�

breast�c ancer��

(ii)� Limited�a ccess�t o�c linical�m aterial�f rom�pa tients�b efore� and,�i n�pa rticular,�

during�t reatment� �

Page 32: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

31�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

(iii)� A�s evere�l ack�of �m aterial�f rom�m etastatic�de posits�m ade�a vailable� for�s tudies�

of�t arget�hi ts�a nd�bi ological�r esponse�t o�t herapies.� �

The�ne oadjuvant�m odel�p rovides�a �w indow�of �opp ortunity�w here�t herapy�c an�be �t ested�i n�

vivo�i n�hum ans�t o�a ssess�t he�e ffects�of �a n�i ntervention.� It�a llows�bi ological�e valuation�of �

tumour�m arkers�a nd�no rmal�t issue�r esponses�b y�h istological,�bi ochemical,�m olecular,�

imaging�or �c linical�t echniques.�H owever,�ne oadjuvant�s tudies�ha ve�not �us ually�i nvolved�

adequate�num bers�of �pa tients�f or�w hat� can�be �i ntensive�s tudy�a nd�i ndividual�c entres�o ften�

recruit�t oo�f ew�pa tients�i n�s pecific� groups�t o�e nsure�m eaningful� analysis;�a �m ulticentre�

approach�i s�r equired�t o� ensure�pr ogress.�

Identifying�n ew�t herapeutic�t argets�i s�ha mpered�b y� our�l imited�unde rstanding�of �t he� role�

of�t he�t umour�m icroenvironment�a nd�i nteractions� with�c ancer�s tem�c ells�i n� the�

development�a nd�pr ogression�of �br east�c ancer.� In� addition�w e�do�not �unde rstand�t he�

mechanisms�unde rlying�t he�a cquired�r esistance�t o� anti-cancer�t herapies.�T here�a re�t oo�

few�s tudies�a cross�di sciplines�t o�i ncrease�ou r�unde rstanding�o f�t he�r ole�of �t he�i mmune�

system,�a n� area�w here�t here�i s�a �l ack�of �a ppropriate�m odel�s ystems�a nd�i nsufficient�hi gh-

quality�s tudies�c arried�ou t�i n�hum ans.�N ot�e nough� attention�ha s�be en�pa id�t o�how �dr ug�

metabolism�b y�i ndividuals�a ffects�r esponse�t o�t reatment.�T his�i mportant�poi nt�i s�not �

considered�i n�dr ug�t rials�on�a n�i ndividual�ba sis,�or �l inked�t o�m easurements� of�r esponse,�

but�m ay�pa rtly� explain�w hy�t here�i s�s uch�va riation�be tween�p atients�r eceiving�i dentical�

treatments.�A s�a ssays� for�dr ug�m etabolising�c ytochrome�p450s �be come� available�( for�

example�2D 6�f or�t amoxifen�m etabolism),�t his�m ay�m ove�i nto�c linical�pr actice.�

These� gaps�m ay�b e�f illed�b y�de veloping�i mproved�m odel�s ystems�t hat�s eek� to�r eflect�t he�

complexity�of �t he�hum an�di sease,�c ombined�w ith�i ncreased�e fforts�t o�de sign�m ulticentre�

studies�us ing�c linical�m aterial�c ollected�a nd�pr ocessed�i n�a �uni form�w ay.�P articular�a reas�

that�w e�ne ed�t o�s trengthen�a re�t he�i ncreased�us e�of �ne oadjuvant�s tudies,�pr oviding�

researchers�w ith�va luable�c linical�m aterial�f rom�br east�c ancer�p atients�dur ing�t reatment�i n�

the�f orm�of �r epeated�bi opsies.� �

Page 33: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

32�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

Few�s tudies�ha ve�i nvolved�i nvestigations�of �m etastatic�de posits,�s o�our �unde rstanding�of �

the�bi ological� changes�o f�t he�t umour�c ells�a s�t hey� adapt�t o�ne w�e nvironments�i s�l imited.�

Not�m any�p atients�w ill�unde rgo�pr ocedures�t hat�a llow�c ollection�of �m aterial�f rom�

metastatic�s ites,�a nd�no�s ingle� centre�i s�l ikely�t o�be �a ble�t o�c ollect�s ignificant�num bers�of �

quality�s pecimens� for�r esearch.� As�bui lding�t hese�t ypes�o f�‘ bio�r epositories’�f or�f uture�

research�i s�l ikely�t o�t ake� many� years�t o�a ccumulate�num bers�t hat�a llow�m eaningful�d ata�

analysis,�t his�r equires�a � collaborative,�l ong-term�a pproach�f or�w hich�f unding�m ay�b e�

difficult�t o�obt ain�( most�f unding�bodi es�ope rate�on �a �t hree-�t o�f ive-year�t ime�s cale�be fore�

results�a re� expected).��

We�t herefore�s ee� an�ur gent�ne ed�f or�hi gh-quality,� comprehensive,�l ongitudinal�s ample�

collections�( tumour,�D NA,�s erum,�pl asma,�ur ine)� from�br east� cancer�pa tients,�c oupled�

with�e xtensive�c linical�i nformation.�W here�a ppropriate,�c ollaborations�w ith�r esearchers�i n�

other�f ields�( for�e xample� immunologists�w orking�i n�r heumatology�o r�a uto-immune�

diseases)�a re�ne eded.�

Translational� implications�

If�w e� could�f ill�t he�ga ps�i dentified�he re�w e� anticipate�t hat�w e�w ould�b e�a ble�t o�s elect�

patients�f or�a ppropriate�t herapy�m ore�a ccurately,� start�pa tients�on�t herapies�e arlier� and�

monitor�pr ogression�a nd� response.�W e�w ould�ha ve�a �be tter�und erstanding� of�how �t o�

sequence� and�c ombine�t herapies,� an�i ncreased� capacity�t o�d evelop�i nnovative�a nd�

immunologically�b ased�t herapies�t hat�s ubsequently� prove�s uitable�f or�t reating�t he�di sease.�

For�e xample,�pr oof�o f�pr inciple�e xperimental�da ta� reveal�t hat�i ntelligent�t argeting�of �

induced�s ignalling�a longside�t he�pr imary�t herapy�c an�a chieve�a �pr eviously�u nobtainable�

level�of �c ancer�c ell�ki ll�a nd�s ubstantially�i mprove� anti-tumour�r esponse�[ 76].� If�t he�dr ug-

induced�c oncept�i s�r eproduced�i n�vi vo,�r ationally� designed� combination�s trategies�c ould�

have�pot ential�t o�i mprove�i nitial�r esponse�a nd�de lay� resistance�a nd�pr ogression;�t his�

would�ha ve�a �pos itive�i mpact�on�br east�c ancer�s urvival�r ates.�W e�w ould�t hen�be �be tter�

placed�t o�de velop�dr ugs� with�a n�i mproved�t herapeutic�w indow�a nd�f ewer� side-effects,�

and�be �a ble�t o�i mprove�b reast�c ancer�s urvival�r ates. �

Page 34: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

33�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

5.�D isease�M arkers�i n�B reast�C ancer�( Table�5) �

Developing�ne w�t reatments�f or�br east� cancer�a nd� refining�e xisting�r egimens�a re�c learly�

important�a nd�e xciting�a reas�of �r esearch.�T he�c hallenge�i s�t o�e nsure�t hat�n ew�t herapies�

reach�t he�pa tients�w ho�w ill�be nefit�m ost,�a nd�t o�i dentify�pa tients�f or�w hom�t he�ha rms�

outweigh�t he�b enefits,�or � for�w hom�t he�t reatment�w ill�be �i neffective�[ 80].� To�a chieve�

these�a ims�w e�ne ed�va lidated�pr edictive� and�pr ognostic�m arkers.��

What�do�w e� know?�

The�g old�s tandard�f or�c omparing�n ew�m arkers�i s�t esting�a gainst�hi gh-quality� pathological�

assessment�of �t umour�t ype,�s ize,�g rade�a nd�l ymph� node�s tage.��

Only�t wo�m arkers�h ave�b een�e stablished�s o�f ar�i n�t he�r outine�a ssessment�of � breast�c ancer:��

(i)� ER�( for�pr edicting�r esponse�t o�e ndocrine�t herapies)�[ 80]�

(ii)� HER2�( for�pr edicting� response�t o�t rastuzumab)�[ 80,81].�

Although�t heses�m arkers� for�pr edicting�t he� response�t o�e ndocrine� and�bi ological�t herapies�

are�a lready� available,� even�E R�a nd�H ER2�a re� far� from�pe rfect;�f or�e xample,� assessment�

of�H ER2�s tatus�w ill�s till�i nclude�s ome�non- responding�pa tients�[ 81].�

�Intelligent�t rial�de sign�i nvolving�m ultidisciplinary�t eams�i s�e ssential�t o�e nsure�ne w�

treatments�a re�t ested�i n�p atient�g roups�s tratified�us ing�bi omarkers.� Large-scale�s tudies�of �

invasive�br east�c ancer�t hat�ha ve�a nd� are�us ing�t hese�pr inciples�s uccessfully�i nclude�t he�

trials�of �t rastuzumab�a fter�a djuvant�c hemotherapy� in�H ER2-positive�br east� cancer�[ 81].�

Biomarker-based�t rials�m ay� also�be �us ed�t o�a ssess�t reatments�f or� advanced� breast�c ancer,�

but�m ay�be � confounded�b y� prior� exposure�of �s uch� cancers�t o�m ultiple�t herapies.��

Ideally,�how ever,�pr eoperative�( neoadjuvant)�s tudies�a re�r equired,�us ing�c linically�

relevant�m odels�a nd� crossover�de signs�t o�pr ovide� early�e vidence�o f�a �t herapeutic�e ffect�

and�t o�di fferentiate�r esponsive�f rom�non- responsive�gr oups�of �pa tients�[ 82].�

Page 35: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

34�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

What�ar e�t he�gaps ?�

Innovative�t rial�a nd�s tudy� design�

Disease�m arker� concepts� should�be �a pplied�t o�t rials�of �t reatments�f or�p re-invasive�di sease�

including�D CIS�a nd�t o�m odels�of �s entinel�l ymph�n ode�a ssessment,�w here�f unding�i s�

limited�a nd�w here�l ong-term�f ollow-up�i s�r equired�t o�obt ain�r obust�c linical�da ta,�but �

where� we�ne ed�a �be tter�u nderstanding�of �t he�pa thophysiological�pr ocesses�i nvolved.�T wo�

areas� we�ne ed�t o�a ddress� are:��

(i)� The�l evel�of �s entinel�l ymph�node �i nvolvement�t hat�ha s�a �c linical�i mpact�

(ii)� Optimum�pr otocols�f or�pa thological�a ssessment�a nd�s ystems�f or� reproducibly�

categorising�c linically�r elevant�pa thological�m etastatic�di sease�[ 83].�

Additional�c hallenges�i nclude�r ecognising�t he�di fferences�be tween�l aboratory�s tudies� and�

in�vi vo�s tudies�i n�hum ans�w here�i nteractions�be tween�t umour�a nd�s troma,�t hree-

dimensional�e ffects�a nd� vascularisation�be come�r elevant.�F urthermore,�c ombining�

clinical,�r adiological,�pa thological� and� genomic�d ata�i n�t rial�popul ations�w ith�i nnovative�

trial�de signs�( such�a s�i n�t he�M INDACT�t rial�[ 84])�w ill�a llow�us �t o�r elate,�c ompare�a nd�

combine�e stablished�m arkers�t o,�a nd�w ith,�ne w�t echnologies�i n�a � range�of � settings.�

Success�de pends�on� close�m ultidisciplinary�c ollaboration�a t�a n�e arly�s tage,� as�w ell�a s�t he�

highest�qua lity�hi stopathological� and�s cientific�e valuation.�

Validating�n ew�m arkers�

New�m arkers�m ay�b e�be st�va lidated�i n�t rials�of �ne oadjuvant�or �a djuvant�t herapies�a nd�i n�

advanced�di sease,� where� clinical�da ta�a nd�out comes�a re� robust�a nd�s tatistically�

significant.�H owever,�l arge�num bers�of �p atients�m ay�b e�r equired�f or�s mall�i ncremental�

differences�i n�out come.�

The� key� question� is:� ‘does� introducing� a� new� marker� change� clinical� practice� and�

therefore� patient� outcome?’� In� the� past,� researchers� have� not� paid� enough� attention� to�

experimental� design� when� assessing� this;� consequently� the� results� have� not� always� been�

standardised,� reproducible� or� robust� enough� to� apply� to� clinical� practice.� Developing�

Page 36: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

35�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

rigorously� controlled� reagents,� technical� methods� and� appropriate� interpretation� requires�

adequate� resources�a nd�t o�da te�t his�ha s�r arely�be en�f orthcoming.�

While�E R-negative�p atients�r arely�r espond�t o�hor mone�t herapies,� a�pr oportion�of �t hose�

classified�a s�ha ving�E R-positive�di sease�w ill�a lso�not �r espond�[ 85].�N o�r obust�va lidated�

markers�ha ve� yet�be en�de veloped�f or�pr edicting�r esponse�t o�c hemotherapy� or�

radiotherapy.�M any�m arkers�a re�f avoured�b y�l ocal�e nthusiasts�( eg�pr ogesterone�r eceptor�

[PgR],�P S2�a nd�c athepsin�D )�but �w e�ne ed�hi gh-quality� clinical�e vidence�t o�s upport�t heir�

more�w idespread�us e.��

Markers�i ndicative�of �r esistance�t o�t herapy� (for� example�E R-positive,�P gR-negative�

tamoxifen-resistant�c ancers)�ha ve�be en�p roposed,� but�t here�i s�l ittle�a greement�a bout�

methodology�or �c ut-offs� of�s cores� for�c linical� application,�or �i ndeed�t heir�o verall�va lue.� In�

addition,�s ome�m arkers� may�not �be �us eful�onc e�r egimens�o r�t herapies�a re� superseded.�W e�

therefore�ne ed�t o�c ompare,�a nd�pot entially�c ombine,�m arkers�s uch�a s�t he�E R�a nd�P gR�

with�pa thological�m arkers�( such�a s�hi stological�t ype,�gr ade� and�node �m etastasis),�w hich�

have�pr ognostic�i mportance.�F unding� for�r obust�s tudies�e valuating�t hese�m arkers�i s�

crucial,�but �i s�r arely�a chieved�w ithout�f inancial�s upport�f rom�t he�pha rmaceutical�i ndustry.�

��

Researchers� have� identified� validated� intermediate� end� points,� such� as� the� effects� on�

apoptosis,� proliferation� and� ER� down-regulation� (for� example� with� fulvestrant� therapy).�

However,� further� work� is� urgently� needed� using� tumour� pathology� (eg� lymphovascular�

invasion� and� microstaging)� and� molecular� biology,� and� exploring� the� potential� of� disease�

response� markers,� such� as� serum� proteomic� markers� and� circulating� tumour� cells.�

Subclass-specific� markers� based� on� microarray� approaches� have� been� identified� and�

validated� by� immunohistochemistry� [86,87],� but� have� yet� to� be� applied� in� clinical� trials�

and�c linical�pr actice.��

Therefore,� although� breast� cancer� can� be� classified� according� to� histology� and� expression�

of� RNA� and� protein,� for� example� into� basal,� HER2,� luminal� A� and� luminal� B� and� normal�

Page 37: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

36�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

breast-like� subtypes� [86,87],� we� need� to� develop� this� further� to� predict� the� prognosis� of�

each�s ubtype� and�t he�l ikelihood�of �r esponse�t o�t herapies.��

A�f urther� challenge�i s�i n� understanding�t he�c omplex�f actors�i nfluencing�pr ognosis�a nd�i n�

improving�t he�qua lity�c ontrol�of �r eagents�us ed�i n�ne w�t echnologies�( such�a s�pr oteomics,�

phosphoproteomics,�e pigenetics�a nd�a ssays�of �m icroRNA)�s o�t hat�t hey�c an� be�e ffectively�

applied�t o�r outinely� available�c linical�m aterial.� In� particular,�i ntegrating�ol d�a nd�ne w�

methods�a nd�c ombining�t echniques�( such�a s�t issue�m icroarray,�i mmunohistochemistry,�

fluorescence�i n�s itu�h ybridisation,�da ta�s torage�a nd�a nalytical�m ethods)�m ay�a llow�us �t o�

develop�ne w� composite�pr ognostic�i ndices.�A �s ignificant�c hallenge�t o�t he�de velopment�

and�va lidation�of �pr edictive�m arkers�i s�c ounteracting�t he� effects�of �s toring�t umours�a nd�

blood�de rivatives�on�pr oteins�( including�phos phorylated�p roteins)�a nd�i n�pr oteomic�

studies.�W e�c learly�ne ed� careful�r esearch�i nto�t hese�pr ocesses�a nd�how �t o�t ake�t hem�i nto�

account.�

What�ar e�t he�pr oblems?�

Any�n ew�a ssays�t hat�a re� developed�m ust�s tand�up� to�t he�da y-to-day� challenges�o f�c linical�

practice.� The�qua lity�of �s ervice�d elivered�i n�r outine�c linical�pr actice�v aries,� even�f or�b asic�

markers�s uch� as�E R�a nd� HER2�[ 88].� RNA-dependent�a ssays�ha ve�be en� considered�l ess�

robust�t han�pr otein-�or �D NA-based� assays�i n�t he�b reast�c ancer�s etting.� However,�R NA�

based�P CR�t echnology�m ay� well�be come�a �s tandard�of �c are�a s�a n�i ntra-operative�

detection�m ethod�f or�t umour�i n�s entinel�l ymph�no des.�T echniques�m ust�un dergo�r egular�

quality�a ssurance�bot h�du ring�de velopment�( in�t he� research�s etting)�a nd�i n�s ubsequent�

laboratory�a nd� clinical�us e;�m arker�v alidation�r equires�t ime�a nd�r esources� and�

subsequently� convincing� the�pr ofessions�t o�a pply�t hem.��

Implementing�a dvances�i n�m olecular�unde rstanding�m ay�b e�l imited�t o�pa raffin�t issues�a s�

a�s ource�o f�s tandardised� and�s table�pr ocessed�m aterial�i n�t he�f oreseeable�f uture.�

Advances� rely�on�ha ving� appropriate�t echnologies� and�t issues�a vailable�a nd� on�t raining�

for�s cientists�a nd�c linicians.�T he�t iming�a nd�qua lity� of� fixation�m ethods,�t issue�ha ndling�

and�pr eparation�a re�c ritical�bot h�i n�t rials�a nd�i n�r outine�c linical�us e.�C linical�t rials�ha ve�

Page 38: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

37�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

rarely�d eveloped�s tandard�pr ocedures�f or� collecting�a nd�do cumenting�t issue,�a lthough,�

more�r ecent,�i nnovative�t rials�do�s o�[ 84].�E ven�t hen,�de livery�t ime�a nd�c osts�m ay�pr event�

techniques�a nd�m arkers�f rom�be ing� widely�us ed�i n�c linical�pr actice.��

Smaller�c ancers,�of ten�d etected�b y�br east�s creening,�pr esent�pa rticular�pr oblems.�N ot�onl y�

may�t here�be �l ittle�m aterial�f or�s tudying�t he�p rimary� tumour,�but �l ymph�nod e�

micrometastases�a re�m ore�l ikely�t o�be �p resent�t han�l arger�d eposits�a nd�m ay� change�t he�

classification�of �noda l�s tatus.�S uch�pa tients�m ay�s till�ha ve�a n�e xcellent�pr ognosis,�

although�c onventional�i ndices�r elating�node �i nvolvement�t o�di sease�be haviour�m ay� result�

in�a djuvant�( over)�t reatment�be ing� given.�

Additional�i ssues�i nfluencing�t he�d evelopment,�c hoice�a nd�us e�o f�m arkers�i nclude�t he�

impact�of �l egislation�( such�a s� Good�C linical�P ractice� and �G ood�L aboratory�P ractice)�a nd�

ethical�a pproval�pr ocesses�on�t he�f unding,�m anagement,�ow nership�a nd�a ccess�t o�t issue�

collections�a nd�a ssociated�c linical�da ta.�A cademic�pr essures�( particularly�t he�i nfluence�i n�

the�U K�of �t he�R esearch� Assessment�E xercise)�m ay� be� counterproductive�t o�c ollaborative�

translational�r esearch,� which�s hould�( but�m ay�not �be )�r ecognised�a s�o f�hi gh�va lue.� �

Translational� implications�

Integrating�e stablished� and�ne w�a pproaches�t o�p rediction�a nd�pr ognosis�c ontinues�t o�

present�c hallenges.�N etworks�of �c ollaboration�( for�e xample,�t issue�ba nking� and�c ollection�

of�l inked�pa tient,�t umour�a nd�m olecular�d ata)�e mploying�s ystems�bi ology�( eg�i nformation�

technology,�m odelling,�i dentification�of �ke y�nod es)�a re�s till�ne eded�f or�br east�c ancer�

research,�de spite� UK�a nd�E uropean�i nitiatives.�S uch�de velopments�c ould�s peed�t he�

development,�t esting� and�i mplementation�of �ne w� methods�of �de tection�a nd�m arkers�of �

disease�be haviour.�

We�ne ed�t o�r ecognise�t he�di versity�of �b reast�c ancer�us ing�bot h�t raditional�a nd�ne w�

markers�t o�i ndividualise�t herapy.�T raditionally,�t rials�ha ve�c lassed�a ll�w omen�w ith�br east�

cancer�a s� a�s ingle�popul ation�w ith�a �s ingle�di sease�a nd�m any�ha ve� focused� on�w omen�

who�ha ve�a � good�p rognosis.�F uture�s tudies�s hould�a lso�i nvestigate�ot her� groups,�s uch�a s�

Page 39: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

38�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

women�l east�l ikely�t o�b enefit�f rom�a djuvant�t herapy�a nd�t hose�w ith�a �hi gher�r isk�of �

relapse.�T argeting�br east� cancer�t herapies�t o�t hose� most�l ikely�t o�be nefit�a nd�a voiding�

treatment�i n�pa tients�or �t umours�not �r esponsive�c ould�s ignificantly�f ocus�b enefits�on�

patients�l ikely�t o�r espond�but �a lso�pr event�a voidable�t oxicity.�

Page 40: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

39�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

6.�P revention�of �B reast� Cancer�( Table�6) �

Prediction�an d�pr imary� prevention�of �br east�c ancer�

What�do�w e� know?�

Several�l arge-scale�r andomised�c ontrolled�t rials�s how�t hat�e ndocrine� chemoprevention�f or�

oestrogen-responsive�t umours�w orks�[ 89,90].�B reast�c ancer�p revention�pr ogrammes�ne ed�

to�t arget�w omen�a t�hi ghest�r isk.�R isk�pr ediction�pr ogrammes�pr edict�how �m any� cancers�

will�oc cur�i n�a �popul ation�[ 91],�bu t�w e�ne ed�t o�i mprove�t heir�s pecificity.�W e�c urrently�

need�t o�t reat�50� ‘high-risk’�w omen�t o�pr event�one �c ancer.�

Observational�s tudies�de fine�m ammographic�de nsity�a s�one � of�t he�s trongest� risk�f actors�

for�br east�c ancer� (relative�r isk�4.64�[ 3.64–5.91]�> � 75%�r elative�t o�< �5 %�de nsity)�[ 92].�

Expert�opi nion�s uggests� 20–80%�of �r isk�i s�l inked�t o�di et�[ 93].�M easurement�e rror�w ith�

accepted�di et�a ssessment� methods�( food�f requency�que stionnaires)�m ay,�ho wever,� fail�t o�

correctly�i dentify�di etary� risk�f actors.� For�e xample,�r ecent�s tudies�us ing�f ood�di aries,�but �

not�f ood�f requency�que stionnaires,�ha ve�l inked�di etary�f at�t o�r isk�[ 94,95].� Gene–

environment�( diet)�i nteractions�a re�a � further� complexity.�F ailure�t o�c onsider�ge notype�

may�m ask�s ignificant�a ssociations�w ith�di et;�l ikewise,�t he�e ffects�of � genetic�

polymorphisms�m ay� be�d etectable�onl y�w ith�s pecific�di etary� exposures�( ie�t he�e ffect�of �

dietary�i soflavone�i ntake� on�l evels�of �s ex-hormone�bi nding� globulin�a mong� women�w ith�

the�N -variant�of �t he�D 356N�ge ne)�[ 96].�

Observational�da ta�l ink�w eight� gain�t o�r isk�of �pos t-menopausal�br east�c ancer�a nd�l ack�of �

exercise�t o�bot h�pr e-� and� post-menopausal�br east�c ancer.�W eight�l oss�be fore�a nd�a fter�t he�

menopause�r educes�pos t-menopausal�r isk�b y�up�t o�40% �[ 97,98].�T he�obs ervational�na ture�

of�t hese�s tudies�m eans�t he�i ndependent� effect�of �e nergy�r estriction,�e xercise,�or �r eductions�

in�a diposity�on� risk�r eduction�i s�not �know n.�

What�ar e�t he�gaps ?�

The�l ong-term�e ffects�of � chemoprevention�f or�E R-positive�t umours�( beyond�f ive-year�

study�pe riods)� are�not �know n,�w hile�pr eventing�E R-negative�t umours�r emains�a �

challenge.�K ey�r esearch� areas�t o�i nform�t he�de velopment�of �c hemoprevention�a gents�a re�

Page 41: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

40�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

to�unde rstand�w hat�i s�t he�t arget�c ell�( stem�o r�E R-negative�c ells)�a nd�t he�t arget�l esion�i n�

the�br east�( hyperplasia,� atypical�du ctal�h yperplasia,�h yperplastic� enlarged�l obular�uni t�or �

DCIS)� and�w hy�t he�E R�b ecomes�de regulated.�W e� need�s hort-term�i ntervention�s tudies�of �

preventive�a gents�a nd�s trategies,�us ing�p re-� and�p ost-intervention�bi opsies�a nd�f ine�ne edle�

aspirates�( Ki67,�E R).�

Risk�pr ediction�m odels�ne ed�t o�be �i mproved�b y�i ncluding�m odifiable� risk�f actors,�s uch�a s�

mammographic�de nsity�a nd�l ifestyle�f actors.�K ey� questions�t hat�ne ed�t o�be � resolved�

regarding�br east�de nsity� are:�w hat�do es�m ammographic�br east�de nsity� actually�m easure?�

And�i s�a bsolute�or �pe rcentage�br east�de nsity�m ost�r elated�t o�r isk?�P rospective�s tudies�of �

breast�de nsity�( using�s tandardised�m ethods)�a nd�d emographic�( body�s ize�a nd�dr ug�

history)�d ata�a re�r equired�t o�e lucidate�f actors�( ie� age� and�l ifestyle�f actors,�a nd�w eight)�

that�m odify�br east�de nsity,�a nd� whether�t hese�m odify�t he� relationship�be tween�de nsity�

and�r isk.�

Elucidating�t he� role�of �di et�i n�t he�a etiology�o f�br east�c ancer�r equires�pr ospective�s tudy�o f�

diet�a nd�ge netic�v ariation,�us ing�s ensitive�di etary� assessment�m ethods�( food�di aries).�T he�

relative�e ffects�of �e nergy� restriction,�e xercise�a nd� reduced� adiposity�on�r isk� are�unl ikely�

to�be �de termined�f rom�e pidemiology�a nd�ne ed�t o�b e�unr avelled�b y�s hort-term�c ontrolled�

biomarker�t rials.� In� addition,�t he�r ole�of �a dipose�t issue�a nd�i ts�s ecretory�pr oducts�

(oestrogen�a nd�a dipokines)�i n�br east�c ancer�de velopment�a nd�pr ogression�n eed�t o�be �

examined�f rom�l aboratory� studies.�S ince�w eight�l oss�i s�di fficult�t o�a chieve�a nd�m aintain,�

effective�w eight-loss�s trategies� and�t he�be nefits�of �e nergy�r estriction�m imetic�f or�c ancer�

prevention�ne ed�t o�b e�de termined�[ 99].�P sychosocial�r esearch�i s�r equired�t o� explore�t he�

health�be liefs�of �hi gh-risk�a nd�popul ation-risk�w omen,�a nd�t o�de termine�t heir�pot ential�

interest�i n�l ifestyle�o r�pha rmacological�s trategies�f or�br east�c ancer�pr evention.��

What�ar e�t he�pr oblems?�

Accrual�a nd�r etention�i n�pr evention�t rials�i s�a �pr oblem;�t here�i s�c urrently� around�a �10% �

uptake�a nd�a �30 %�dr op-out�r ate.�B etter�r isk�pr ediction�w ould�e nable�r ecruitment�t o�be �

targeted�a t�w omen�w ith�hi gher�l evels�of �r isk�a nd�m otivation.�W e�a lso�ne ed�t o�m ake�t he�

Page 42: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

41�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

public�a ware�of �t he� cancer�pr evention�m essage�( as� with�t he� Know� Your�G ail�Sc ore�

campaign�i n�t he�U SA).� We�ne ed�m ore�di verse�r ecruitment�t o�s tudies�i n�t erms�of �a ge�a nd�

ethnicity.�

Transdisciplinary�i nput�i s�ne eded�w ithin�pr evention�t rials�( eg� geneticists,�e pidemiologists,�

nutritionists,�ps ychologists�a nd�c linicians)�t o�s tudy�t he�ps ychosocial,�c ompliance� and�

genetic�a spects�of �pr evention.�

We�a lso�ne ed�be tter�m odels�t o�r esearch�ne w�c hemoprevention�a gents,�s uch� as�s tem�c ell�

progenitor�a ssays� and�hu man�br east�t issue�i n�nude �m ice,�a nd�be tter�s urrogate�m arkers�of �

breast�c ancer�r isk.�F urther�m ammographic�de nsity�r esearch�r equires�s tandardised�

methods�of �m easurement�t hat�ne ed�t o�ke ep�p ace�w ith�t echnology�i n�br east�s creening� (eg�

digitised�m ammography� and�c omputer-aided�de tection�pr ogrammes).�

��

Funding�i s� an�i ssue�be cause�pr evention�a nd�ps ychosocial�r esearch�h as�not �be en�a �hi gh�

priority.� Intervention�s tudies�a re�l abour�i ntensive� and�of ten�r equire�m ore�f unding�t han�

basic�s cience�r esearch�or � than�t hat�c urrently� available�i n�pr oject� grants.��

Translational� implications�

Identifying� women�w ho� are�a t�hi gh�r isk�of �d eveloping�br east�c ancer� would�e nable�

clinicians�t o�t arget�c hemoprevention�m ore� effectively.� Likewise,�unr avelling�t he�l inks�

between�di et� and�l ifestyle,�ge netic�v ariation�a nd�r isk�w ould�e nable�us �t o�t arget�l ifestyle�

cancer�pr evention�s trategies�a t�t he�w omen�w ho�w ould�be nefit�m ost.�E lucidating�how �

lifestyle�f actors�i nfluence�r isk�w ould�unde rpin�a n�e vidence-based�l ifestyle� cancer�

prevention�m essage,� and� may� enable�us �t o�de velop�dr ugs�t hat�m imic�t heir�e ffects�( ie�

energy�r estriction�m imetics).�

Breast�s creening��

What�do�w e� know?�

Breast�s creening�us ing�m ammography�r educes�m ortality�f rom�b reast�c ancer�i n�w omen�

older�t han�50�[ 100],�a nd�t here�i s�l imited�e vidence� among�w omen� at�hi gh�r isk�of �br east�

Page 43: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

42�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

cancer�( lifetime�r isk� >�1: 6)�a ged�40�or �ol der�[ 101-103].�C ontrast-enhanced� magnetic�

resonance�i maging�( MRI)�i s�m ore�s ensitive�t han� mammography� for�de tecting�c ancer�i n�

high-risk�w omen�[ 104].�

What�ar e�t he�gaps ?�

We�do�not �know �t he�be nefits�of �s creening�w omen� younger�t han�40�or �w hether�M RI�

reduces�m ortality�f rom�br east�c ancer�a mong�hi gh-risk�w omen.�W e�a lso�ne ed�t o�de termine�

whether�t he�n ewer�3�T esla�M RI�m achines�a re�m ore�s ensitive�t han�t he�1.0–1 .5�T esla�M RI�

machines�t hat�w ere�us ed� in�e arlier�s tudies.�W e�ne ed�t o�c onduct�f urther�s tudies�t o�de fine�

the�be st�s urveillance�m ethod�f or�w omen�w ith�de nse�br easts,�w omen�a t�hi gh� risk�a nd�

women�w ho�ha ve�h ad�br east�c ancer,� and�c onsider�t he�pot ential�f or�us ing�ot her�t echniques,�

such�a s�ul trasound�or �i nfrared�i maging,�t o�s creen�t hese�w omen.�

What�ar e�t he�pr oblems?�

Research�n eeds�t o�ke ep�p ace�w ith�i mproving�i maging�t echnology.�

There� are� few�d ata�on�t he�upt ake�of �w omen�ol der�t han�70�t o�t he�N ational�B reast�

Screening�P rogramme.�T he�r ecent�de cline�i n� attendance�f or�s creening�i n�t he�ge neral�

(eligible)�popul ation�s uggests�w e�ne ed�t o� explore�w omen’s�he alth�be liefs�r egarding�br east�

screening.� For� example,�doe s�a ttending�s creening� negate�w omen’s�i nterest� in�pr evention�

strategies�be cause�m any� women�pe rceive�s creening�a s�p revention?�

Translational� implications�

Defining� optimum�s creening�m ethods�i n�di fferent� populations�m ay�s ave�l ives�a nd�e nsure�

more�e ffective�us e�of �l imited�r esources�w ithin�t he�N HS.�

The�i mportance�of �di et�an d�e xercise�af ter�a�di agnosis�of �e arly�br east�c ancer��

What�do�w e� know?�

Weight,�di et�a nd�e xercise�i mpact�on�out come�a fter�a �di agnosis�of �br east�c ancer.�M any�

breast�c ancer�pa tients�a re�ove rweight�a t�t he�t ime�o f�di agnosis,�w hile�m any� more�ga in�

weight� after�di agnosis,�w hich�m ay�i ncrease�t heir� risk�of �d ying�f rom�br east�c ancer�

[105,106]�or �f rom�w eight-related� co-morbidities�[ 107]�( eg�c ardiovascular�di sease�a nd�

Page 44: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

43�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

other�c ancers).�R ecent�d ata�f rom�a �r andomised�c ontrolled�t rial�( the�W omen's� Intervention�

Nutrition�S tudy�[ WINS])�i n�t he�U SA�r eported� a�2 4%�i mproved�r elapse-free�s urvival�ove r�

five� years�a mong�pos t-menopausal�br east�c ancer� patients�f ollowing�a �l ow-fat�di et�

(commenced� within�t he�f irst� year�of �di agnosis),� compared�w ith�t he� group�r eceiving�us ual�

care�[ 108].�S ince�w eight�c ontrol�oc curred�a longside�t his�l ow-fat�di et�i t�i s�unc lear�w hether�

low�f at�or �w eight�c ontrol� was�l inked�w ith�i mproved�s urvival�i n�t his�s tudy.�

The�f easibility�o f�f ollowing�a �l ow-fat�di et� among� breast�c ancer�pa tients�ha s�be en�pi loted�

in�t he�W INS�U K�s tudy,� where�50 %�of �br east�c ancer�pa tients� achieved� a�l ow-fat�i ntake�

(less�t han�20% �e nergy�f rom�f at)�[ 108].�O bservational�da ta�l ink�e xercise�a fter�di agnosis�

(more�t han�t hree�hour s�p er�w eek)�w ith�i mproved�s urvival�[ 109].�A �r ecent�s ystematic�

review�l inked�e xercise�d uring�a nd�a fter�t reatment�t o�i mproved�ph ysical�f unction�a nd�

reduced� fatigue,�w hile�b enefits�i n�qua lity�of �l ife� were�m ainly�s een�i n�t he�po st-treatment�

phase�[ 110].��

What�ar e�t he�gaps ?�

The�da ta�on�w eight� and�o utcome�ha ve� come�f rom� historic�c ohorts.�T he�e ffect�of �w eight�

and�w eight� gain�on�out come�a longside� current�a djuvant�t herapies�n eeds�t o� be�de termined.�

We�ne ed�t o�de fine�d eliverable�di et�a nd� exercise�i nterventions�a fter�di agnosis,�a nd�t he�

optimum�t iming�a nd�m ode�of �de livery� for�i nterventions�ne ed�t o�be �de rived� from�hi gh-

quality�r andomised� controlled�t rials�bot h�dur ing�a nd�a fter�t reatment.�

Improved�br east�c ancer�s urvival�a mong� recent�c ohorts�s hifts�t he�f ocus�t o�c o-morbidities.�

However,�t here� are� few�d ata�on�t he�pr evalence�of � co-morbidities�or �t heir�e ffect�on�

outcome.��

What�ar e�t he�pr oblems?�

There�h as�be en� a�poor �up take�t o�di et�a nd�e xercise�t rials�pos t�di agnosis.�M ore�pa tient-

centred�qu alitative�s tudies�a re�ne eded�t o�e stablish� preferences�a long�w ith�b arriers� and�

motivators�t o�c hanging�b ehaviour�a fter�di agnosis.� The�f easibility�o f�de livering�di et�a nd�

exercise�i nterventions�po st�di agnosis�w ithin�t he�N HS�i s�a �pot ential�c oncern.�H ealthcare�

Page 45: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

44�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

professionals�ne ed�t o�‘ buy� in’�a s�di et�a nd�e xercise� traditionally�a re�not �pr iorities�a mong�

breast�c ancer�t eams.��

We�a lso�ne ed�t o�c onsider�pot ential�f unding,�a ttitudes�a nd�w ork�p ressures�o f� healthcare�

professionals,�t o�de cide� who�i s�be st�pl aced�t o�de liver�i nterventions.�G ood�b iomarkers�of �

prognosis�a nd�m easurements�of �qua lity�of �l ife�a mong�br east�c ancer�pa tients�ne ed�t o�be �

defined�s o�w e� can� evaluate�t he�e ffect�of �di et� and�e xercise�i nterventions�i n�t rials.�

Translational� implications�

Optimum�di et�a nd�e xercise�i nterventions�m ay�i mprove�out comes�a nd�qu ality� of�l ife�f or�

people�w ith�br east� cancer.��

Page 46: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

45�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

7.�P sychosocial�A spects� of�B reast�C ancer�( Table�7) �

Primary�pr evention�of �b reast�c ancer:�ps ychosocial�as pects�of �r isk�an d�pr evention�

Genetic�t esting�of fers�ps ychosocial�be nefits�f or�m any� women�a t�hi gh�r isk�o f�de veloping�

breast�c ancer,�but �pa tients’�pe rceptions�of �r isk�a re� often�i naccurate� and�w hile�m any�

methods�ha ve�be en�us ed� to�c ommunicate�i nformation�a bout�r isk,�t hey�do�no t�a lways�

improve�pa tients’�unde rstanding�[ 111].��

What�do�w e� know?�

Research�i nto�t he�ps ychosocial�i mpact�of �bi lateral�r isk-reducing�m astectomy� is�l imited,�

but�s uggests�t hat�w hile�w omen�m ay�b e�s atisfied�w ith�t heir�de cision�t o�unde rgo�s urgery,�

they�m ay� report�di ssatisfaction�w ith�t heir�bod y�i mage�a fterwards.�M ost�w omen�a re�l ess�

worried�a bout� cancer�a fter�s urgery,�but �t his�m ay�be �be cause�t hey�ove restimate�t heir�r isk�

of�de veloping�br east�c ancer.�T hey�ne ed�t o�und erstand�t heir�t rue�r isk�b efore� considering�

mastectomy�[ 112].�T here�i s�g ood�e vidence�t hat�c ounselling�c an�i mprove�t he�a ccuracy�of �

perceived�r isk,�but �t o�a �v aried�e xtent.��

Breast�s creening�pr ogrammes�f or�w omen�a t�i ncreased�r isk�do�not �i ncrease� anxiety�i n�

women�w ho�do�not �r equire�f urther�i nvestigation,�but �w omen�w ho�a re�r eferred�f or�f urther�

investigations�a re�e vidently�m ore� anxious�[ 113].� �

What�ar e�t he�gaps ?�

Exploring�i ssues�a round� cancer� genetics�i s�pa ramount,�s uch�a s�f ollow-up�s tudies�of �

carriers�w ho�ha ve�or �h ave�not �unde rgone� risk-reducing�s urgery,� and�t heir� partners.�

Research�i s�n eeded�i nto�t he�i mpact�of �di fferent�m odes�of �r isk�c ounselling�o n�pe rceived�

risk�a ccuracy,�h ealthcare� behaviour�a nd�upt ake�of � risk-management�opt ions.�W e�a lso�

need�t o�de velop� and�e valuate�de cision�a ids�f or�r isk�m anagement�a nd� choice�of �s urgery.�

Research� also�ne eds�t o�e xamine�f urther�t he�e ffect� of�c ommunicating� risk�a mong�pa rtners�

and�f amilies�of �w omen�di agnosed�or �i dentified� as� having� an�i ncreased� chance�of �

developing�t he�di sease. ��

Page 47: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

46�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

After�di agnosis:�ps ychosocial�as pects�f or�pat ients�w ith�e arly�an d�adv anced�di sease�

What�do�w e� know?�

Areas� currently�w ell�s upported�i nclude�de scriptive�s tudies�of �t he�e xperiences�of �pa tients,�

carers,�f amily�a nd�p artners�[ 114,115];� the�c omparative�i mpact�of �m astectomy�ve rsus�

conservative�s urgery�[ 116],�a nd�of �br east�r econstruction�[ 117];�a spects�of �doc tor–patient�

communication�[ 118,119];�r ecognition�of �t he�ne ed�t o�i nclude�qua lity-of-life�e valuation�i n�

cancer�t reatment�t rials;�r eturn�t o�w ork�a fter�t reatment�[ 120]�a nd�pot ential�b enefits�of �

exercise�on�qua lity�o f�l ife�[ 121].�T his�r esearch�ha s� fruitfully�e mployed�bot h� quantitative�

and�qua litative�m ethods�t o�de monstrate�t hat�bi omedical�de velopments�a re�n ot�a �pa nacea�

for�t he�ps ychosocial�di stress�a ssociated�w ith�t he�di sease.�P sychosocial�i nterventions�ha ve�

been�s hown�t o�be nefit�di stressed�pa tients,�but �a re�o f�l ess�va lue�i n�pa tients�un selected�on�

grounds�o f�ps ychological�f unctioning�[ 122].�

What�ar e�t he�gaps ?�

It�i s�i mperative�t hat�ps ychosocial�r esearch�k eeps�p ace�w ith�de velopments�i n�bi omedical�

treatment�a nd�c are,�i ncluding�s urgical�a nd�a djuvant�opt ions�a vailable�( eg�n ew�s urgical�

procedures�f or� reconstructive�s urgery�a nd�d evelopments�i n�hor mone�t herapy),� ways�of �

effectively�c ommunicating�i nformation�a bout�t hese�opt ions�a nd�a iding�p atient�de cision�

making�w here� appropriate.�A n�e valuation�of �s elf-help�s trategies�i s�w arranted�a nd�w e�a lso�

need�t o�br oaden�t he�r esearch�a genda�be yond�ps ychological�di stress�t o�i nclude�

interventions�f or�bod y�i mage�a nd�s exual�pr oblems.�

Research�h as�i dentified�p atients’�pr iorities�f or�f uture�r esearch,�na mely�t he�i mpact�of �

cancer�on�l ife�( how�t o�l ive�w ith�c ancer),� risk�f actors�a nd�c auses,�e arly�de tection�a nd�

prevention�[ 123]. � Psychosocial�r esearch� currently� focuses�on�e arly�a nd� end-stage�b reast�

cancer,� yet�m ost�pa tients� are�not �unde r�t he�c are�o f� a�pa lliative�t eam�a nd�h ave�t o�l ive�w ith�

their�di sease�a nd�t he�s ymptoms�of �a djuvant�t reatment�( for�e xample�bone �p ain,�

neuropathy,�ph ysical� changes�t o�a ppearance)�a s� a� chronic�c ondition.�T he� experiences�of �

patients�i n�t his�s ituation�a re�a �s ignificant� gap�i n�our �know ledge.� Future� research�t herefore�

needs�t o�c onsider�b reast� cancer�i n�t erms�of �t hree�p eriods� –�e arly,� chronic� and�e nd�–�a nd�t o�

examine�t he�s pecific�ne eds�of �pa tients�a ssociated� with�e ach�s tage�[ 123].�T he�s pecific�

Page 48: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

47�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

support�ne eds�of �bot h�br east�c ancer�pa tients�a nd�t heir�f amilies�f ollowing�di agnosis�of �

recurrence�a lso�w arrants�f urther�r esearch�[ 124]. �

There�i s�onl y�l imited�r esearch�i nto�c o-morbidities,� yet� cancer�i s�r arely�e xperienced�i n�

isolation�a nd�m any�pa tients�a re�f aced�w ith�t he� effects�of �t he�di sease�a longside�ot her,�of ten�

chronic,�he alth�c onditions.�W e�ne ed�t o�i nvestigate�how �t o�pr ovide�a ppropriate�

psychosocial�c are�f or�pa tients�i n�t his�s ituation.��

Topics�an d�i ssues�r elevant�t o�bot h�pr eventative�a nd�pos t-diagnosis�r esearch�

What�do�w e� know?�

There�i s�now � a�s ignificant�bod y�of �r esearch�i nto�t he�m any�ps ychosocial�i ssues�

surrounding�b reast� cancer.�T his�r esearch�h as�e mployed� a�r ange�of �r esearch� methods�t o�

explore�pa tients’�e xperiences�bot h�be fore�a nd� after�di agnosis.�A lthough�t he�ps ychosocial�

impact�of �br east�c ancer�d iagnosis�a nd�t reatment�ha s�be en�i ncreasingly� recognised�b y�

researchers�a nd�c linicians�i n�r ecent� years,�t here�i s� still�g reat�pot ential�f or�ps ychosocial�

research�t o�i nform�t he�p rovision�of �c are� and�i mprove�pa tients’�e xperiences.��

What�ar e�t he�gaps ?�

Existing�r esearch�i nto�bo th�pr eventative�a nd�pos t-diagnosis�i ssues�i s�pr edominantly�

focused�on�t he� experiences�of �w hite�w omen�i n�t he�U K�a nd�U SA�w ith�a �f luent�

understanding�of �E nglish.�W e�ur gently�ne ed�a dditional�r esearch�i nto�t he�e xperiences�of �

breast�c ancer�pa tients�f rom�a �br oad�r ange�of � ethnic�m inority�popul ations�a nd�of �t hose�w ho�

do�not �f ully�unde rstand� English�s o�t hat�t ailored�c are�c an�b e�pr ovided.�S imilarly,�t he�

experiences�of �ol der�w omen�a re�und er-represented.� �

While�w e�ha ve�i dentified�t he�na ture�of �m any�ps ychosocial�i ssues�f aced�b y� patients,�t here�

is�a �pr essing�n eed�t o�de velop�a nd�r igorously�e valuate�a ppropriate�ps ychosocial�

interventions.�T hese�s hould�i nclude�t ools�t o�he lp�pa tients�m ake�de cisions,� optimal�

methods�f or�c ommunicating�r isk,�w ays�o f�de aling� with�t he�e ffects�of �t reatment�a nd�r eturn�

to�w ork�a nd�s upport�f or�h ealthcare�s taff�a t�r isk�of �b urnout.�R esearch�i n�t his�a rea�c an�

identify�t he�m ost�e ffective�m eans�of �d elivering�c ost-effective,�a ccessible�i nterventions�( eg�

Page 49: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

48�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

timing�of �i nterventions,�r oles�of �he althcare�p rofessionals�i n�de livering�i nterventions,�

comparing� group�a nd�i ndividual�i nterventions,�a nd�us ing�de velopments�i n�t echnology� for�

providing�i nformation�a nd�de cision�m aking).��

Cross-specialty�c ollaboration�i n�br east�c ancer�r esearch�t hat�i ncorporates�ps ychological�

theory�s hould�b e�a �pr iority.� For�e xample,�ps ychological�t heories�i n�r elation�t o�be haviour�

change� could�e nhance�r esearch�i nto�di et,�e xercise� and�c hemoprevention�i nterventions�s o�

that�f actors�i nfluencing�u ptake�a nd�a dherence� are� examined.��

What�ar e�t he�pr oblems?�

A�num ber�of �i ssues�r elating�t o�t he�m ethods�c urrently�e mployed�i n�ps ychosocial�r esearch�

should�be �a ddressed.� These�i nclude�a �ne ed�f or�l onger-term� follow-up�of �t he�i mpact�of �

surgical�pr ocedures� and�r isk�c ounselling,�t o�de velop�a ppropriate�v alid�a nd�r eliable�

measures,�t o�c onsult�pa tients�a bout�r esearch�p riorities�a nd�t o�i nvolve�a �w ider�r ange�of �

research�pa rticipants�( see�a bove).�T he�l imited�f unding�a vailable�f or�ps ychosocial�r esearch�

is�a �pr oblem�a nd�l imits�t he�dur ation�of �f ollow-up� and�pr ospective�s tudies,�e specially�f or�

trials�of �ps ychological�i nterventions.�

We�m ust�i dentify� and�a ddress�t he�ba rriers�t o�t he�u ptake�of �r esearch�f indings,�f or�e xample�

by�c ontinuing�t o�r aise� awareness�o f�t he�i mportance�of �ps ychosocial�r esearch�a nd�

interventions�a nd�t he�pot ential�r ole�t hat�a ll�he althcare�s taff�i n�bot h�pr imary� and�s econdary�

care� can�pl ay�i n�p roviding�ps ychosocial�c are�[ 125].�T his�i s�i mportant�be cause�t he�

essential�r ole�pl ayed�b y�s pecialist�nur ses�i n�pr oviding�ps ychosocial�c are�a nd�t he�

facilitation�of �r esearch�i n�t his�a rea�i s�of ten�und ervalued�i n�t he�N HS.�

Translational� implications�

Further� rigorous�r esearch�i n�t his�a rea�c ould�di rectly� improve�t he� experience�of �pa tients,�

their�f amilies�a nd�t hose�a t�i ncreased� risk�of �br east�c ancer�be cause�t heir�ps ychosocial�

needs�w ould�be �m ore�a ppropriately�a nd� effectively�m et�a t�a ll�s tages�of �t heir� cancer�

journey.��

Page 50: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

49�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

Conclusion�

Research�i nto�t he�p athophysiology,�de tection,�t reatment,�pr evention�a nd�ps ychosocial�

aspects�of �br east�c ancer�h as�pr oduced� a�w ealth�of � knowledge�a nd�h as�l ed�t o�s ubstantial�

improvements�i n�t he�c are�of �pe ople�w ith�br east�c ancer�or � at�hi gh� risk�of �de veloping�t he�

disease.��

This�a nalysis�ha s�i dentified�num erous� gaps�t hat,�i f�r esolved,�c ould�ha ve�a �s ubstantial�

impact�on�t he�di agnosis,�m anagement�a nd�p revention�of �br east�c ancer.�F or� progress�t o�

occur,�t he� gap�a nalysis�p anel�ha s�m ade�t hree�k ey�r ecommendations�f or� each�of �t he�s even�

research�a reas�( Table�8 ).� While�r ecognising�t he�b arriers�t o�a chieving�t hese� aims,�B reast�

Cancer�C ampaign�u rges�r esearchers� and�f unding�b odies�w orldwide�t o�t arget�t heir�

resources�a t�t hese�p riority� areas.�

Page 51: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

50�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

Abbreviations�

COX-2�= �c yclo-oxygenase-2��

DCIS�= �du ctal�c arcinoma�i n�s itu��

DDR�= �D NA�d amage�r esponse�

DNA�= �de oxyribonucleic�a cid�

EGFR�= �e pidermal� growth�f actor�r eceptor�

ER�= �oe strogen�r eceptor�

MRI�= �m agnetic�r esonance�i maging�

mRNA�= �m essenger� ribonucleic�a cid�

NHS�= �N ational�H ealth�S ervice�

RNA�= �r ibonucleic� acid�

RTK�= �r eceptor�t yrosine� kinase�

SNP�= �s ingle�nuc leotide� polymorphism��

TMA�= �t issue�m icroarray�

UK�= �U nited�K ingdom�

USA�= �U nited�S tates�of � America�

WINS�= �W omen's� Intervention�N utrition�S tudy�

Competing� interests�

AT,�J G,�D H,�M H�a nd� IH�a re�c urrent�m embers�of � Breast�C ancer�C ampaign’s�S cientific�

Advisory� Board.�A T,�K B,�A C,�J G,�D H,�M H,� IH� and�C S�a re�c urrent�B reast� Cancer�

Campaign� grant�hol ders.�

Authors’� contributions�

AT,�K B,�A C,�J G,�D H,�M H�a nd� IH�d esigned�t he�m eeting� format.�A ll�a uthors�r ead�a nd�

approved�t he� final�m anuscript.�

Page 52: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

51�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

Acknowledgements�

The�f ollowing�i ndividuals�pa rticipated�i n�t he� gap� analysis�m eeting� (*denotes�r ecipient�of �

current�or �p revious� Breast�C ancer�C ampaign�f unding,� +denotes�c urrent�o r�pr evious�B reast�

Cancer�C ampaign�S cientific�A dvisory�B oard�m embership).�

Dr� Liz�A nderson,�D r�J ohn�B artlett,�D r�S helia� Bingham,�D r�J eremy�B laydes*,�D r�S imon�

Boulton*,�P rofessor�N igel�B undred*+,�D r�R obert� Clarke*+,�P rofessor�R obert�C oleman*,�

Professor�C harles�C oombes,�P rofessor�J essica�C orner*,�P rofessor�J ack�C uzick,�P rofessor�

Trevor�D ale*,�D r� Amanda�D aley,�D r� Isabel�dos �S antos�S ilva*,�D r�A lison�D unning*,�D r�

Suzanne�E ccles*+,�D r�P aul�E dwards*,�P rofessor� Dylan�E dwards*,�P rofessor� Ian�E llis*,�

Dr�O livia�F letcher*,�D r� Thomas�F riedberg*,�P rofessor�W illiam�G ullick*,� Professor� Ian�

Hart*+,�D r�P enelope� Hopwood+,�P rofessor�W en�J iang*,� Dr�S tephen�J ohnston*+,�P rofessor�

Louise�J ones*+,�P rofessor�W illiam�M iller*+,�D r�S otiris�M issailidis*,�M s�B arbara�P arry,�

Professor�J ulian�P eto,�D r�S arah�P inder+,�D r�C olin�P urdie,�D r�E rik�S ahai*,� Dr�A ndrew�

Schofield*,�D r�M atthew� Smalley,�D r� Valerie�S peirs*+,�P rofessor�J oyce�T aylor-

Papadimitriou*,�P rofessor�G erry�T homas,�P rofessor�A shok�V enkitaraman*,�P rofessor�

Rosemary�W alker*+,�D r� Andrew�W ardley+,�D r�R uth�W arren*+�a nd�D r�C hristine�W atson*�

Rachel�W heeler� acted� as� scientific�e ditor�a nd�w as� funded�b y�B reast�C ancer� Campaign.��

Breast�C ancer�C ampaign�s taff�A rlene�W ilkie�a nd�D r� Lisa�W ilde�a ssisted�i n�t he�de sign�

and�i mplementation�of �t he�m eeting�f ormat� and�a cted�a s�f acilitators�t hroughout�t he�

process.�D r� Annabelle� Ballsdon�w as�r esponsible�f or�t he�m eeting�l ogistics�a nd�a cted�a s� a�

facilitator�a t�t he�m eeting.�A my�C aldwell,�P amela�G oldberg,�C laire� Learner�a nd�T anya�

Sadhwani�a cted� as�f acilitators�a t�t he�m eeting.�

The�ga p�a nalysis�m eeting�w as�he ld�a t�T he� Novartis�F oundation�a �r egistered�c harity�i n�

England� and�W ales�w hich�ha s�no�c ommercial�t ies.�

Page 53: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

52�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

References�

1.�T he�C HEK2�B reast�C ancer�C ase-Control�C onsortium:� CHEK2*1100delC�an d�

susceptibility�t o�b reast�c ancer:�a� collaborative� analysis�i nvolving�10,86 0�b reast�

cancer� cases�an d�9,065�c ontrols�f rom�10�s tudies. � Am�J �H um�G enet �2004 ,� 74:1175-

1182.�

2.�R enwick�A ,�T hompson�D ,�S eal�S ,�K elly�P ,�C hagtai�T ,�A hmed�M ,� North� B,�J ayatilake�

H,�B arfoot�R ,�S panova�K ,� et�al :� ATM�m utations�t hat�c ause�at axia-telangiectasia�ar e�

breast�c ancer�s usceptibility�al leles.� Nat�G enet �2006,� 38:873-875.�

3.�S eal�S ,�T hompson�D ,�R enwick�A ,�E lliott�A ,�K elly�P ,�B arfoot�R ,�C hagtai�T ,�J ayatilake�

H,�A hmed�M ,�S panova�K ,� et�al :� Truncating�m utations�i n�t he�F anconi�an emia�J�ge ne�

BRIP1�ar e�l ow-penetrance�b reast�c ancer�s usceptibility�al leles. � Nat�G enet �2006,�

38:1239.�

4.�T he�B reast�C ancer�A ssociation�C onsortium:� Commonly�s tudied�S NPs�an d�b reast�

cancer:�n egative�r esults�f rom�12,000�- �32,000� cases�an d�c ontrols�f rom�t he�B reast�

Cancer�A ssociation�C onsortium. � J�N atl�C ancer�I nst �2006, �98 :1382-1396.�

5.�C ox�A ,�D unning�A M,�G arcia-Closas�M ,�B alasubramanian�S ,�R eed�M W,�P ooley�K A,�

Scollen�S ,�B aynes�C ,�P onder�B A,�C hanock�S ,� et�al :� A�c ommon�c oding�var iant�i n�

CASP8�i s�as sociated�w ith�b reast�c ancer� risk.� Nat�G enet �2007,� 39:352-358.�[ Erratum:�

Nature�G enet�2007,�39: 688.]�

6.�S tacey�S N,�M anolescu�A ,�S ulem�P ,�R afnar�T ,�G udmundsson�J ,�G udjonsson�S A,�

Masson�G ,�J akobsdottir� M,�T horlacius�S ,�H elgason�A ,� et�al :� Common�var iants�on �

chromosomes�2q 35�an d�16q 12�c onfer�s usceptibility�t o�e strogen�r eceptor-positive�

breast�c ancer.� Nat�G enet �2007, �39 :865-869.�

7.�H unter�D J,�K raft�P ,�J acobs�K B,�C ox�D G,�Y eager�M ,�H ankinson�S E,�W acholder�S ,�

Wang� Z,�W elch�R ,�H utchinson�A ,�W ang�J ,� et�al :� Genome-wide�as sociation�s tudy�

identifies�al leles�i n�F GFR2�as sociated�w ith�r isk� of�s poradic�p ostmenopausal�b reast�

cancer.� Nat�G enet �2007,� 39:870-874.�

8�E aston�D F,�P ooley�K A,�D unning�A M,�P haroah�P D,�T hompson�D ,�B allinger�D G,�

Struewing�J P,�M orrison�J ,�F ield�H ,� Luben�R ,� et�al :� Genome-wide�as sociation�s tudy�

identifies�n ovel� breast�c ancer�s usceptibility�l oci. � Nature� 2007:447:1087-1093.�

Page 54: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

53�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

9.�S haran�S K,�M orimatsu�M ,�A lbrecht�U ,� Lim�D S,�R egel�E ,� Dinh�C ,�S ands�A ,�E ichele�G ,�

Hasty�P ,� Bradley�A :� Embryonic�l ethality�an d�r adiation�h ypersensitivity�m ediated�b y�

Rad51�i n�m ice�l acking�B rca2.� Nature� 1997,� 386:804-810.�

10.�S cully�R ,�C hen�J ,�P lug�A ,�X iao�Y ,�W eaver�D ,� Feunteun�J ,�A shley� T,� Livingston�D M:�

Association�of �B RCA1�w ith�R ad51�i n�m itotic�a nd�m eiotic� cells. � Cell �1997,� 88:265-

275.�

11.�P olanowska�J ,�M artin�J S,�G arcia-Muse�T ,�P etalcorin�M I,�B oulton�S J:� A� conserved�

pathway�t o�ac tivate�B RCA1-dependent�u biquitylation�at �D NA�d amage�s ites. � EMBO�

J�2006,� 25:2178-2188.�

12.�Y u�X ,�F u�S ,� Lai�M � Baer�R ,�C hen�J :� BRCA1�u biquitinates�i ts�p hosphorylation-

dependent�b inding� partner�C tIP.� Genes�D ev�20 06, �20 :1721-1726.�

13.�H owlett�N G,�T aniguchi�T ,�O lson�S ,�C ox�B ,�W aisfisz�Q ,�D e�D ie-Smulders�C ,�P ersky�

N,�G rompe�M ,�J oenje�H ,� Pals�G ,� et�al :� Biallelic�i nactivation�of �B RCA2�i n� Fanconi�

anemia. � Science� 2002, �2 97:606-609.�

14.�R ahman,�N ,� Seal,�S ,�T hompson,�D ,�K elly,�P ,� Renwick,�A ,�E lliott,�A ,�R eid,�S �S panova,�

K,�B arfoot,�R ,�C hagtai,�T ,� et�al :� PALB2,�w hich�e ncodes�a�B RCA2-interacting�p rotein,�

is�a�b reast�c ancer�s usceptibility�ge ne.� Nat�G enet �2007,� 39:165-167.�

15.�S jöblom�T ,� Jones�S ,� Wood�L D,�P arsons�D W,�L in�J ,�B arber�T D,�M andelker�D ,� Leary�

RJ,� Ptak� J,�S illiman�N ,� et�al :� The�c onsensus�c oding�s equences�of �h uman�b reast�an d�

colorectal�c ancers.� Science�2006,� 314:268-274.�

16.�H uang�H E,�C hin�S F,� Ginestier�C ,�B ardou�V J,�A délaïde�J ,� Iyer�N G,� Garcia�M J,�P ole�

JC,� Callagy�G M,�H ewitt�S M,� et�al :� A�r ecurrent� chromosome�b reakpoint�i n�b reast�

cancer�at � the�N RG1/neuregulin�1/ heregulin�ge ne. � Cancer�R es �2004,� 64:6840-6844.�

17.�S treuli�C �( Ed):� Key�s tages�of �m ammary�gl and�d evelopment.�[ Review�s eries].� In�

Breast�C ancer�R es �[ �ht tp://breast-cancer-research.com/articles/review-

series.asp?series=bcr_keystages]�

18.� Ip�M M,�A sch�B B:� Methods�i n�m ammary�gl and�bi ology�and�br east�c ancer�r esearch. �

New�Y ork,� Kluwer;�2000 .�

19.�S hackleton�M ,�V aillant�F ,�S impson�K J,� Stingl�J ,�S myth�G K,�A sselin-Labat�M L,�W u�

L,� Lindeman�G J,�V isvader�J E:� Generation�of �a�f unctional�m ammary�gl and�f rom�a�

single�s tem� cell.� Nature� 2006,� 439:84-88.�

Page 55: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

54�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

20.�S tingl�J ,�E irew�P ,�R icketson� I,�S hackleton�M ,� Vaillant�F ,�C hoi�D ,� Li� HI,�E aves�C J:�

Purification�an d�u nique�p roperties�of �m ammary�e pithelial�s tem� cells. � Nature�2006,�

439:993-997.�

21.�F owler� KJ,�W alker�F ,�A lexander�W ,�H ibbs�M L,�N ice�E C,�B ohmer�R M,�M ann�G B,�

Thumwood�C ,�M aglitto�R ,�D anks�J A,� et�al :� A�m utation�i n�t he�e pidermal� growth�f actor�

receptor�i n�w aved-2�m ice�h as�a�p rofound�e ffect�on �r eceptor�b iochemistry�t hat�

results�i n�i mpaired�l actation. � Proc�N atl�A cad�Sc i�U SA�1995,� 92:1465-1469.�

22.�S ternlicht�M D,�S unnarborg�S W,�K ouros-Mehr�H ,�Y u�Y ,� Lee�D C,�W erb�Z :�

Mammary�d uctal� morphogenesis�r equires�p aracrine�ac tivation�of �s tromal�E GFR�vi a�

ADAM17-dependent�s hedding�o f�e pithelial�am phiregulin. � Development� 2005,�

132:3923-3933.�

23.�J ohnston� SR,�L eary� A:� Lapatinib:�a�n ovel�E GFR/HER2�t yrosine�k inase�i nhibitor�

for�c ancer.� Drugs�T oday�( Barc)�2006,� 42:441-453.�

24.�S tylianou�S ,�C larke�R B,�B rennan�K :� Aberrant�ac tivation�of �n otch�s ignaling�i n�

human�b reast�c ancer.� Cancer�R es �2006,� 66:1517-1525.�

25.�B rennan�K R,�B rown� AM:� Wnt�p roteins�i n�m ammary�d evelopment�an d�c ancer. � J�

Mammary�G land�B iol�N eoplasia �2004,�9: 119-131.�

26.�S achdev�D ,�Y ee�D :� Inhibitors�of �i nsulin-like�gr owth�f actor�s ignaling:�a�

therapeutic�ap proach�f or�b reast�c ancer. � J�M ammary�G land�B iol�N eoplasia� 2006,�

11:27-39.�

27.�S erra�R ,�C rowley�M R:� Mouse�m odels�of �t ransforming�gr owth�f actor�b eta�i mpact�

in�b reast�d evelopment�an d�c ancer. �E ndocr�R elat�C ancer �2005,� 12:749-760.�

28.�W atson�C J:� Post-lactational�m ammary�gl and�r egression:� molecular�b asis�an d�

implications�f or�b reast� cancer.� Expert�R ev�M ol� Med �2006,� 8:1-15.�

29.�B on�G ,� Folgiero�V ,�D i�C arlo�S ,�S acchi�A ,�F alcioni�R :� Involvement�of �al pha6beta4�

integrin�i n�t he�m echanisms�t hat� regulate�b reast�c ancer�p rogression. � Breast�C ancer�

Res �2007,� 9:203.�

30.�S ternlicht�M D:� Key�s tages�i n�m ammary�gl and�d evelopment:� the�c ues�t hat�

regulate�d uctal�b ranching�m orphogenesis. � Breast�C ancer�R es �2006,� 8:201.�

Page 56: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

55�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

31.�S chwertfeger�K L,�R osen�J M,�C ohen�D A:� Mammary�gl and�m acrophages:�

pleiotropic�f unctions� in� mammary�d evelopment. � J�M ammary� Gland�B iol�N eoplasia �

2006,� 11:229-238.�

32.�K atz�E ,�S treuli�C H:� The�e xtracellular�m atrix�as �an �ad hesion�c heckpoint�f or�

mammary� epithelial�f unction. � Int�J �B iochem�C ell�B iol �2006,� 39:715-726.�

33.�A randa� V,�H aire�T ,�N olan�M E,�C alarco�J P,�R osenberg�A Z,� Fawcett�J P,� Pawson�T ,�

Muthuswamy�S K:� Par6-aPKC�u ncouples�E rbB2�i nduced�d isruption�o f�p olarized�

epithelial�or ganization�f rom�p roliferation�c ontrol.� Nat�C ell�B iol �2006,� 8:1235-1245.�

34.� Larue� L,� Bellacosa�A :� Epithelial-mesenchymal�t ransition�i n�d evelopment�an d�

cancer:� role�of �p hosphatidylinositol�3 '�k inase/AKT�p athways. � Oncogene� 2005,�

24:7443-7454.�

35.�S leeman�K E,�K endrick�H ,�A shworth�A ,� Isacke�C M,�S malley�M J:� CD24�s taining�o f�

mouse� mammary�gl and�c ells�d efines�l uminal�e pithelial,�m yoepithelial/basal�an d�n on-

epithelial�c ells.� Breast�C ancer�R es �2006,� 8:R7.�

36.�A sselin-Labat�M L,�S hackleton�M ,�S tingl�J ,�V aillant�F ,�F orrest�N C,�E aves�C J,�

Visvader�J E,� Lindeman� GJ:� Steroid�h ormone�r eceptor�s tatus�of �m ouse� mammary�

stem�c ells.� J�N atl�C ancer�I nst �2006,� 98:1011-1014.�

37.�J onker�J W,�F reeman� J,�B olscher�E ,�M usters�S ,�A lvi�A J,�T itley� I,�S chinkel�A H,�D ale�

TC:� Contribution�o f�t he�A BC�t ransporters�B crp1�an d�M dr1a/1b�t o�t he�s ide�

population�p henotype�i n�m ammary�gl and�an d� bone�m arrow�of �m ice.� Stem�C ells �

2005,� 23:1059-1065.�

38.�Z hang�M ,�R osen�J M:� Stem�c ells�i n�t he�e tiology�an d�t reatment�of �c ancer. � Curr�O pin�

Genet�D ev� 2006,� 16:60-64.�

39.�G reen� KA,�S treuli�C H:� Apoptosis�r egulation�i n�t he�m ammary�gl and.� Cell�M ol�L ife�

Sci �2004,� 61:1867-1883.�

40.�W atson�C J:� Involution:�ap optosis�an d�t issue�r emodelling�t hat�c onvert�t he�

mammary�gl and�f rom� milk�f actory�t o�a�q uiescent�or gan.� Breast�C ancer� Res �2006,�

8:203.�

41.�P olyak�K :� Pregnancy�an d�b reast�c ancer:� the�ot her�s ide�of �t he�c oin. � Cancer�C ell �

2006,� 9:151-153.�

Page 57: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

56�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

42.�K enny�P A,� Lee� GY,� Myers�C A,�N eve�R M,�S emeiks�J R,� Spellman�P T,� Lorenz�K ,� Lee�

EH,�B arcellos-Hoff�M H,� Petersen�O W,� et�al :� The�m orphologies�of �b reast�c ancer� cell�

lines�i n�t hree-dimensional�as says�c orrelate�w ith�t heir�p rofiles�of �ge ne�e xpression.�

Molecular�O ncology�200 7,� 1:84-96.�

43.�D ebnath�J ,�B rugge�J S:� Modelling�gl andular�e pithelial�c ancers�i n�t hree-

dimensional�c ultures. � Nat�R ev�C ancer �2005 ,� 5:675-688.�

44.�C larke�R B:� Isolation�an d�c haracterization�of �h uman�m ammary�s tem�c ells. � Cell�

Prolif� 2005,� 38:375-386.�

45.�W olf�K ,�F riedl�P :� Molecular� mechanisms�of �c ancer�c ell�i nvasion�an d� plasticity. � Br�

J�D ermatol� 2006,� Suppl� 1:11-15.�

46.�S idani�M ,�W yckoff�J ,�X ue�C ,�S egall�J E,�C ondeelis�J :� Probing�t he�

microenvironment�of � mammary�t umors�u sing�m ultiphoton�m icroscopy.� J�M ammary�

Gland�B iol�N eoplasia� 2006,� 11:151-163.�

47.�H ennighausen� L,�R obinson�G W:� Information�n etworks�i n�t he�m ammary�gl and. �

Nature�R ev� 2005,� 6:715-725.�

48.�T eulière�J ,�F araldo�M M,�D eugnier�M A,�S htutman�M ,�B en-Ze'ev� A,�T hiery�J P,�

Glukhova�M A:� Targeted�ac tivation�of �b eta-catenin�s ignaling� in�b asal�m ammary�

epithelial�c ells�af fects� mammary�d evelopment�an d�l eads�t o�h yperplasia.� Development�

2005,� 132:267-277.�

49.�M oody�S E,�P erez�D ,� Pan�T C,�S arkisian�C J,� Portocarrero�C P,�S terner�C J,�

Notorfrancesco� KL,�C ardiff�R D,�C hodosh� LA:� The�t ranscriptional�r epressor�S nail�

promotes� mammary� tumor�r ecurrence. � Cancer�C ell �2005,� 8:197-209.�

50.�D asGupta�R ,�F uchs�E :� Multiple�r oles�f or�ac tivated�L EF/TCF�t ranscription�

complexes�d uring�h air�f ollicle�d evelopment�an d�d ifferentiation.� Development� 1999,�

126:4557-4568.�

51.�K uperwasser�C ,�C havarria�T ,�W u�M ,�M agrane�G ,�G ray�J W,�C arey� L,� Richardson�A ,�

Weinberg�R A:� Reconstruction�of � functionally�n ormal�an d�m alignant�h uman�b reast�

tissues�i n�m ice. � Proc�N atl�A cad�Sc i � USA�2004,� 101:4966-4971.�

52.�R ennstam�K ,�H edenfalk� I:� High-throughput�ge nomic� technology�i n�r esearch�an d�

clinical�m anagement�of �b reast�c ancer.�M olecular�s ignatures�of �p rogression�f rom�

benign�e pithelium�t o� metastatic�b reast�c ancer. � Breast�C ancer�R es�2006,� 8:213.�

Page 58: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

57�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

53.�K inzler�K W,�V ogelstein�B :� Lessons�f rom�h ereditary�c olorectal�c ancer.� Cell� 1996,�

87:159-170.�

54.�S ims�A H,�O ng�K R,�C larke�R B,� Howell�A :� High-throughput�ge nomic�t echnology�i n�

research�an d�c linical�m anagement�of �b reast�c ancer. � Exploiting�t he�p otential�of �ge ne�

expression�p rofiling:�i s� it�r eady�f or�t he�c linic?� Breast�C ancer�R es �2006, � 8:214.�

55.�S chiff�R ,�M assarweh� SA,�S hou� J,�B harwani� L,� Arpino�G ,�R imawi�M ,�O sborne�C K:�

Advanced�c oncepts�i n�e strogen�r eceptor�b iology�an d�b reast�c ancer�e ndocrine�

resistance:�i mplicated�r ole�of �gr owth� factor�s ignaling�a nd�e strogen�r eceptor�

coregulators.� Cancer�C hemother�P harmacol �2005 ,� Suppl�1: 10-20.�

56.�B ritton�D J,�H utcheson� IR,�K nowlden�J M,�B arrow�D ,�G iles�M ,�M cClelland�R A,�G ee�

JM,�N icholson�R I:� Bidirectional�c ross�t alk�b etween�E Ralpha�an d� EGFR�s ignalling�

pathways�r egulates�t amoxifen-resistant�gr owth. � Breast�C ancer�R es�T reat �2006,�

96:131-146.�

57.�S peirs�V ,�W alker�R A:� New�p erspectives�i nto�t he�b iological�an d�c linical�r elevance�

of�oe strogen�r eceptors�i n�t he�h uman�b reast.� J�P athol �2007,� 211:499-506.�

58.�N icholson�R I,�H utcheson� IR,� Hiscox�S E,�K nowlden�J M,�G iles�M ,�B arrow�D ,�G ee�J M:�

Growth�f actor�s ignalling�an d�r esistance�t o�s elective�oe strogen�r eceptor� modulators�

and�p ure�an ti-oestrogens:�t he�u se�of �an ti-growth�f actor�t herapies�t o�t reat�or �d elay�

endocrine�r esistance�i n� breast�c ancer.� Endocr�R elat�C ancer �2005,� Suppl� 1:S29-36.�

59.�A nand�S ,�P enrhyn-Lowe�S ,�V enkitaraman�A R:� AURORA-A�a mplification�

overrides�t he� mitotic�s pindle�as sembly�c heckpoint,�i nducing�r esistance�t o�T axol. �

Cancer�C ell �2003,� 3:51-62.�

60.�S ledge�G W:� VEGF-targeting�t herapy�f or�b reast�c ancer. � J�M ammary�G land�B iol�

Neoplasia� 2005,� 10:319-323.�

61.�H iscox�S ,�M organ� L,� Barrow�D ,�D utkowskil�C ,�W akeling�A ,�N icholson� RI:�

Tamoxifen�r esistance�i n�b reast�c ancer�c ells�i s�ac companied�b y�an �e nhanced� motile�

and�i nvasive�p henotype:�i nhibition�b y�ge fitinib� ('Iressa',�Z D1839). � Clin�E xp�

Metastasis �2004,� 21:201-212.�

62.�J ones� JL,�J A�S haw,�J H�P ringle,�W alker�R A:� Primary�b reast� myoepithelial�c ells�

exert�an �i nvasion-suppressor�e ffect�on �b reast�c ancer�c ells�vi a�p aracrine�

Page 59: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

58�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

downregulation�of �M MP�e xpression�i n�f ibroblasts�an d�t umour�c ells. � J� Pathol �2003,�

201:562-572.�

63.�A dams�M ,�J ones� JL,� Walker�R A,�P ringle�J H,�B ell�S C:� Changes�i n�T enascin-C�

isoforms�e xpression�i n�i nvasive�an d�p reinvasive�b reast�d isease.� Cancer� Res �2002,�

62:3289-3297.�

64.�B arnes�N ,�H aywood� P,�F lint�P ,�K nox�W F,�B undred�N J:� Survivin�e xpression�i n�i n�

situ�an d�i nvasive�b reast�c ancer� relates� to�C OX-2�e xpression�an d�D CIS� recurrence. �

Br�J �C ancer� 2006,� 94:253-258.�

65.�K amb�A :� What's�w rong�w ith�o ur�c ancer� models? �N at�R ev�D rug�D iscov�2005,�

4:161-165.�

66.�C leator�S J,�P owles�T J,�D exter�T ,�F ulford� L,�M ackay�A ,�S mith� IE,�V algeirsson�H ,�

Ashworth�A ,�D owsett�M :� The�e ffect�of �t he�s tromal�c omponent�of �b reast� tumours�on �

prediction�of �c linical�o utcome�u sing�ge ne�e xpression�m icroarray�an alysis. � Breast�

Cancer�R es �2006,� 8:R32.��

67.�F oulkes�W D:� BRCA1�an d�B RCA2:�c hemosensitivity,�t reatment�ou tcomes�an d�

prognosis.� Fam�C ancer �2006,� 5:135-142.�

68.�S candinavian�B reast�G roup�T rial�9401,�T anner�M ,� Isola�J ,�W iklund�T ,� Erikstein�B ,�

Kellokumpu-Lehtinen�P ,�M almström�P ,�W ilking�N ,�N ilsson�J ,�B ergh�J :� Topoisomerase�

II�al pha�ge ne�am plification�p redicts�f avourable� treatment�r esponse�t o�t ailored�an d�

dose-escalated�an thracycline-based�ad juvant�c hemotherapy�i n�H ER-2/neu-amplified�

breast�c ancer:�S candinavian�B reast�G roup�T rial�9401.� J�C lin�O ncol �2006,� 24:2428-

2436.�

69.�G ee�J M,�R obertson�J F,�G utteridge�E ,� et�a l:� Epidermal�g rowth�f actor�

receptor/HER2/insulin-like�gr owth� factor�r eceptor�s ignalling�a nd�oe strogen�

receptor�ac tivity�i n�c linical�b reast�c ancer.� Endocr�R elat�C ancer �2005,� Suppl�1 :S99-

S111.�

70.�S arwar�N ,� Kim�J S,� Jiang�J ,�P eston�D ,�S innett�H D,�M adden�P ,�G ee�J M,�N icholson�R I,�

Lykkesfeldt�A E,�S housha�S ,�C oombes�R C,�A li�S :� Phosphorylation�of �E Ralpha�at �

serine�118�i n�p rimary�b reast�c ancer�an d�i n�t amoxifen-resistant�t umours�i s�i ndicative�

of�a�c omplex�r ole�f or�E Ralpha�p hosphorylation�i n�b reast�c ancer�p rogression.� Endocr�

Relat�C ancer� 2006,� 13:851-861.�

Page 60: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

59�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

71.� Leake�R ,� Barnes�D ,�P inder�S ,�E llis� I,�A nderson� L,�A nderson�T ,�A damson�R ,�R hodes�

T,�M iller�K ,�W alker�R :Immunohistochemical�d etection�of �s teroid�r eceptors�i n�b reast�

cancer:�a�w orking�p rotocol.�U K�R eceptor� Group,�U K�N EQAS,�T he�S cottish�B reast�

Cancer� Pathology� Group,�an d�T he�R eceptor�an d�B iomarker�S tudy�G roup�of �t he�

EORTC. � J�C lin�P athol �2 000,� 53:634-635. 72.�E llis� IO,� Bartlett�J ,�D owsett�M ,�H umphreys�S ,�J asani�B ,�M iller�K ,�P inder�S E,�R hodes�

A,�W alker�R :� Best�P ractice�N o�176: �u pdated�r ecommendations�f or�H ER2�t esting�i n�

the�U K. � J�C lin�P athol �2004,� 57:233-237.�

73.�W alker�R A:� Quantification�of �i mmunohistochemistry� -�i ssues�c oncerning�

methods,�u tility�an d�s emiquantitative�as sessment�I .� Histopathology�2006,� 49:406-410.�

74.�P erou�C M,�S ørlie�T ,�E isen�M B,�va n�d e�R ijn�M ,�J effrey�S S,�R ees�C A,�P ollack�J R,�

Ross�D T,�J ohnsen�H ,�A kslen� LA,� et�al :� Molecular�p ortraits�of �h uman�b reast� tumours.�

Nature�2000, �406 :747-752.�

75.�G ee�J M,�S haw�V E,�H iscox�S E,�M cClelland�R A,�R ushmere�N K,�N icholson�R I:�

Deciphering�an ti�h ormone-induced�c ompensatory� mechanisms�i n�b reast�c ancer�an d�

their�t herapeutic�i mplications. � Endocr�R elat�C ancer �2006,� Suppl�1 :� S77-88.�

76.�G ee�J M,�H arper�M E,� Hutcheson� IR,�M adden� TA,�B arrow�D ,� Knowlden� JM,�

McClelland�R A,�J ordan�N ,�W akeling�A E,� Nicholson�R I:� The�an ti-epidermal�gr owth�

factor�r eceptor�ag ent�ge fitinib�( ZD1839/Iressa)� improves�an ti-hormone�r esponse�

and�p revents�d evelopment�of �r esistance�i n�b reast�c ancer�i n�vi tro.� Endocrinology�

2003,� 144:5105-5117.�

77.�H utcheson� IR,�K nowlden�J M,� Jones�H E,�B urmi�R S,�M cClelland�R A,� Barrow�D ,�G ee�

JM,�N icholson�R I:� Inductive� mechanisms�l imiting�r esponse�t o�an ti-epidermal�gr owth�

factor�r eceptor� therapy. � Endocr�R elat�C ancer �2 006,� Suppl�1 :S89-97.�

78.�T iligada�E ,�M iligkos� V,�D elitheos�A :� Cross-talk�b etween�c ellular�s tress,�c ell�c ycle�

and�an ticancer�age nts:� mechanistic�as pects. � Curr�M ed�C hem�A nti-Canc� Agents �2002,�

2:553-566.�

79.�D ent�P ,�Y acoub�A ,�C ontessa�J ,�C aron�R ,�A morino�G ,�V alerie�K ,�H agan�M P,�G rant�S ,�

Schmidt-Ullrich�R :� Stress�an d�r adiation-induced�ac tivation�of �m ultiple�i ntracellular�

signaling� pathways. � Radiat�R es �2003,� 159:283-300.�

Page 61: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

60�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

80.�R odger� A,�S tebbing�J ,�T hompson�A M:� Breast�c ancer�( non-metastatic). � Clin�E vid �

2006, �15 :2360-2392.�

81.�P iccart-Gebhart�M J,�P rocter�M ,� Leyland-Jones�B ,�G oldhirsch�A ,�U ntch�M ,�S mith�I ,�

Gianni� L,� Baselga�J ,�B ell�R ,�J ackisch�C ,� et�al :� Trastuzumab�af ter�ad juvant�

chemotherapy�i n�H ER2-positive�b reast�c ancer. � N�E ngl�J �M ed�2005,� 353:1659-1672.�

82.�D ixon� JM:� The�s cientific�val ue�of � preoperative�s tudies�an d�h ow�t hey�c an�b e�u sed�

to�i dentify�b iomarkers.� Breast�C ancer�R es�T reat � 2004,� 87:S19-S26.�

83.�P urdie�C A:� Sentinel� lymph�n ode�b iopsy:�r eview�of �t he�l iterature�an d�gu idelines�

for�p athological�h andling�an d�r eporting. � Current�D iagnostic�P athology,�i n�pr ess.� �

84.�B ogaerts�J ,�C ardoso�F ,�B uyse�M ,�B raga�S ,� Loi�S ,�H arrison�J A,�B ines�J ,�M ook�S ,�

Decker�N ,�R avdin�P ,� et�a l:� TRANSBIG�c onsortium.� Gene�s ignature� evaluation�as �a�

prognostic�t ool:�c hallenges�i n�t he�d esign�of �t he� MINDACT�t rial.� Nat�C lin�P ract�O ncol �

2006,� 3:540-551.��

85.�G oulding�H ,�P inder�S ,�C annon�P ,�P earson�D ,� Nicholson�R ,�S nead�D ,�B ell�J ,�E lston�

CW,�R obertson� JF,�B lamey�R W,�e t�a l:� A�n ew�i mmunohistochemical�an tibody�f or�t he�

assessment�of �e strogen� receptor�s tatus�on �r outine�f ormalin�f ixed�t issue� samples. � Hum�

Pathol� 1995,� 26:291-294.�

86.�S orlie�T ,�T ibshirani�R ,�P arker�J ,�H astie�T ,�M arron�J S,�N obel�A ,�D eng� S,�J ohnsen�H ,�

Pesich�R ,�G eisler�S :� Repeated�ob servations�of �b reast�t umor�s ubtypes�i n�i ndependent�

gene�e xpression�d atasets.� Proc�N atl�A cad�Sc i�U SA�2003,� 100:8418-8423.�

87.�A bd�E l-Rehim�D M,�B all�G ,�P inder�S E,�R akha�E ,�P aish�C ,�R obertson�J F,�M acmillan�

D,�B lamey�R W,�E llis� IO:� High-throughput�p rotein�e xpression�an alysis�u sing�t issue�

microarray�t echnology�of �a�l arge�w ell-characterised�s eries�i dentifies�b iologically�

distinct�c lasses�of �b reast�c ancer� confirming�r ecent�c DNA� expression�an alyses. � Int�J �

Cancer �2005,� 116:340-350.��

88.�B artlett�J M,� Ibrahim�M ,�J asani�B ,�M organ�J M,�E llis� I,�K ay�E ,�M agee� H,�B arnett�S ,�

Miller�K :� External�q uality�as surance�of �H ER2�f luorescence�i n�s itu�h ybridisation�

testing:�r esults�of �a�U K� NEQAS�p ilot�s cheme. � J� Clin�P athol �2007,� 60:816-819.�

89.�H owell�A ,�C uzick�J ,� Baum�M ,� Buzdar�A ,�D owsett�M ,�F orbes�J F,�H octin-Boes�G ,�

Houghton�J ,� Locker�G Y,� Tobias�J S:� Results�of �t he�A TAC�( Arimidex,�T amoxifen,�

Page 62: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

61�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

Alone�or �i n�C ombination)�t rial�af ter�c ompletion�of �5�ye ars'�ad juvant�t reatment�f or�

breast�c ancer. � Lancet �20 05,� 365:60-62.�

90.�V ogel�V G,�C ostantino�J P,� Wickerham�D L,�C ronin�W M,�C ecchini�R S,� Atkins�J N,�

Bevers�T B,�F ehrenbacher� L,�P ajon�E R�J r,�W ade�J L�3r d,� et�al :� Effects�of �t amoxifen�vs �

raloxifene�on �t he�r isk�of �d eveloping�i nvasive�b reast�c ancer�an d�ot her�d isease�

outcomes:� the�N SABP� Study�o f�T amoxifen�an d�R aloxifene�( STAR)�P -2�t rial. � JAMA�

2006,� 295:2727-2741.�

91.�A mir�E ,�E vans�D G,�S henton�A ,� Lalloo�F ,�M oran�A ,�B oggis�C ,�W ilson�M ,�H owell�A :�

Evaluation�o f�b reast�c ancer�r isk�as sessment�p ackages�i n�t he�f amily�h istory�

evaluation�an d�s creening�p rogramme. � J�M ed�G enet �2003,� 40:807-814.�

92.�M cCormack�V A,�dos �S antos�S ilva� I:� Breast�d ensity�an d�p arenchymal�p atterns�as �

markers�of �b reast�c ancer�r isk:�a� meta-analysis. � Cancer�E pidemiol�B iomarkers�P rev�

2006,� 15:1159-1169.�

93.�D oll�R ,�P eto�R :� The�c auses�of �c ancer:�q uantitative�e stimates�of �avoi dable�r isks�o f�

cancer�i n�t he�U nited�S tates�t oday.� J�N atl�C ancer�I nst �1981,� 66:1191-1308.�

94.�B ingham�S A,� Luben� R,�W elch�A ,�W areham�N ,�K haw�K T,�D ay�N :� Are� imprecise�

methods�ob scuring�a�r elation�b etween�f at�an d� breast�c ancer?� Lancet �2 003,� 362:212-

214.�

95.�F reedman� LS,�P otischman�N ,�K ipnis�V ,�M idthune�D ,�S chatzkin�A ,�T hompson�F E,�

Troiano�R P,�P rentice�R ,�P atterson�R ,�C arroll�R ,� et�al :� A�c omparison�of �t wo�d ietary�

instruments�f or�e valuating�t he�f at-breast�c ancer�r elationship.� Int�J �E pidemiol �2006,�

35:1011-1021.�

96.� Low� YL,�D unning�A M,�D owsett�M ,� Luben�R N,�K haw�K T,�W areham� NJ,�B ingham�

SA:� Implications�of �ge ne-environment�i nteraction�i n�s tudies�of �ge ne�va riants�i n�

breast�c ancer:�an �e xample�of �d ietary�i soflavones�an d�t he�D 356N�p olymorphism�i n�

the�s ex�h ormone-binding�gl obulin�ge ne.� Cancer�R es �2006,� 66:8980-8983.�

97.�H arvie�M ,�H owell�A ,�V ierkant�R A,�K umar�N ,� Cerhan�J R,�K elemen� LE,�F olsom�A R,�

Sellers�T A:� Association�of �gai n�a nd�l oss�o f� weight�b efore�an d�af ter�m enopause�w ith�

risk�of �p ostmenopausal� breast�c ancer�i n�t he�I owa� women's�h ealth�s tudy.� Cancer�

Epidemiol�B iomarkers�P rev�2005,� 14:656-661.�

Page 63: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

62�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

98.�E liassen�A H,�C olditz� GA,�R osner�B ,�W illett�W C,�H ankinson�S E:� Adult� weight�

change�an d�r isk�o f�p ostmenopausal�b reast�c ancer.� JAMA�2006,� 296:193-201.�

99.�H arvie�M ,�H owell�A :� Energy�b alance�ad iposity�an d�b reast�c ancer� -�e nergy�

restriction�s trategies�f or�b reast�c ancer�p revention.� Obes�R ev�2006, �7 :33-47.�

100.� International�A gency� for�R esearch�on�C ancer�E xpert�G roup:� Breast�C ancer�

Screening.� In� IARC�H andbooks�of �C ancer�P revention.� Volume�7 .� Lyon,� France:� IARC;�

2002:248. 101.�M aurice�A ,� Evans�D G,�S henton�A ,�A shcroft� L,� Baildam�A ,� Barr� L,� Byrne�G ,�

Bundred� N,�B oggis�C ,�W ilson�M ,�e t�a l:� Screening�you nger�w omen�w ith�a�f amily�

history�of �b reast�c ancer�- �d oes�e arly�d etection�i mprove�ou tcome? � Eur�J �C ancer �2006,�

42:1385-1390. 102.�G ui�G P,�K adayaprath�G ,�D arhouse� N,�S elf�J ,�W ard�A ,�A 'Hern�R ,�E eles�R :� Clinical�

outcome�an d�s ervice�i mplications�of � screening�w omen�at �i ncreased�b reast�c ancer�

risk�f rom�a�f amily�h istory.� Eur�J �Sur g�O ncol �200 6,� 32:719-724.��

103.�C ortesi� L,�T urchetti� D,�M archi� I,� Fracca�A ,�C anossi�B ,�R achele�B ,�S ilvia�R ,�R ita�P A,�

Pietro�T ,�M assimo�F :� Breast�c ancer�s creening�i n�w omen�at �i ncreased�r isk�ac cording�

to�d ifferent�f amily�h istories:�an �u pdate�of �t he�M odena�S tudy�G roup�e xperience.�

BMC�C ancer� 2006,� 6:210.�

104� Leach�M O,� Boggis� CR,�D ixon�A K,�E aston�D F,�E eles�R A,�E vans�D G,� Gilbert�F J,�

Griebsch� I,� Hoff�R J,�K essar�P ,� et�al :� Screening�w ith�m agnetic�r esonance�i maging�an d�

mammography�of �a�U K�p opulation�at �h igh� familial�r isk�o f�b reast�c ancer:�a�

prospective� multicentre�c ohort�s tudy�( MARIBS). � Lancet �2005,� 365:1769-1778.�

105.�K roenke�C H,�C hen� WY,�R osner�B ,�H olmes� MD:� Weight,�w eight�gai n,�an d�

survival�af ter�b reast�c ancer�d iagnosis. � J�C lin�O ncol �2005,� 23:1370-1378.�

106.�C amoriano�J K,� Loprinzi�C L,� Ingle�J N,�T herneau�T M,�K rook�J E,�V eeder�M H:�

Weight�c hange�i n�w omen�t reated�w ith�ad juvant�t herapy�or �ob served�f ollowing�

mastectomy�f or�n ode-positive�b reast�c ancer. � J� Clin�O ncol �1990,� 8:1327-1334.�

107.�D ignam�J J,� Wieand�K ,�J ohnson�K A,�F isher�B ,�X u� L,�M amounas�E P:� Obesity,�

tamoxifen�u se,�an d�ou tcomes�i n�w omen�w ith�e strogen�r eceptor-positive�e arly-stage�

breast�c ancer.� J�N atl�C ancer�I nst �2003,� 95:1467-1476.�

Page 64: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

63�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

108.�C hlebowski�R T,�B lackburn�G L,�T homson�C A,�N ixon�D W,� Shapiro�A ,�H oy�M K,�

Goodman�M T,�G iuliano�A E,�K aranja�N ,�M cAndrew�P ,� et�al : �D ietary�f at�r eduction�an d�

breast�c ancer�ou tcome:� interim�e fficacy�r esults�f rom�t he�Wo men's�I ntervention�

Nutrition�S tudy. � J�N atl� Cancer�I nst �2006,� 98:1767-1776.�

109.�H olmes�M D,�C hen�W Y,�F eskanich�D ,� Kroenke�C H,�C olditz�G A:� Physical�ac tivity�

and�s urvival�a fter�b reast�c ancer�d iagnosis.� JAMA�2005,� 293:2479-2486.�

110.�M cNeely�M L,�C ampbell�K L,�R owe�B H,�K lassen�T P,�M ackey�J R,�C ourneya�K S:�

Effects�of �e xercise�on �b reast�c ancer�p atients�an d�s urvivors:�a�s ystematic�r eview�an d�

meta-analysis. �C MAJ�20 06,� 175:34-41.�

111.�J ulian-Reynier�C ,�W elkenhuysen�M ,�H agoel� L,�D ecruyenaere�M ,�H opwood�P ;�

CRISCOM�Wor king�G roup:�R isk�c ommunication�s trategies:�s tate�of �t he�ar t�an d�

effectiveness�i n�t he�c ontext�of �c ancer�g enetic�s ervices.� Eur�J �H um� Genet � 2003,� 11:725-

736.�

112.� Lostumbo� L,�C arbine�N ,�W allace�J ,�E zzo� J:� Prophylactic� mastectomy�f or�t he�

prevention�of �b reast�c ancer. � Cochrane�D atabase�Sy st�R ev�2004,� 4:CD002748.�

113.�B rett�J ,�B ankhead�C ,�H enderson� B,�W atson�E ,�A ustoker�J :� The�p sychological�

impact�of � mammographic�s creening.�A �s ystematic�r eview.� Psychooncology�2005,�

14:917-938.�

114.�B rennan�J ,�M oynihan,C:� Cancer�i n�C ontext:�A �P ractical�G uide�t o�Suppor tive�C are. �

Oxford:�O xford�U niversity�P ress;�2004.�

115.�W agner�C D,� Bigatti�S M,�S torniolo�A M:� Quality�of �l ife�of � husbands�o f�w omen�

with�b reast�c ancer. � Psychooncology� 2006,� 15:109-120.�

116.�M oyer�A :� Psychological�ou tcomes�of �b reast-conserving�s urgery�v ersus�

mastectomy:�a� meta-analytic�r eview. � Health�P sychol �1997,� 16:284-298.�

117.�H arcourt�D M,�R umsey� NJ,�A mbler�N R,�C awthorn�S J,� Reid�C D,�M addox�P R,�

Kenealy�J M,�R ainsbury� RM,�U mpleby�H C:� The�p sychological�i mpact�of �m astectomy�

with�or �w ithout�i mmediate�b reast� reconstruction:�a�p rospective,� multi-centred�

study. � Plast�R econstr�Sur g �2003,� 111:1060-1068.�

118.�S cott�J T,�H armsen�M ,�P rictor�M J,�E ntwistle�V A,�S owden�A J,�W att�I :� Recordings�or �

summaries�of �c onsultations�f or�p eople� with�c ancer. � Cochrane�D atabase� Syst�R ev�

2003,� 2:CD001539.�

Page 65: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

64�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

119.�F allowfield� L,�J enkins�V ,�F arewell�V ,�S olis-Trapala� I:� Enduring�i mpact�of �

communication�s kills�t raining:�r esults�of �a�12- month�f ollow-up. � Br�J �C ancer �2003,�

89:1445-1449.�

120.�M ain�D S,�N owels�C T,�C avender�T A,�E tschmaier�M ,�S teiner�J F:� A�q ualitative�s tudy�

of�w ork�a nd� work�r eturn�i n�c ancer�s urvivors. � Psychooncology�2005,� 14:992-1004.�

121.�M cNeely�M L,�C ampbell�K L,�R owe�B H,�K lassen�T P,�M ackey�J R,�C ourneya�K S:�

Effects�of �e xercise�on �b reast�c ancer�p atients�an d�s urvivors:�a�s ystematic�r eview�an d�

meta-analysis. � CMAJ�20 06,� 175:34-41.�

122.�S heard�T ,�M aguire� P:� The�e ffect�of �p sychological�i nterventions�on �an xiety�an d�

depression�i n�c ancer�p atients:�r esults�of �t wo�m eta-analyses. � Br�J �C ancer �1999,�

80:1770-1780.�

123.�C orner�J ,�W right�D ,�F oster�C ,�G unaratnam�Y ,�H opkinson�J ,�O kamoto�I :� The�

Macmillan�L istening�St udy:�L istening�t o�t he�V iews�of �P eople�A ffected�by �C ancer�about �

Cancer�R esearch.�P ublished�R eport.� London,�U K:�M acmillan�C ancer�S upport;�2006.� �

124.�S chofield�P ,�C arey� M,�B onevski�B ,�S anson-Fisher�R :� Barriers�t o�t he�p rovision�o f�

evidence-based�p sychosocial�c are�i n�on cology. � Psychooncology� 2006,� 15:863-872.�

125.�N orthouse� LL,�M ood�D ,�K ershaw�T ,�S chafenacker� A,�M ellon�S ,�W alker�J ,�G alvin�E ,�

Decker�V :� Quality�of �l ife�of �w omen�w ith�r ecurrent�b reast�c ancer�an d�t heir�f amily� m�

embers. � J�C lin�O ncol� 2002,�20 :4050-4064.�

Page 66: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

65�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

Table�1: �S ummary�of �G ap�A nalysis� for�G enetics�of �B reast�C ancer��What�do�w e�know :�

• Multiple�g enes�of �di fferent�pe netrance�a re�i nvolved�i n�t he�pr edisposition�t o� breast�

cancer�

• Genome�w ide�s creens�a nd�s omatic�g enetic�a pproaches�a re�i dentifying�f urther�

genes�i nvolved�i n�br east�c ancer�

Gaps�

• Detailed�unde rstanding�o f�t he�a ctions�of � BRCA1�a nd�B RCA2�

• Knowledge�of �l arge�s cale�g enetic�r earrangements�i n�t umour�c ells�

• The�i mportant�va riants,�e ffects�a nd�i nteractions�of �l ow�pe netrance� genes�

• Further�i dentification�of � point�m utations�a nd�e pigenetic�c hanges�

Problems�

• The�qua lity,�qu antity�a nd�a ccessibility�o f�m aterials�

• Funding� for�l arge�s cale�e xperiments�( such�a s�s equencing)�us ing�e xpensive�

equipment�

• Bioinformatic�a nalysis�s kills�

Translational�i mplications�

• Classifying�br east�t umours�a ccording�t o�t he�s ignalling�pa thways�t hat� are�di srupted�

to�pr edict�pr ognosis�a nd�r esponse�t o�t herapy�

• Determining�t he�r elevance�of �s omatic�e vents�t o�pr ognosis�a nd�r esponse�t o�t herapy�

• Generate�ne w,�t argeted�t herapies�b ased�on�t arget� discovery�

• Better� genetic�r isk� estimation�

Recommendations�

• Encourage�de velopment� of�r esearch�t echniques�t o� allow�i ntegrated�a nalysis�of �

sequence�l evel,�e pigenetic�a nd�l arge-scale�s omatic�c hanges�

• Engage�i n�na tional�i nitiatives�f or�a ctivities�s uch�a s�hi gh-throughput�r e-sequencing�

and�U K�c ontrols�

• Encourage�r esearch�i nvolving�i ntermediate�phe notypes�

Page 67: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

66�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

Table�2: �S ummary�of �G ap�A nalysis� for�t he�I nitiation�of �B reast�C ancer�

What�do�w e�know ?�

• Animal�m odels�ha ve� given�us �gr eat�i nsight�i nto�t he�m olecular�p athways�i nvolved�

in�br east�de velopment� and�d ysregulation�i n�c ancer�

What�a re�t he�G aps?�

• The�r elationship�of �s ignalling�pa thways�t o�duc tal� and�a cinar�br east�a rchitecture�

• The�ne ed� for�w idespread� use�of �m ore�a ppropriate�i n�vi vo�a nd�c ulture�m ethods�

• The�i mportance�o f�s troma�a nd�ot her� cell�t ypes,�c ell�a dhesion�a nd�t he�e xtracellular�

matrix.�

• Understanding�s tem�c ells�

• Understanding�m echanisms�of �e pithelial�a poptosis�

• Understanding�how �pr egnancy�a nd�f unctional�di fferentiation�i n�t he�br east�pr otect�

against�br east�c ancer�

Problems�

• The�br east�c ell�l ines�us ed�a nd�t heir�c ulture� conditions�

• A�w ider�va riety�of �pr omoters�w ith�s patial,�t emporal�a nd�di fferentiation�c ontrol�o f��

gene�e xpression�i s�ne eded�

• The�ne ed� for�m ouse�m odels�of �s pecific�b reast� cancer�t ypes� eg�t riple�ne gative�

breast�c ancer�

• The�i mplantation�m ethods�f or�s ingle� cells�i n�vi vo�

Translational�i mplications�

• Understanding�t he�c omplex�i nteractions�be tween� cell�t ypes�s hould�pr ovide� new�

opportunities�f or�i ntervention�

• Identifying�p reinvasive� changes�ha s�i mplications�f or�pa tient�t ailored�a pproaches�

Recommendations�

• Develop�t hree-dimensional�c ell�c ulture�m odels,�c ontaining�m ultiple�c ell�t ypes,�t hat�

reflect�t he�t issue�a rchitecture�of �t he�nor mal� and�di seased�br east�

• Generate�be tter�a nimal�m odels,�i n�w hich�ge ne�e xpression�c an�be �m anipulated�i n�e ach�

cell�t ype�of �t he�m ammary� gland� and�w ill�not �be �a ltered�b y�t ransdifferentiation�or �

dedifferentiation�

Page 68: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

67�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

• Gain�a � greater�und erstanding�of �t he� genetic�c hanges�t hat�oc cur� within�a typias�a nd�

DCIS�

Page 69: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

68�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

Table�3: �S ummary�of �G ap�A nalysis� for�P rogression�of � Breast�C ancer�

What�do�w e�know ?�

• Oestrogen�r eceptor,�r eceptor�t yrosine�ki nase�( RTK)�a nd�D NA�r epair�pa thways�

have�be en�e xtensively�r esearched�

• Around�50% �of �D CIS�w ill�pr ogress�t o�i nvasive�di sease�i f�unt reated,�w ith�12 –20%�

recurring� at�10� years�de spite�a ppropriate�t reatment.�

What�a re�t he�G aps?�

• Understanding�t he�c omplexities�of �br east�c ancer�i ntracellular�s ignal�t ransduction�

pathways,�pa racrine�pa thways,�i nvasion,�a ngiogenesis�a nd�m etastasis�i ncluding�

relevance�of �t hese�m echanisms�t o�c linical�pr ogression��

• Whether�t here� are�i nherently�m igratory�s tem�c ells�or �i s�m etastatic�c apacity�

acquired�

• Understanding�t ime-dependent�pr ogression�e vents,�not ably�dor mancy�a nd�

reactivation�of �m icrometastasis,�a t�pa rticular�s econdary�s ites�

• Understanding�t he�e merging�r elationship�be tween� therapeutic� resistance� and�

metastasis��

• Causative�f actors�unde rlying�r ecurrence�of �D CIS�o r�pr ogression�t o�i nvasive�

disease�

• Understanding�i nterplay� between�s troma,�m yoepithelial�a nd�e pithelial�c omponents�

during�e arly�pr ogression� and�i nterplay�be tween�t umour�c ells,�s troma�a nd�i mmune�

system�i n�m etastasis�

• The�ne ed� for�i mproved�p reclinical�m odels�of �t he�i nfluences�of �t he�

microenvironment,�s ite�s pecific�m etastasis� and�do rmancy� �

• In�vi vo�i maging�t echnologies�t o�s tudy�t he�d ynamics�of �m etastasis�a nd�r elate�t his�

to�s ignalling�m echanisms,�a s�w ell�a s�m eans�t o�m anipulate�t hese�m echanisms�t o�

evaluate�t argeting�pot ential�

Problems�

• Appropriate� clinical�s amples�t o�e valuate�bi omarkers�a nd�c ellular�e ndpoints�

• Appropriate�p reclinical� models�a nd�i mproved�r esearch� reagents�

• Increasingly� complex�a nd�m ultidisciplinary� research�i nfrastructure���

Translational�i mplications�

Page 70: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

69�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

• Identifying�p atients�a t�i ncreased�r isk�of �di ssemination��

• Effectively�p redict�t herapeutic�r esponse� with�g rowth�i nhibitors.��

• Improve�s election�of �pa tients�w ith�D CIS�f or� adjuvant�r adiotherapy�or �e ndocrine�

therapies,��

• Identify�c ellular�t argets�f or�de veloping�ne w� agents�t o�t arget�br east� cancer�

progression�e ffectively� and�s electively�

Recommendations�

• Improve�pr eclinical�m odels,�r esearch�r eagents�a nd�t echnologies�( including�i maging)�

• Enhance� access�t o�a ppropriate�c linical�m aterial,�n otably�m atched�s amples� during�

progression�a nd�s equential�s amples�obt ained�dur ing�t reatments�i ncluding�n ew�a gents� �

• Consider�t he�ge netic�s ignature/specific� genetic�l esions�w hen�e xploring�pr ogression�

biology�a nd�de signing�c linical�t rials�

Page 71: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

70�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

Table�4: �S ummary�of �G ap�A nalysis� for�T herapies�an d�T argets�i n�B reast�C ancer�

What�do�w e�know ?�

• The�s elective�us e�of �c ombinations�of �s urgery,�r adiotherapy,�c hemotherapy,� and�

biological�t herapies�ha s�i mproved�pa tient�s urvival�i n�r ecent� years.�

• Not�a ll�t herapies�us ed� are�e ffective�on�a ll�pa tients�

What�a re�t he�G aps?�

• There�i s�a n�i ncomplete�u nderstanding�of �t he�bi ology�of �b reast�c ancer�i ncluding�t he�

effects�of �c ompensatory� signalling�p athways�r esponsible�f or�dr ug�r esistance�

• We�c annot�de termine�w ho�g oes�on�t o�d evelop�m etastatic�di sease�o r�dr ug�r esistant�

cancers�

• Individualisation�of �t herapies�c ould�be �i mproved�

• The�opt imal�dur ation�of �t herapy�i s�unc lear�f or�m any� drugs�

Problems�

• There� are�i nsufficient�m odel�s ystems�f or�t he�c omplexity�a nd�di versity�of �b reast�

cancer�

• The�ne ed�t o�unde rstand�n ot�onl y�t he�c ancer�but �t he�t umour�m icroenvironment�a nd�

patient�c haracteristics�( including�dr ug�m etabolism�a nd�i mmune�m echanisms)�

• Availability�of �c linical�m aterial�i s�s carce,�p articularly�f rom�m etastatic�di sease�

tissues�

• The�ne oadjuvant�m odel� could�be �us ed�m ore�e ffectively��

Translational�i mplications�

• Patients�c ould�be �s elected�f or�a ppropriate�t herapy� more�e ffectively�

• Enhanced�und erstanding� of�t he�s equencing,� combinations�a nd�dur ation�of �

treatments�

Recommendations�

• Build�r esources�t hrough� high-quality,�uni form,�m ulticentre�c ollection�of � clinical�

material�f rom�br east�c ancer�pa tients�be fore� and�dur ing�t reatment�( including�

neoadjuvant�s tudies),�i ncluding�s amples�of �pr imary� tumours�a s�w ell�a s�m etastatic�

deposits�

• Develop�m ethods�f or� easy,�r eproducible�m onitoring�of � response�t o�a nd�

development�of �r esistance�t o�t herapy,�a s� well�a s�e arly�di sease�p rogression�

Page 72: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

71�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

• Increase�r esearch� efforts� into�t he�r ole�of �t he�t umour�m icroenvironment�a nd�t he�

immune�s ystem�i n�t he�de velopment�a nd�t reatment� of�br east�c ancer�

Page 73: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

72�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

Table�5: �S ummary�of �G ap�A nalysis� for�D isease�M arkers�i n�B reast�C ancer�

What�do�w e�know ?�

• Patient�g roups�c an�be �s uccessfully�s tratified�i n�c linical�t rials�us ing�bi omarkers�

What�a re�t he�G aps?�

• Optimum�pr otocols�f or�pa thological�a ssessment�of �D CIS�a nd�s entinel�l ymph�

nodes�

• Combining�c linical,�r adiological,�p athological�a nd�g enomic�d ata�i n�t rial�

populations�

• No�r obust�va lidated�m arkers�ha ve� yet�be en�d eveloped�f or�pr edicting� response�t o�

chemotherapy�o r�r adiotherapy�

• There�i s�no�c onsensus�f or�m arkers�i ndicative�o f�r esistance�t o�t herapy�

• There�i s�a �n eed�f or�i mproved�pr ognostic�i ndices�ba sed�on�di sease�m arkers�

Problems�

• New�a ssays�m ust�be � robust�a nd�r eproducible�

• There�i s�a �n eed�f or�s tandardisation�of �t issue�ha ndling�

• The�i mpact�of �l egislation,�i ndustrial�i nvolvement�a nd�a cademic�pr essures�

• Networks�of � collaboration�e mploying�s ystems�bi ology�a re�r equired�

Translational�i mplications�

• Accurate�r ecognition�of �t he�di versity�o f�br east�c ancer�

• Identification�of �pa tients� most�l ikely�t o�be nefit�

• Identification�of �pa tients� least�l ikely�t o�be nefit�f rom�t herapy�a nd�he nce� able�t o�

avoid�t oxicity.�

Recommendations�

• Design�i nnovative�t rials�a nd�t ranslational�s tudies�t o�de velop�a nd�e valuate�

predictive�a nd�p rognostic�m arkers�

• Develop�c lose�m ultidisciplinary� collaboration�w ith�hi gh-quality�hi stopathology�

and�r igorous�s cientific� assessments�t o�va lidate�ne w�m arkers�i mportant�f or� patient�

outcome�

Page 74: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

73�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

• Identify�r obust�m arkers�o f�r esistance�or �s ensitivity� to�t herapy�t hat�c an�b e�a pplied�

across�t he�s pectrum�of �br east�di sease� from�s creen-detected�t o�m etastatic�b reast�

cancer�

Page 75: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

74�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

Table�6: �S ummary�of �G ap�A nalysis� for�P revention�of � Breast�C ancer�

What�do�w e�know ?�

• Endocrine�c hemoprevention�f or�oe strogen-responsive�t umours�w orks�

• Key�r isk�f actors�i nclude� mammographic�de nsity,� post-menopausal�w eight� gain,�

high�e nergy,�hi gh�f at�di ets�a nd�l ack�of � exercise��

• Breast�s creening�i s�e ffective.�M RI�s creening�i s�m ore�s ensitive��t han�

mammography� for�hi gh�r isk�w omen��

• Epidemiological�da ta�s uggest�w eight�c ontrol,�l ow� fat�di et�a nd�e xercise� after�

diagnosis�i mproves�out come�of �e arly�b reast� cancer�pa tients.��

What�a re�t he�G aps?�

• The�l ong�t erm�e ffects�of � chemoprevention�of �E R�pos itive�c ancers�a re�unkn own�

• Prevention�of �E R-negative�c ancers�r emains�a � challenge�

• There�i s�a �n eed�t o�unde rstand�t he�t arget�c ell�f or�br east�c ancer�p revention�

• Need��t o�i mprove��c urrent�r isk�pr ediction�m odels�by � �i ncluding��m odifiable�r isk�

factors����

• The�he alth�be liefs�o f�hi gh-risk�a nd�popul ation�r isk�w omen�r equire�e xploration�

• The�e ffects�of �b reast�s creening�out �w ith�c urrently�t argeted� groups�i s�not �know n�

• To�de fine�de liverable�di et�a nd�e xercise�i nterventions�f or�t he�pr imary� and�

secondary�p revention�of � breast�c ancer.�

• To�e lucidate�t he�m echanism��f or�br east� cancer�pr evention�w ith�e nergy�r estriction�

Problems�

• Accrual�a nd�r etention�of � women�i n�pr evention�t rials�

• Better�m odels�t o�r esearch�ne w�c hemoprevention�a gents�

• Breast�s creening�l ags�be hind�a dvances�i n�i maging� technology�

• Poor�upt ake�t o�di et�a nd�e xercise�t rials��a fter�di agnosis��

Translational�i mplications�

• Better�i dentification�of �hi gh�r isk�w omen� would�a llow�c hemoprevention�t o�be �

targeted�m ore�e ffectively�

• Defining� optimum�s creening�m ethods��w ill�e nsure� more�e ffective�us e�of �l imited�

NHS�r esources.�

Page 76: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

75�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

• The�de velopment�of � energy�r estriction�m imetics�f or�br east�c ancer�pr evention�

Optimal�di et�a nd�e xercise�i nterventions�c ould�i mprove�qua lity�o f�l ife�a nd�o utcome�

for�w omen�w ith�br east�c ancer��

Recommendations�

• Improve�br east�c ancer� risk�pr ediction�m odels��

• Encourage�t ransdisciplinary�i nput�t o�pr evention�t rials�( eg� geneticists,�

epidemiologists,�nut ritionists,�ps ychologists�a nd�c linicians)�t o�s tudy�t he�

psychosocial,�c ompliance�a nd� genetic�a spects�of � prevention�

• Establish�t he�pot ential�be nefits�of �di et�a nd�e xercise�pos t�di agnosis�on�out come�a nd�

quality�of �l ife� for�br east�c ancer�p atients�

Page 77: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

76�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

Table�7: �S ummary�of �G ap�A nalysis� for�P sychosocial�A spects�of �B reast� Cancer�

What�do�w e�know ?�

• There� are�ps ychosocial�e ffects��of � genetic�t esting,� prophylactic�m astectomy�a nd�

breast�s creening�

• Descriptive�s tudies�of �t he�e xperiences�of �b reast�c ancer�pa tients�us ing�qua ntitative�

and�qua litative�m ethods�s how�w omen�s till�e xperience�ps ychosocial�di stress�

despite�i mprovements�i n�t reatment�a nd�pr ognosis.� �

• Psychosocial�i nterventions�ha ve�be en�s hown�t o�be nefit�w omen,�i ncluding� those�

identified�a s�e xperiencing�hi gh�l evels�of �di stress.�

What�a re�t he�G aps?�

• Evaluation�of �de cision�a ids�f or�r isk�m anagement�a nd�c hoice�of �p reventative�

surgery�a mongst�hi gh�r isk�w omen.�

• Ways�of �e ffectively�c ommunicating�i nformation�a nd�a iding�pa tient�t reatment�

decision�m aking�

• Defining� patient�e xperiences�i n�e arly,� chronic� and� end�s tage�br east�c ancer� �

• Limited�r esearch�i nto�c o-morbidities�a mongst�br east�c ancer�pa tients��

• Experiences�of �e thnic�m inority�popul ations�a nd�ol der�w omen�

• The�ne ed�t o�de velop�a nd� evaluate� appropriate�ps ychosocial�i nterventions�f or�hi gh�

risk�w omen�a nd�t hose�di agnosed� as�ha ving�br east�c ancer��

• Use�of �ps ychological�t heories�i n�be haviour�c hange�t hat�c ould�e nhance�c ompliance�

to�l ifestyle�a nd� chemoprevention�t rials.�

Problems�

• The�ne ed� for�t he�l ong�t erm�f ollow�up�i n�ps ychosocial�r esearch�

• Barriers�t o�t he�upt ake�of � research�f indings�

Translational�i mplications�

• Direct�i mprovement�i n�t he�e xperience�o f�pa tients,� their�f amilies�a nd�t hose�a t�

increased�r isk�

Recommendations�

• Develop�a nd�r igorously� evaluate�a ppropriate�ps ychosocial�i nterventions�

• Encourage�c ross-speciality�c ollaboration�t o�i ncorporate�ps ychosocial�i ssues�a nd�

psychological�t heory�( eg� psychological�t heories�i n�r elation�t o�be haviour� change�

Page 78: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

77�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

are�r elevant�t o�t hose�r esearching�pr evention�w ith�di et�a nd�e xercise�or �

chemoprevention)�

• Ensure�r esearch� gives� greater� attention�t o�a ll�s tages�of �br east�c ancer� and�t hat�t he�

needs�of �ol der�w omen�a nd�t hose�f rom�a �r ange�of � ethnic�g roups� are�i ncluded�

Page 79: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

78�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

Table� 8:� � Gap� analysis� recommendations� and� future� directions�

Generic�ne eds:�

• Improved�pr eclinical�m odels�

• Access�t o�a ppropriate� and�a nnotated�c linical�m aterial�

• Cross�di sciplinary�w orking�

1.�G enetics�of �br east�c ancer�

• Encourage�de velopment� of�r esearch�t echniques�t o� allow�i ntegrated�a nalysis�of �

sequence�l evel,�e pigenetic�a nd�l arge-scale�s omatic�c hanges�

• Engage�i n�na tional�i nitiatives�f or�a ctivities�s uch�a s�hi gh-throughput�r e-sequencing�a nd�

UK�c ontrols�

• Encourage�r esearch�i nvolving�i ntermediate�phe notypes�

2.�I nitiation�of �br east�c ancer�

• Develop�t hree-dimensional�c ell�c ulture�m odels,�c ontaining�m ultiple�c ell�t ypes,�t hat�

reflect�t he�t issue�a rchitecture�of �t he�nor mal� and�di seased�br east�

• Generate�be tter�a nimal�m odels,�pa rticularly�f or�E R-positive�t umours,�i n�w hich�ge ne�

expression�c an�be �m anipulated�i n�a ll�c ell�t ypes�of � the�m ammary� gland�a nd� will�not �be �

altered�b y�t ransdifferentiation�or �de differentiation�

• Gain�a � greater�und erstanding�of �t he� genetic�c hanges�t hat�oc cur� within�a typias�a nd�

DCIS�

3.�P rogression�of �br east�c ancer�

• Improve�pr eclinical�m odels,�r esearch�r eagents�a nd�t echnologies�( including�i maging)�

• Enhance� access�t o�a ppropriate�c linical�m aterial,�i ncluding�s equential�s amples�

obtained�dur ing�t reatments�e xtending�t o�ne w�a gents� �

• Consider�ge netic�s ignature/specific� genetic�l esions�w hen�e xploring�pr ogression�

biology�a nd�de signing�c linical�t rials�

4.�T herapies�and�t argets�i n�br east�c ancer�

• Build�r esources�t hrough� high-quality,�uni form,�m ulticentre�c ollection�of � clinical�

material�f rom�br east�c ancer�pa tients�be fore� and�dur ing�t reatment�( including�

neoadjuvant�s tudies),�i ncluding�s amples�of �pr imary� tumours�a s�w ell�a s�m etastatic�

deposits�

Page 80: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

79�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�

• Develop�m ethods�f or� easy,�r eproducible�m onitoring�of � response�t o�a nd�d evelopment�

of�r esistance�t o�t herapy,� as�w ell�a s�e arly�di sease�p rogression�

• Increase�r esearch� efforts� into�t he�r ole�of �t he�t umour�m icroenvironment�a nd�t he�

immune�s ystem�i n�t he�de velopment�a nd�t reatment� of�br east�c ancer�

5.�D isease�m arkers�i n�br east�c ancer�

• Design�i nnovative�t rials�a nd�t ranslational�s tudies�t o�de velop�a nd�e valuate�p redictive�

and�pr ognostic�m arkers�

• Develop�c lose�m ultidisciplinary� collaboration�w ith�hi gh-quality�hi stopathology�a nd�

rigorous�s cientific�a ssessments�t o�va lidate�ne w�m arkers�i mportant�f or�p atient�

outcome�

• Identify�r obust�m arkers�o f�r esistance�or �s ensitivity� to�t herapy�t hat�c an�b e�a pplied�

across�t he�s pectrum�of �br east�di sease� from�s creen-detected�t o�m etastatic�b reast�

cancer�

6.�P revention�of �br east�c ancer�

• Improve�br east�c ancer� risk�pr ediction�m odels� �

• Encourage�t ransdisciplinary�i nput�t o�pr evention�t rials�( for�e xample� geneticists,�

epidemiologists,�nut ritionists,�ps ychologists�a nd�c linicians)�t o�s tudy�t he�

psychosocial,�c ompliance�a nd� genetic�a spects�of � prevention�

• Establish�t he�pot ential�be nefits�of �di et�a nd�e xercise�pos t�di agnosis�on�out come�a nd�

quality�of �l ife� for�br east�c ancer�p atients�

7.�P sychosocial�as pects�o f�br east�c ancer�

• Develop�a nd�r igorously� evaluate�a ppropriate�ps ychosocial�i nterventions�

• Encourage�c ross-speciality�c ollaboration�t o�i ncorporate�ps ychosocial�i ssues�a nd�

psychological�t heory�( for�e xample�ps ychological�t heories�i n�r elation�t o�be haviour�

change� are� relevant�t o�t hose�r esearching�pr eventative�l ifestyles�i ncluding�di et�a nd�

exercise)�

• Ensure�r esearch� gives� greater� attention�t o�a ll�s tages�of �br east�c ancer� and�t hat�t he�

needs�of �ol der�w omen�a nd�t hose�f rom�a �r ange�of � ethnic�g roups� are�i ncluded�

Page 81: Br east Cancer Resear ch - em-online.com · 2 B reastC anc erC am pa igng ap ana lysisdoc um ent 9B reastC anc erP reventionC entre,S out hM anc he sterU nive rsityH os pitalsN H

80�

Breast�C ancer�C ampaign�g ap� analysis�doc ument�